Advertisements



Elon Musk Says He Isn"t The "Doge CEO," Ability To Take Action "Is Limited"

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk said Tuesday that his ability to “take action is limited” when it comes to Dogecoin (DOGE). read more.....»»

Category: blogSource: benzingaMay 25th, 2021

Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress

Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP). Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment. Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD). Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung. Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to nomacopan. NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the second quarter of 2021, as well as recent clinical progress. Akari's two lead programs, in BP and HSCT-TMA, are in Phase III clinical development and have been granted both Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA). The Company also has earlier stage programs with nomacopan addressing ophthalmology and pulmonary diseases. "We have made progress with our clinical pipeline since the beginning of 2021, and have two orphan disease programs in Phase III clinical development," said Clive Richardson, Chief Executive Officer of Akari Therapeutics. "In parallel we are actively exploring partnering opportunities for disease areas such as those for the eye and the lung, using different routes of administration for nomacopan." Clinical highlights Phase III clinical trial in patients with bullous pemphigoid BP is a severe autoimmune blistering disease of the elderly with no specific approved treatments. The Company is opening sites for a Phase III study of nomacopan for the treatment of BP. The FDA and the European Medicines Agency (EMA) have granted Orphan Drug Designation for nomacopan for the treatment of BP, and the FDA has granted Fast Track designation to nomacopan in BP. Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, recently presented a poster at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium which outlines the design of the Company's Phase III planned pivotal study of nomacopan in patients with moderate to severe BP. The Company is considering additional opportunities to expand into other dermatological conditions where both complement C5 activation and LTB4 are believed to have key roles in driving the disease pathology including hidradenitis suppurativa (HS) and other pemphigoids. Phase III clinical trial in patients with HSCT-TMA HSCT-TMA is a severe disease in pediatric patients with an estimated 80% mortality rate and no approved treatments. Phase III study in pediatric HSCT-TMA is open for enrollment at sites in the U.S. and Europe, subject to the ongoing impact of COVID-19 related restrictions. Akari has FDA Fast Track and Orphan Drug Designations for pediatric HSCT-TMA patients. Success in pediatric HSCT-TMA would provide opportunities to expand into adult HSCT-TMA and related TMA-like diseases where complement and LTB4 are believed to have important roles such as atypical hemolytic uremic syndrome, systemic lupus erythematosus and anti-phospholipid syndrome. Long term data Our first PNH patient has now been treated with nomacopan for over five years. Over 35 cumulative patient years of long-term treatment data shows the drug is well tolerated with a marked clinical effect such that 79% of formerly transfusion dependent patients became transfusion independent. OTHER CLINICAL PROGRAMS Akari Therapeutics is also pursuing other earlier stage programs that are primarily focused on large disease areas with high unmet need. For these programs we are using alternative formulations of nomacopan (topical, nebulized or long acting), which provides an opportunity for separate partnering options. Ophthalmology program Ongoing PK studies with PAS-nomacopan, an engineered form of nomacopan with an extended half-life, to estimate injection interval in the back of the eye are ongoing, with data expected by the end of 2021. Recent publications (Eskandarpour et al 2020 and 2021) support a potential therapeutic role for PAS-nomacopan in sight threatening retinal diseases given its inhibition of both complement and VEGF via LTB4. This unique combination may be particularly relevant to dry AMD where complement is a key treatment target and VEGF inhibition may prevent the risk of conversion to wet AMD where VEGF inhibitors are the primary treatment. A recent publication (Sanchez-Tabernero et al 2021) highlights that nomacopan delivered topically in Part A of a Phase I/II study in patients with atopic keratoconjunctivitis had a positive safety profile and was well tolerated. Part B of the study confirmed these findings. The Company is currently exploring options for a Phase II study in the front of the eye. To maximize the potential of nomacopan in the ophthalmology setting, Akari is exploring opportunities to collaborate with partners to accelerate the development of these ophthalmology programs. Lung program Learning from the viral induced mechanisms of COVID-19 pneumonia that involve terminal complement pathway and LTB4 dysregulations we are exploring the development of nomacopan in severe asthma to reduce the use of systemic steroids, and hospital admissions.  This remains an area of unmet medical need where respiratory viral infection still triggers life threatening exacerbations across a range of inflammatory lung conditions. Proposed publication of the Akari sponsored observational study and role of nomacopan in COVID-19 patients is in preparation. Initiation of further studies is subject to optimizing patient selection to align with the findings of the review. Trauma The role of both C5 and LTB4 has been implicated in trauma and Akari is exploring both blast injury and hemorrhagic shock with the USAISR. In addition, a separate new collaborative study in traumatic brain injury and subarachnoid hemorrhage is being initiated. Histamine inhibitor Votucalis is a new histamine inhibitor with a similar structure to nomacopan but a distinct and unique mode of action by binding directly to histamine and thereby preventing the activation of all four histamine G-protein coupled receptors. Ongoing work in collaboration with Durham and Newcastle Universities in the UK is focused on using votucalis to expand the Company's existing dermatology franchise in atopic dermatitis and pain management. In both cases initial skin penetration data indicates a potential opportunity for topical delivery. Second Quarter 2021 Financial Results As of June 30, 2021, the Company had cash of approximately $3.8 million, compared to cash of approximately $14.1 million at December 31, 2020. Following the end of the second quarter, Akari closed a private placement of approximately $12.3 million in gross proceeds by issuing approximately 7.9 million ADSs. Furthermore, Akari received approximately $3 million in annual R&D tax credits from the UK tax authorities. In June 2020, Akari entered into a securities purchase agreement with Aspire Capital Fund, LLC (Aspire Capital) whereby Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company's ADSs. During the six months ended June 30, 2021, the Company sold to Aspire Capital ordinary shares for gross proceeds of $2.0 million. As of June 30, 2021, $22.0 million of the original purchase commitment remains available. Research and development expenses for the second quarter 2021 were approximately $2.2 million, as compared to approximately $3.0 million in the same quarter the prior year. This decrease in expenses was primarily due to lower expenses incurred for clinical trials during the year. General and administrative expenses for the second quarter 2021 were approximately $2.1 million, as compared to approximately $2.9 million in the same quarter the prior year. The decrease was primarily due to a one-time non-cash financing expense related to the 2020 Purchase Agreement with Aspire Capital. For the second quarter 2021, total other expense was approximately $16,000 as compared to total other expense of approximately $1.5 million in the second quarter of 2020. This change was primarily due to the accounting reclassification of warrant liabilities to shareholders' equity as of December 2020. Net loss for the second quarter 2021 was approximately $4.3 million, as compared to approximately $7.4 million for the period of 2020. This decrease was primarily due to the aforementioned lower research and development expenses as well as lower total other expense. About Akari Therapeutics Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung. Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance upon the Company's forward-looking statements. Except as required by law, the Company undertakes No obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this press release. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for Nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Nomacopan and any other product candidates and unexpected costs that may result therefrom; difficulties enrolling patients in our clinical trials; our ability to enter into collaborative, licensing, and other commercial relationships and on terms commercially reasonable to us; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected; risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission (SEC), including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.     AKARI THERAPEUTICS, Plc   CONDENSED CONSOLIDATED BALANCE SHEETSAs of June 30, 2021 and December 31, 2020(in U.S. dollars, except share data)                    .....»»

Category: earningsSource: benzingaSep 22nd, 2021

Cracker Barrel Reports Fourth Quarter And Full Year Fiscal 2021 Results And Declares Quarterly Dividend

LEBANON, Tenn., Sept. 21, 2021 /PRNewswire/ -- Cracker Barrel Old Country Store, Inc. ("Cracker Barrel" or the "Company") (Nasdaq: CBRL) today reported its financial results for the fourth quarter of fiscal 2021 ended July 30, 2021. Fourth Quarter Fiscal 2021 Highlights Total revenue in the fourth quarter of $784.4 million was approximately flat compared to the fourth quarter of fiscal 2019 total revenue of $787.1 million. Compared to the fourth quarter of fiscal 20191, comparable store restaurant sales decreased 6.8% and comparable store retail sales increased 18.2%. Comparable store off-premise restaurant sales grew 108.6% compared to the fourth quarter of 20191 and represented approximately 19% of restaurant sales. GAAP operating income in the fourth quarter was $62.7 million, or 8.0% of total revenue, and adjusted2 operating income was $65.9 million, or 8.4% of total revenue. GAAP net income was $36.4 million, or 4.6% of total revenue. EBITDA was $93.5 million, or 11.9% of total revenue, which represented a 30 basis point sequential improvement compared to fiscal 2021 third quarter EBITDA margin. GAAP earnings per diluted share were $1.53, and adjusted2 earnings per diluted share were $2.25. The Company announced that its Board of Directors declared a regular quarterly dividend of $1.30 per share and authorized share repurchases up to $100 million of the Company's outstanding common stock. Commenting on the fourth quarter results, Cracker Barrel President and Chief Executive Officer Sandra B. Cochran said, "Despite the well-known headwinds that the industry continues to face with respect to staffing, commodity and wage inflation, and the resurgence of the pandemic, we were pleased that our fourth quarter profitability continued to trend positively from the third quarter and that our off-premise sales, retail business, and Maple Street Biscuit Company concept continued to outperform.  In addition to these strengths, our impressive field and home office support teams delivered on multiple fronts throughout the year, including cost-savings, the introduction of our new dinner menu and the continued roll-out of beer and wine to our stores, and helped ensure our continued recovery in 2021.  I'm confident that these and other initiatives position us well for 2022 despite the uncertain environment." Fourth Quarter Fiscal 2021 Results RevenueThe Company reported total revenue of $784.4 million for the fourth quarter of fiscal 2021, representing an increase of 58.4% compared to the fourth quarter of fiscal 2020, and a decrease of 0.3% compared to the fourth quarter of 2019.   Cracker Barrel comparable store restaurant and retail sales compared to the fourth quarter of fiscal 20191 and versus the fourth quarter of fiscal 2020 were as follows: Versus FY19Comparable Period1 Versus FY20 Comparable Period Fourth Quarter Ended7/30/21 Fourth Quarter Ended7/30/21 Comparable restaurant sales -6.8% 53.5% Comparable retail sales 18.2% 74.8% Operating IncomeGAAP operating income in the fourth quarter was $62.7 million, or 8.0% of total revenue. Excluding the approximately $3.2 million in non-cash amortization related to the gains on the previously disclosed sale and leaseback transactions adjusted2 operating income for the fourth quarter was $65.9 million, or 8.4% of total revenue. Net Income, EBITDA and Earnings per Diluted Share GAAP net income in the fourth quarter was $36.4 million, or 4.6% of total revenue, and EBITDA was $93.5 million, or 11.9% of total revenue. GAAP earnings per diluted share were $1.53, and adjusted2 earnings per diluted share were $2.25. Convertible Debt OfferingAs previously disclosed, during the fourth quarter the Company completed the private offering of $300 million of 0.625% convertible senior notes due 2026, which generated net proceeds of approximately $291 million. The Company used approximately $30 million net, of the proceeds to fund the cost of entering into certain convertible note hedging transactions to minimize the risk of potential future dilution from the offering. The remainder of the proceeds were used to pay down debt under the Company's revolving credit facility. The Company ended the fourth quarter with approximately $327 million in total debt. The Company also paid approximately $18 million to terminate the interest rate swaps that it had been using to hedge interest rate risk on the debt outstanding under the Company's revolving credit facility. We anticipate this action will result in savings on interest expense over the next two years. In connection with the offering, the Company also repurchased $35 million of its common stock. Quarterly Dividend and Share Repurchase AuthorizationThe Company's Board of Directors declared a quarterly dividend to common shareholders of $1.30 per share, payable on November 9, 2021 to shareholders of record on October 22, 2021. This dividend represents a return to the Company's pre-pandemic quarterly dividend level. Additionally, the Board of Directors authorized share repurchases up to $100 million of the Company's outstanding common stock. Fiscal 2021 ResultsRevenueThe Company reported total revenue of $2.81 billion for fiscal 2021, representing an increase of 11.8% compared to fiscal 2020 and a decrease of 8.2% compared to fiscal 2019. Comparable store restaurant sales for fiscal 2021 increased 8.4% compared to fiscal 2020, including a 5.3% increase in store traffic and a 3.1% increase in average check. Comparable store retail sales for fiscal 2021 increased 20.9% compared to fiscal 2020. Operating IncomeGAAP operating income in fiscal 2021 was $366.7 million, or 13.0% of total revenue, compared to $103.6 million, or 4.1% of total revenue, in fiscal 2020. Adjusted2 operating income for fiscal 2021 was $166.8 million. Net Income, EBITDA and Earnings per Diluted Share GAAP net income was $254.5 million, or 9.0% of total revenue, and EBITDA was $488.0 million, or 17.3% of total revenue, in fiscal 2021. Adjusted2 EBITDA was $275.4 million, or 9.8% of total revenue. GAAP earnings per diluted share were $10.71, and adjusted2 earnings per diluted share were $5.14. Fiscal 2022 OutlookAs a result of the ongoing business impact and significant uncertainty created by the COVID-19 pandemic, including the nationwide increase in infections and responsive public health restrictions brought about by the rise of the "Delta variant" of the virus, the Company is not providing its customary annual earnings guidance for fiscal 2022 at this time. For the full fiscal year 2022, the Company expects: Commodity and wage inflation in the mid-to-high single digits; Capital expenditures of approximately $120 million; An effective tax rate of approximately 18%; and The opening of three new Cracker Barrel locations and 15 new Maple Street Biscuit Company locations. The Company reminds investors that its outlook for fiscal 2022 reflects a number of assumptions, many of which are outside the Company's control.  1 For the purpose of comparing to fiscal 2019, comparable stores are defined as restaurants open a full 30 months before the beginning of the applicable period.2 For Non-GAAP reconciliations, please refer to the Reconciliation of GAAP-basis operating results to non-GAAP operating results section of this release. Fiscal 2021 Fourth Quarter Conference CallAs previously announced, the live broadcast of Cracker Barrel's quarterly conference call will be available to the public on-line at investor.crackerbarrel.com today beginning at 11:00 a.m. (ET). The on-line replay will be available at 2:00 p.m. (ET) and continue through October 5, 2021. About Cracker Barrel Old Country Store®Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL) provides a caring and friendly home-away-from-home experience while offering guests high-quality homestyle food to enjoy in-store or to-go and unique shopping — all at a fair price. Established in 1969 in Lebanon, Tenn., Cracker Barrel and its affiliates operate more than 660 company-owned Cracker Barrel Old Country Store® locations in 45 states and own the fast-casual Maple Street Biscuit Company. For more information about the Company, visit crackerbarrel.com. CBRL-F Except for specific historical information, certain of the matters discussed in this press release may express or imply projections of revenues or expenditures, statements of plans and objectives or future operations or statements of future economic performance. These, and similar statements are forward-looking statements concerning matters that involve risks, uncertainties and other factors which may cause the actual performance of Cracker Barrel Old Country Store, Inc. and its subsidiaries to differ materially from those expressed or implied by this discussion. All forward-looking information is subject to completion of our financial procedures for Q4 FY 2021 and is provided pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995 and should be evaluated in the context of these factors. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "trends," "assumptions," "target," "guidance," "outlook," "opportunity," "future," "plans," "goals," "objectives," "expectations," "near-term," "long-term," "projection," "may," "will," "would," "could," "expect," "intend," "estimate," "anticipate," "believe," "potential," "regular," "should," "projects," "forecasts," or "continue" (or the negative or other derivatives of each of these terms) or similar terminology and include the expected effects of COVID-19 on our business, financial condition and results of operations and of operational improvement initiatives, such as new menu items and retail offerings. Factors which could materially affect actual results include, but are not limited to: risks and uncertainties associated with the COVID-19 pandemic, including the duration of the COVID-19 pandemic and its ultimate impact on our business, levels of consumer confidence in the safety of dine-in restaurants, restrictions (including occupancy restrictions) imposed by governmental authorities, the effectiveness of cost saving measures undertaken throughout our operations, disruptions to our operations as a result of the spread of COVID-19 in our workforce, and our level of indebtedness, or constraints on our expenditures, ability to service our debt obligations or make cash distributions to our shareholders or cash management generally, brought on by additional borrowing necessitated by the COVID-19 pandemic; general or regional economic weakness, business and societal conditions, and weather on sales and customer travel; discretionary income or personal expenditure activity of our customers; information technology-related incidents, including data privacy and information security breaches, whether as a result of infrastructure failures, employee or vendor errors, or actions of third parties; our ability to identify, acquire and sell successful new lines of retail merchandise and new menu items at our restaurants; our ability to sustain or the effects of plans intended to improve operational or marketing execution and performance; uncertain performance of acquired businesses, strategic investments and other initiatives that we may pursue now or in the future; changes in or implementation of additional governmental or regulatory rules, regulations and interpretations affecting tax, wage and hour matters, health and safety, pensions, insurance or other undeterminable areas; the effects of plans intended to promote or protect our brands and products; commodity price increases; the ability of and cost to us to recruit, train, and retain qualified hourly and management employees; the effects of increased competition at our locations on sales and on labor recruiting, cost, and retention; workers' compensation, group health and utility price changes; consumer behavior based on negative publicity or changes in consumer health or dietary trends or safety aspects of our food or products or those of the restaurant industry in general, including concerns about outbreaks of infectious disease, as well as the possible effects of such events on the price or availability of ingredients used in our restaurants; the effects of our indebtedness, including under our credit facility and our convertible senior notes, and associated restrictions on our financial and operating flexibility and ability to execute or pursue our operating plans and objectives; changes in interest rates, increases in borrowed capital or capital market conditions affecting our financing costs and ability to refinance all or portions of our indebtedness; the effects of dilution of our existing stockholders' ownership interest that may ensue from any conversions of our convertible senior notes or the related warrants issued in connection with our convertible note hedging transactions; the effects of business trends on the outlook for individual restaurant locations and the effect on the carrying value of those locations; our ability to retain key personnel; the availability and cost of suitable sites for restaurant development and our ability to identify those sites; our ability to enter successfully into new geographic markets that may be less familiar to us; changes in land, building materials and construction costs; the actual results of pending, future or threatened litigation or governmental investigations and the costs and effects of negative publicity or our ability to manage the impact of social media associated with these activities; economic or psychological effects of natural disasters or unforeseen events such as terrorist acts, social unrest or war and the military or government responses to such events; disruptions to our restaurant or retail supply chain, including as a result of COVID-19; changes in foreign exchange rates affecting our future retail inventory purchases; the impact of activist shareholders; our reliance on limited distribution facilities and certain significant vendors; implementation of new or changes in interpretation of existing accounting principles generally accepted in the United States of America ("GAAP"); and other factors described from time to time in our filings with the Securities and Exchange Commission, press releases, and other communications. Any forward-looking statement made by us herein, or elsewhere, speaks only as of the date on which made. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.   CRACKER BARREL OLD COUNTRY STORE, INC. CONDENSED CONSOLIDATED INCOME STATEMENT (Unaudited) (In thousands, except share and per share amounts, percentages and ratios)    Fourth Quarter Ended   Twelve Months Ended Percentage Percentage 7/30/21 7/31/20 Change 7/30/21 7/31/20 Change Total revenue $784,405 $495,065 58% $2,821,444 $2,522,792 12% Cost of goods sold, exclusive of depreciation and rent 235,754 150,778 56 865,261 779,937 11 Labor and other related expenses 268,702 187,785 43 983,120 924,994 6 Other store operating expenses 180,333 141,267 28 676,301 614,733 10 General and administrative expenses 36,948 40,950 (10) 147,825 146,975 1 Gain on sale and leaseback transactions 0 (69,954) (100) (217,722) (69,954) 211 Impairment 0 4,160 (100) 0 22,496 (100) Operating income 62,668 40,079 56 366,659 103,611 254 Interest expense 24,964 9,944 151 56,108 22,327 151 Income before income taxes 37,704 30,135 25 310,551 81,284 282 Provision for income taxes (income tax benefit) 1,341 5,069 (74) 56,038 (28,683) 295 Loss from unconsolidated subsidiary 0 0 0 (142,442) Net income (loss) $36,363 $25,066 45.....»»

Category: earningsSource: benzingaSep 21st, 2021

BTFD Arrives: Futures Rebound, Europe Surges While Asia Slumps On Evergrande Fears

BTFD Arrives: Futures Rebound, Europe Surges While Asia Slumps On Evergrande Fears Even though China was closed for a second day, and even though the Evergrande drama is nowhere closer to a resolution with a bond default imminent and with Beijing mute on how it will resolve the potential "Lehman moment" even as rating agency S&P chimed in saying a default is likely and it does not expect China’s government “to provide any direct support” to the privately owned developer, overnight the BTFD crew emerged in full force, and ramped futures amid growing speculation that Beijing will rescue the troubled developer... Algos about to go on a rampage — zerohedge (@zerohedge) September 21, 2021 ... pushing spoos almost 100 points higher from their Monday lows, and European stock were solidly in the green - despite Asian stocks hitting a one-month low - as investors tried to shake off fears of contagion from a potential collapse of China’s Evergrande, although gains were capped by concerns the Federal Reserve could set out a timeline to taper its stimulus at its meeting tomorrow. The dollar dropped from a one-month high, Treasury yields rose and cryptos rebounded from yesterday's rout. To be sure, the "this is not a Lehman moment" crowed was out in full force, as indicated by this note from Mizuho analysts who wrote that “while street wisdom is that Evergrande is not a ‘Lehman risk’, it is by no stretch of the imagination any meaningful comfort. It could end up being China’s proverbial house of cards ... with cross-sector headwinds already felt in materials/commodities.” At 7:00 a.m. ET, S&P 500 e-minis were up 34.00 points, or 0.79% and Nasdaq 100 e-minis 110.25 points, or 0.73%, while futures tracking the Dow  jumped 0.97%, a day after the index tumbled 1.8% in its worst day since late-July,  suggesting a rebound in sentiment after concerns about contagion from China Evergrande Group’s upcoming default woes roiled markets Monday. Dip-buyers in the last hour of trading Monday helped the S&P 500 pare some losses, though the index still posted the biggest drop since May. The bounce also came after the S&P 500 dropped substantially below its 50-day moving average - which had served as a resilient floor for the index this year - on Monday, its first major breach in more than six months. Freeport-McMoRan mining stocks higher with a 3% jump, following a 3.2% plunge in the S&P mining index a day earlier as copper prices hit a one-month low. Interest rate-sensitive banking stocks also bounced, tracking a rise in Treasury yields. Here are some of the biggest U.S. movers today: U.S.-listed Chinese stocks start to recover from Monday’s slump in premarket trading as the global selloff moderates. Alibaba (BABA US), Baidu (BIDU US), Nio (NIO US), Tencent Music (TME US)and Bilibili (BILI US) are among the gainers Verrica Pharma (VRCA US) plunges 30% in premarket trading after failing to get FDA approval for VP-102 for the treatment of molluscum contagiosum ReWalk Robotics (RWLK US) shares jump 43% in U.S. premarket trading amid a spike in volume in the stock. Being discussed on StockTwits Aprea Therapeutics gains 21% in U.S. premarket trading after the company reported complete remission in a bladder cancer patient in Phase 1/2 clinical trial of eprenetapopt in combination with pembrolizumab Lennar (LEN US) shares fell 3% in Monday postmarket trading after the homebuilder forecast 4Q new orders below analysts’ consensus hurt by unprecedented supply chain challenges ConocoPhillips (COP US) ticks higher in U.S. premarket trading after it agreed to buy Shell’s  Permian Basin assets for $9.5 billion in cash, accelerating the consolidation of the largest U.S. oil patch SmileDirect (SDC US) slightly higher in premarket trading after it said on Monday that it plans to enter France with an initial location in Paris KAR Global (KAR US) shares fell 4.6% in post-market trading on Monday after the company withdrew is full-year financial outlook citing disruption caused by chip shortage Sportradar (SRAD US) shares jumped 4.5% in Monday postmarket trading, after the company said basketball legend Michael Jordan will serve as a special adviser to its board and also increase his investment in the sports betting and entertainment services provider, effective immediately Orbital Energy Group (OEG US) gained 6% postmarket Monday after a unit won a contract  to construct 1,910 miles of rural broadband network in Virginia. Terms were not disclosed “So much of this information is already known that we don’t think it will necessary set off a wave of problems,” John Bilton, head of global multi-asset strategy at JPMorgan Asset Management, said on Bloomberg TV. “I’m more concerned about knock-on sentiment at a time when investor sentiment is a bit fragile. But when we look at the fundamentals -- the general growth, and direction in the wider economy -- we still feel reasonably confident that the situation will right itself.” Aside from worries over Evergrande’s ability to make good on $300 billion of liabilities, investors are also positioning for the two-day Fed meeting starting Tuesday, where policy makers are expected to start laying the groundwork for paring stimulus.  Europe's Stoxx 600 index climbed more than 1%, rebounding from the biggest slump in two months, with energy companies leading the advance and all industry sectors in the green. Royal Dutch Shell rose after the company offered shareholders a payout from the sale of shale oil fields. Universal Music Group BV shares soared in their stock market debut after being spun off from Vivendi SE. European airlines other travel-related stocks rise for a second day following the U.S. decision to soon allow entry to most foreign air travelers as long as they’re fully vaccinated against Covid-19; British Airways parent IAG soars as much as 6.9%, extending Monday’s 11% jump. Here are some of the biggest European movers today: Stagecoach shares jump as much as 24% after the company confirmed it is in takeover talks with peer National Express. Shell climbs as much as 4.4% after selling its Permian Basin assets to ConocoPhillips for $9.5 billion. Bechtle gains as much as 4.3% after UBS initiated coverage at buy. Husqvarna tumbles as much as 9% after the company said it is suing Briggs & Stratton in the U.S. for failing to deliver sufficient lawn mower engines for the 2022 season. Kingfisher slides as much as 6.4% after the DIY retailer posted 1H results and forecast higher profits this fiscal year. The mood was decidedly more sour earlier in the session, when Asian stocks fell for a second day amid continued concerns over China’s property sector, with Japan leading regional declines as the market reopened after a holiday. The MSCI Asia Pacific Index was down 0.5%, headed for its lowest close since Aug. 30, with Alibaba and SoftBank the biggest drags. China Evergrande Group slid deeper in equity and credit markets Tuesday after S&P said the developer is on the brink of default. Markets in China, Taiwan and South Korea were closed for holidays. Worries over contagion risk from the Chinese developer’s debt problems and Beijing’s ongoing crackdowns, combined with concern over Federal Reserve tapering, sent global stocks tumbling Monday. The MSCI All-Country World Index fell 1.6%, the most since July 19. Japan’s stocks joined the selloff Tuesday as investor concerns grew over China’s real-estate sector as well as Federal Reserve tapering, with the Nikkei 225 sliding 2.2% - its biggest drop in three months, catching up with losses in global peers after a holiday - after a four-week rally boosted by expectations for favorable economic policies from a new government. Electronics makers were the biggest drag on the Topix, which declined 1.7%. SoftBank Group and Fast Retailing were the largest contributors to a 2.2% loss in the Nikkei 225. Japanese stocks with high China exposure including Toto and Nippon Paint also dropped. “The outsized reaction in global markets may be a function of having too many uncertainties bunched into this period,” Eugene Leow, a macro strategist at DBS Bank Ltd., wrote in a note. “It probably does not help that risk taking (especially in equities) has gone on for an extended period and may be vulnerable to a correction.” “The proportion of Japan’s exports to China is greater than those to the U.S. or Europe, making it sensitive to any slowdown worries in the Chinese economy,” said Hideyuki Ishiguro, a senior strategist at Nomura Asset Management in Tokyo. “The stock market has yet to fully price in the possibility of a bankruptcy by Evergrande Group.” The Nikkei 225 has been the best-performing major stock gauge in the world this month, up 6.2%, buoyed by expectations for favorable policies from a new government and an inflow of foreign cash. The Topix is up 5.3% so far in September. In FX, the Bloomberg Dollar Spot Index inched lower and the greenback fell versus most of its Group-of-10 peers as a selloff in global stocks over the past two sessions abated; the euro hovered while commodity currencies led by the Norwegian krone were the best performers amid an advance in crude oil prices. Sweden’s krona was little changed after the Riksbank steered clear of signaling any post-pandemic tightening, as it remains unconvinced that a recent surge in inflation will last. The pound bucked a three-day losing streak as global risk appetite revived, while investors look to Thursday’s Bank of England meeting for policy clues. The yen erased earlier gains as signs that risk appetite is stabilizing damped demand for haven assets. At the same time, losses were capped due to uncertainty over China’s handling of the Evergrande debt crisis. In rates, Treasuries were lower, although off worst levels of the day as U.S. stock futures recover around half of Monday’s losses while European equities trade with a strong bid tone. Yields are cheaper by up to 2.5bp across long-end of the curve, steepening 5s30s spread by 1.2bp; 10-year yields around 1.3226%, cheaper by 1.5bp on the day, lagging bunds and gilts by 1bp-2bp. The long-end of the curve lags ahead of $24b 20-year bond reopening. Treasury will auction $24b 20-year bonds in first reopening at 1pm ET; WI yield ~1.82% is below auction stops since January and ~3bp richer than last month’s new-issue result In commodities, crude futures rose, with the front month WTI up 1.5% near $71.50. Brent stalls near $75. Spot gold trades a narrow range near $1,765/oz. Base metals are mostly in the green with LME aluminum the best performer Looking at the day ahead now, and data releases include US housing starts and building permits for August, along with the UK public finances for September. From central banks, we’ll hear from ECB Vice President de Guindos. Otherwise, the General Debate will begin at the UN General Assembly, and the OECD publishes their Interim Economic Outlook. Market Snapshot S&P 500 futures up 1.0% to 4,392.75 STOXX Europe 600 up 1.1% to 459.10 MXAP down 0.5% to 200.25 MXAPJ up 0.2% to 640.31 Nikkei down 2.2% to 29,839.71 Topix down 1.7% to 2,064.55 Hang Seng Index up 0.5% to 24,221.54 Shanghai Composite up 0.2% to 3,613.97 Sensex up 0.4% to 58,751.30 Australia S&P/ASX 200 up 0.4% to 7,273.83 Kospi up 0.3% to 3,140.51 Brent Futures up 1.6% to $75.13/bbl Gold spot down 0.1% to $1,761.68 U.S. Dollar Index little changed at 93.19 German 10Y yield fell 5.0 bps to -0.304% Euro little changed at $1.1729 Top Overnight News from Bloomberg Lael Brainard is a leading candidate to be the Federal Reserve’s banking watchdog and is also being discussed for more prominent Biden administration appointments, including to replace Fed chairman Jerome Powell and, potentially, for Treasury secretary if Janet Yellen leaves Federal Reserve Chair Jerome Powell will this week face the challenge of convincing investors that plans to scale back asset purchases aren’t a runway to raising interest rates for the first time since 2018 ECB Vice President Luis de Guindos says there is “good news” with respect to the euro-area recovery after a strong development in the second and third quarter The ECB is likely to continue purchasing junk-rated Greek sovereign debt even after the pandemic crisis has passed, according to Governing Council member and Greek central bank chief Yannis Stournaras U.K. government borrowing was well below official forecasts in the first five months of the fiscal year, providing a fillip for Chancellor of the Exchequer Rishi Sunak as he prepares for a review of tax and spending next month U.K. Business Secretary Kwasi Kwarteng warned the next few days will be challenging as the energy crisis deepens, and meat producers struggle with a crunch in carbon dioxide supplies The U.K.’s green bond debut broke demand records for the nation’s debt as investors leaped on the long-anticipated sterling asset. The nation is offering a green bond maturing in 2033 via banks on Tuesday at 7.5 basis points over the June 2032 gilt. It has not given an exact size target for the sale, which has attracted a record of more than 90 billion pounds ($123 billion) in orders Germany cut planned debt sales in the fourth quarter by 4 billion euros ($4.7 billion), suggesting the surge in borrowing triggered by the coronavirus pandemic is receding Contagion from China Evergrande Group has started to engulf even safer debt in Asia, sparking the worst sustained selloff of the securities since April. Premiums on Asian investment-grade dollar bonds widened 2-3 basis points Tuesday, according to credit traders, after a jump of 3.4 basis points on Monday Swiss National Bank policy makers watching the effects of negative interest rates on the economy are worrying about the real-estate bubble that their policy is helping to foster Global central banks need to set out clear strategies for coping with inflation risks as the world economy experiences faster-than-expected cost increases amid an uneven recovery from the pandemic, the OECD said A quick look at global markets courtesy of Newsquawk Asian equities traded cautiously following the recent downbeat global risk appetite due to Evergrande contagion concerns which resulted in the worst day for Wall Street since May, with the region also contending with holiday-thinned conditions due to the ongoing closures in China, South Korea and Taiwan. ASX 200 (+0.2%) was indecisive with a rebound in the mining-related sectors counterbalanced by underperformance in utilities, financials and tech, while there were also reports that the Byron Bay area in New South Wales will be subject to a seven-day lockdown from this evening. Nikkei 225 (-1.8%) was heavily pressured and relinquished the 30k status as it played catch up to the contagion downturn on return from the extended weekend with recent detrimental currency inflows also contributing to the losses for exporters. Hang Seng (-0.3%) was choppy amid the continued absence of mainland participants with markets second-guessing whether Chinese authorities will intervene in the event of an Evergrande collapse, while shares in the world’s most indebted developer fluctuated and wiped out an early rebound, although affiliate Evergrande Property Services and other property names fared better after Sun Hung Kai disputed reports of China pressuring Hong Kong developers and with Guangzhou R&F Properties boosted by reports major shareholders pledged funds in the Co. which is also selling key assets to Country Garden. Finally, 10yr JGBs were higher amid the underperformance in Japanese stocks and with the Japan Securities Dealers Association recently noting that global funds purchased the most ultra-long Japanese bonds since 2014, although upside was limited amid softer demand at the enhanced liquidity auction for 2yr-20yr maturities and with the BoJ kickstarting its two-day policy meeting. Top Asian News Richest Banker Says Evergrande Is China’s ‘Lehman Moment’ Hong Kong Tycoons, Casino Giants Find Respite in Stock Rebound Taliban Add More Male Ministers, Say Will Include Women Later Asian Stocks Drop to Lowest Level This Month; Japan Leads Losses European equities (Stoxx 600 +1.1%) trade on a firmer footing attempting to recoup some of yesterday’s losses with not much in the way of incremental newsflow driving the upside. Despite the attempt to claw back some of the prior session’s lost ground, the Stoxx 600 is still lower by around 1.6% on the week. The Asia-Pac session was one characterised by caution and regional market closures with China remaining away from market. Focus remains on whether Evergrande will meet USD 83mln in interest payments due on Thursday and what actions Chinese authorities could take to limit the contagion from the company in the event of further troubles. Stateside, futures are also on a firmer footing with some slight outperformance in the RTY (+1.2%) vs. peers (ES +0.8%). Again, there is not much in the way of fresh positivity driving the upside and instead gains are likely more a by-product of dip-buying; attention for the US is set to become increasingly geared towards tomorrow’s FOMC policy announcement. Sectors in Europe are firmer across the board with outperformance in Oil & Gas names amid a recovery in the crude complex and gains in Shell (+4.4%) after news that the Co. is to sell its Permian Basin assets to ConocoPhillips (COP) for USD 9.5bln in cash. Other outperforming sectors include Tech, Insurance and Basic Resources. IAG (+4.1%) and Deutsche Lufthansa (+3.8%) both sit at the top of the Stoxx 600 as the Co.’s continue to enjoy the fallout from yesterday’s decision by the US to allow travel from vaccinated EU and UK passengers. Swatch (-0.7%) is lagging in the luxury space following a downgrade at RBC, whilst data showed Swiss watch exports were +11.5% Y/Y in August (prev. 29.1%). Finally, National Express (+7.7%) is reportedly considering a takeover of Stagecoach (+21.4%), which is valued at around GBP 370mln. Top European News U.K. Warns of Challenging Few Days as Energy Crisis Deepens Germany Trims Planned Debt Sales as Pandemic Impact Recedes U.K.’s Green Bond Debut Draws Record Demand of $123 Billion Goldman Plans $1.5 Billion Petershill Partners IPO in London In FX, all the signs are constructive for a classic turnaround Tuesday when it comes to Loonie fortunes as broad risk sentiment improves markedly, WTI consolidates within a firm range around Usd 71/brl compared to yesterday’s sub-Usd 70 low and incoming results from Canada’s general election indicate victory for the incumbent Liberal party that will secure a 3rd term for PM Trudeau. Hence, it’s better the devil you know as such and Usd/Cad retreated further from its stop-induced spike to just pips short of 1.2900 to probe 1.2750 at one stage before bouncing ahead of new house price data for August. Conversely, the Swedish Krona seems somewhat reluctant to get carried away with the much better market mood after the latest Riksbank policy meeting only acknowledged significantly stronger than expected inflation data in passing, and the repo rate path remained rooted to zero percent for the full forecast horizon as a consequence. However, Eur/Sek has slipped back to test 10.1600 bids/support following an initial upturn to almost 10.1800, irrespective of a rise in unemployment. NOK/AUD/NZD - No such qualms for the Norwegian Crown as Brent hovers near the top of a Usd 75.18-74.20/brl band and the Norges Bank is widely, if not universally tipped to become the first major Central Bank to shift into tightening mode on Thursday, with Eur/Nok hugging the base of a 10.1700-10.2430 range. Elsewhere, the Aussie and Kiwi look relieved rather than rejuvenated in their own right given dovish RBA minutes, a deterioration in Westpac’s NZ consumer sentiment and near reversal in credit card spending from 6.9% y/y in July to -6.3% last month. Instead, Aud/Usd and Nzd/Usd have rebounded amidst the recovery in risk appetite that has undermined their US rival to top 0.7380 and 0.7050 respectively at best. GBP/CHF/EUR/JPY/DXY - Sterling is latching on to the ongoing Dollar retracement and more supportive backdrop elsewhere to pare losses under 1.3700, while the Franc continues its revival to 0.9250 or so and almost 1.0850 against the Euro even though the SNB is bound to check its stride at the upcoming policy review, and the single currency is also forming a firmer base above 1.1700 vs the Buck. Indeed, the collective reprieve in all components of the Greenback basket, bar the Yen on diminished safe-haven demand, has pushed the index down to 93.116 from 93.277 at the earlier apex, and Monday’s elevated 93.455 perch, while Usd/Jpy is straddling 109.50 and flanked by decent option expiry interest either side. On that note, 1.4 bn resides at the 109.00 strike and 1.1 bn between 109.60-70, while there is 1.6 bn in Usd/Cad bang on 1.2800. EM - Some respite across the board in wake of yesterday’s mauling at the hands of risk-off positioning in favour of the Usd, while the Czk has also been underpinned by more hawkish CNB commentary as Holub echoes the Governor by advocating a 50 bp hike at the end of September and a further 25-50 bp in November. In commodities, WTI and Brent are firmer in the European morning post gains in excess of 1.0%, though the benchmarks are off highs after an early foray saw Brent Nov’21 eclipse USD 75.00/bbl, for instance. While there has been newsflow for the complex, mainly from various energy ministers, there hasn’t been much explicitly for crude to change the dial; thus, the benchmarks are seemingly moving in tandem with broader risk sentiment (see equities). In terms of the energy commentary, the Qatar minister said they are not thinking of re-joining OPEC+ while the UAE minister spoke on the gas situation. On this, reports in Russian press suggests that Russia might allow Rosneft to supply 10bcm of gas to Europe per year under an agency agreement with Gazprom “as an experiment”, developments to this will be closely eyed for any indication that it could serve to ease the current gas situation. Looking ahead, we have the weekly private inventory report which is expected to post a headline draw of 2.4mln and draws, albeit of a smaller magnitude, are expected for distillate and gasoline as well. Moving to metals, spot gold is marginally firmer while silver outperforms with base-metals picking up across the board from the poor performance seen yesterday that, for instance, saw LME copper below the USD 9k mark. Note, the action is more of a steadying from yesterday’s downside performance than any notable upside, with the likes of copper well within Monday’s parameters. US Event Calendar 8:30am: Aug. Building Permits MoM, est. -1.8%, prior 2.6%, revised 2.3% 8:30am: Aug. Housing Starts MoM, est. 1.0%, prior -7.0% 8:30am: Aug. Building Permits, est. 1.6m, prior 1.64m, revised 1.63m 8:30am: Aug. Housing Starts, est. 1.55m, prior 1.53m 8:30am: 2Q Current Account Balance, est. -$190.8b, prior -$195.7b DB's Jim Reid concludes the overnight wrap Global markets slumped across the board yesterday in what was one of the worst days of the year as an array of concerns about the outlook gathered pace. The crisis at Evergrande and in the Chinese real estate sector was the catalyst most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up. Remember that 68% of respondents to my survey last week (link here) thought they’d be at least a 5% correction in equity markets before year end. So this has been front and centre of people’s mind even if the catalyst hasn’t been clear. We’ve all known about Evergrande’s woes and how big it was for a while but it wasn’t until Friday’s story of the Chinese regulatory crackdown extending into property that crystallised the story into having wider implications. As I noted in my chart of the day yesterday link here Chinese USD HY had been widening aggressively over the last couple of months but IG has been pretty rock solid. There were still no domestic signs of contagion by close of business Friday. However as it stands, there will likely be by the reopening post holidays tomorrow which reflects how quickly the story has evolved even without much new news. Before we get to the latest on this, note that we’ve still got a bumper couple of weeks on the calendar to get through, including the Fed decision tomorrow, which comes just as a potential government shutdown and debt ceiling fight are coming into view, alongside big debates on how much spending the Democrats will actually manage to pass. There has been some respite overnight with S&P 500 futures +0.58% higher and 10y UST yields up +1.5bps to 1.327%. Crude oil prices are also up c. 1%. On Evergrande, S&P Global Ratings has said that the company is on the brink of default and that it’s failure is unlikely to result in a scenario where China will be compelled to step in. The report added that they see China stepping in only if “there is a far-reaching contagion causing multiple major developers to fail and posing systemic risks to the economy.” The Hang Seng (-0.32%) is lower but the Hang Seng Properties index is up (+1.59%) and bouncing off the 5 plus year lows it hit yesterday. Elsewhere the ASX (+0.30%) and India’s Nifty (+0.35%) have also advanced. Chinese and South Korean markets are closed for a holiday but the Nikkei has reopened and is -1.80% and catching down to yesterday’s global move. Looking at yesterday’s moves in more depth, the gathering storm clouds saw the S&P 500 shed -1.70% in its worst day since May 12, with cyclical industries leading the declines and with just 10% of S&P 500 index members gaining. There was a late rally at the end of the US trading session that saw equity indices bounce off their lows, with the S&P 500 (-2.87%) and NASDAQ (-3.42%) both looking like they were going to register their worst days since October 2020 and late-February 2021 respectively. However, yesterday was still the 5th worst day for the S&P 500 in 2021. Reflecting the risk-off tone, small caps suffered in particular with the Russell 2000 falling -2.44%, whilst tech stocks were another underperformer as the NASDAQ lost -2.19% and the FANG+ index of 10 megacap tech firms saw an even bigger -3.16% decline. For Europe it was much the same story, with the STOXX 600 (-1.67%) and other bourses including the DAX (-2.31%) seeing significant losses amidst the cyclical underperformance. It was the STOXX 600’s worst performance since mid-July and the 6th worst day of the year overall. Unsurprisingly, there was also a significant spike in volatility, with the VIX index climbing +4.9pts to 25.7 – its highest closing level since mid-May – after trading above 28.0pts midday. In line with the broader risk-off move, especially sovereign bonds rallied strongly as investors downgraded their assessment of the economic outlook and moved to price out the chances of near-term rate hikes. By the close of trade, yields on 10yr Treasuries had fallen -5.1bps to 1.311%, with lower inflation breakevens (-4.1bps) leading the bulk of the declines. Meanwhile in Europe, yields on 10yr bunds (-4.0bps), OATs (-2.6bps) and BTPs (-0.9bps) similarly fell back, although there was a widening in spreads between core and periphery as investors turned more cautious. Elsewhere, commodities took a hit as concerns grew about the economic outlook, with Bloomberg’s Commodity Spot Index (-1.53%) losing ground for a third consecutive session. That said, European natural gas prices (+15.69%) were the massive exception once again, with the latest surge taking them above the peak from last Wednesday, and thus bringing the price gains since the start of August to +84.80%. Here in the UK, Business Secretary Kwarteng said that he didn’t expect an emergency regarding the energy supply, but also said that the government wouldn’t bail out failed companies. Meanwhile, EU transport and energy ministers are set to meet from tomorrow for an informal meeting, at which the massive spike in prices are likely to be discussed. Overnight, we have the first projections of the Canadian federal election with CBC News projecting that the Liberals will win enough seats to form a government for the third time albeit likely a minority government. With the counting still underway, Liberals are currently projected to win 156 seats while Conservatives are projected to win 120 seats. Both the parties are currently projected to win a seat less than last time. The Canadian dollar is up +0.44% overnight as the results remove some election uncertainty. Turning to the pandemic, the main news yesterday was that the US is set to relax its travel rules for foreign arrivals. President Biden announced the move yesterday, mandating that all adult visitors show proof of vaccination before entering the country. Airline stocks outperformed strongly in response, with the S&P 500 airlines (+1.55%) being one of the few industry groups that actually advanced yesterday. Otherwise, we heard from Pfizer and BioNTech that their vaccine trials on 5-11 year olds had successfully produced an antibody response among that age group. The dose was just a third of that used in those aged 12 and above, and they said they planned to share the data with regulators “as soon as possible”. Furthermore, they said that trials for the younger cohorts (2-5 and 6m-2) are expected as soon as Q4. In Germany, there are just 5 days left until the election now, and the last Insa poll before the vote showed a slight tightening in the race, with the centre-left SPD down a point to 25%, whilst the CDU/CSU bloc were up 1.5 points to 22%. Noticeably, that would also put the race back within the +/- 2.5% margin of error. The Greens were unchanged in third place on 15%. Staying with politics and shifting back to the US, there was news last night that Congressional Democratic leaders are looking to tie the suspension of the US debt ceiling vote to the spending bill that is due by the end of this month. If the spending bill is not enacted it would trigger a government shutdown, and if the debt ceiling is not raised it would cause defaults on federal payments as soon as October. Senate Majority Leader Schumer said the House will pass a spending bill that will fund the government through December 3rd and that the “legislation to avoid a government shutdown will also include a suspension of the debt limit through December 2022.” Republicans may balk at the second measure, given that it would take the issue off the table until after the 2022 midterm elections in November of that year. There wasn’t a great deal of data out yesterday, though German producer price inflation rose to +12.0% in August (vs. +11.1% expected), marking the fastest pace since December 1974. Separately in the US, the NAHB’s housing market index unexpectedly rose to 76 in September (vs. 75 expected), the first monthly increase since April. To the day ahead now, and data releases include US housing starts and building permits for August, along with the UK public finances for September. From central banks, we’ll hear from ECB Vice President de Guindos. Otherwise, the General Debate will begin at the UN General Assembly, and the OECD will be publishing their Interim Economic Outlook. Tyler Durden Tue, 09/21/2021 - 07:45.....»»

Category: blogSource: zerohedgeSep 21st, 2021

Elon Musk Says He Isn"t The "Doge CEO," Ability To Take Action "Is Limited"

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk said Tuesday that his ability to “take action is limited” when it comes to Dogecoin (DOGE). read more.....»»

Category: blogSource: benzingaMay 25th, 2021

"Damn You To Hell, You Will Not Destroy America" - Here Is The "Spartacus COVID Letter" That"s Gone Viral

"Damn You To Hell, You Will Not Destroy America" - Here Is The 'Spartacus COVID Letter' That's Gone Viral Via The Automatic Earth blog, This is an anonymously posted document by someone who calls themselves Spartacus. Because it’s anonymous, I can’t contact them to ask for permission to publish. So I hesitated for a while, but it’s simply the best document I’ve seen on Covid, vaccines, etc. Whoever Spartacus is, they have a very elaborate knowledge in “the field”. If you want to know a lot more about the no. 1 issue in the world today, read it. And don’t worry if you don’t understand every single word, neither do I. But I learned a lot. The original PDF doc is here: Covid19 – The Spartacus Letter Hello, My name is Spartacus, and I’ve had enough. We have been forced to watch America and the Free World spin into inexorable decline due to a biowarfare attack. We, along with countless others, have been victimized and gaslit by propaganda and psychological warfare operations being conducted by an unelected, unaccountable Elite against the American people and our allies. Our mental and physical health have suffered immensely over the course of the past year and a half. We have felt the sting of isolation, lockdown, masking, quarantines, and other completely nonsensical acts of healthcare theater that have done absolutely nothing to protect the health or wellbeing of the public from the ongoing COVID-19 pandemic. Now, we are watching the medical establishment inject literal poison into millions of our fellow Americans without so much as a fight. We have been told that we will be fired and denied our livelihoods if we refuse to vaccinate. This was the last straw. We have spent thousands of hours analyzing leaked footage from Wuhan, scientific papers from primary sources, as well as the paper trails left by the medical establishment. What we have discovered would shock anyone to their core. First, we will summarize our findings, and then, we will explain them in detail. References will be placed at the end. Summary: COVID-19 is a blood and blood vessel disease. SARS-CoV-2 infects the lining of human blood vessels, causing them to leak into the lungs. Current treatment protocols (e.g. invasive ventilation) are actively harmful to patients, accelerating oxidative stress and causing severe VILI (ventilator-induced lung injuries). The continued use of ventilators in the absence of any proven medical benefit constitutes mass murder. Existing countermeasures are inadequate to slow the spread of what is an aerosolized and potentially wastewater-borne virus, and constitute a form of medical theater. Various non-vaccine interventions have been suppressed by both the media and the medical establishment in favor of vaccines and expensive patented drugs. The authorities have denied the usefulness of natural immunity against COVID-19, despite the fact that natural immunity confers protection against all of the virus’s proteins, and not just one. Vaccines will do more harm than good. The antigen that these vaccines are based on, SARS-CoV- 2 Spike, is a toxic protein. SARS-CoV-2 may have ADE, or antibody-dependent enhancement; current antibodies may not neutralize future strains, but instead help them infect immune cells. Also, vaccinating during a pandemic with a leaky vaccine removes the evolutionary pressure for a virus to become less lethal. There is a vast and appalling criminal conspiracy that directly links both Anthony Fauci and Moderna to the Wuhan Institute of Virology. COVID-19 vaccine researchers are directly linked to scientists involved in brain-computer interface (“neural lace”) tech, one of whom was indicted for taking grant money from China. Independent researchers have discovered mysterious nanoparticles inside the vaccines that are not supposed to be present. The entire pandemic is being used as an excuse for a vast political and economic transformation of Western society that will enrich the already rich and turn the rest of us into serfs and untouchables. COVID-19 Pathophysiology and Treatments: COVID-19 is not a viral pneumonia. It is a viral vascular endotheliitis and attacks the lining of blood vessels, particularly the small pulmonary alveolar capillaries, leading to endothelial cell activation and sloughing, coagulopathy, sepsis, pulmonary edema, and ARDS-like symptoms. This is a disease of the blood and blood vessels. The circulatory system. Any pneumonia that it causes is secondary to that. In severe cases, this leads to sepsis, blood clots, and multiple organ failure, including hypoxic and inflammatory damage to various vital organs, such as the brain, heart, liver, pancreas, kidneys, and intestines. Some of the most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, and hyperferritinemia, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion. COVID-19 can present as almost anything, due to the wide tropism of SARS-CoV-2 for various tissues in the body’s vital organs. While its most common initial presentation is respiratory illness and flu-like symptoms, it can present as brain inflammation, gastrointestinal disease, or even heart attack or pulmonary embolism. COVID-19 is more severe in those with specific comorbidities, such as obesity, diabetes, and hypertension. This is because these conditions involve endothelial dysfunction, which renders the circulatory system more susceptible to infection and injury by this particular virus. The vast majority of COVID-19 cases are mild and do not cause significant disease. In known cases, there is something known as the 80/20 rule, where 80% of cases are mild and 20% are severe or critical. However, this ratio is only correct for known cases, not all infections. The number of actual infections is much, much higher. Consequently, the mortality and morbidity rate is lower. However, COVID-19 spreads very quickly, meaning that there are a significant number of severely-ill and critically-ill patients appearing in a short time frame. In those who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments are intubation, injected corticosteroids, and blood thinners. This is not the correct treatment for COVID-19. In severe hypoxia, cellular metabolic shifts cause ATP to break down into hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue. This is called ischemia-reperfusion injury, and it’s why the majority of people who go on a ventilator are dying. In the mitochondria, succinate buildup due to sepsis does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals. Make no mistake, intubation will kill people who have COVID-19. The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to “rust” due to damage by oxidative stress. This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes. Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes. This is similar to the pathophysiology of Lupus. COVID-19’s pathology is dominated by extreme oxidative stress and neutrophil respiratory burst, to the point where hemoglobin becomes incapable of carrying oxygen due to heme iron being stripped out of heme by hypochlorous acid. No amount of supplemental oxygen can oxygenate blood that chemically refuses to bind O2. The breakdown of the pathology is as follows: SARS-CoV-2 Spike binds to ACE2. Angiotensin Converting Enzyme 2 is an enzyme that is part of the renin-angiotensin-aldosterone system, or RAAS. The RAAS is a hormone control system that moderates fluid volume in the body and in the bloodstream (i.e. osmolarity) by controlling salt retention and excretion. This protein, ACE2, is ubiquitous in every part of the body that interfaces with the circulatory system, particularly in vascular endothelial cells and pericytes, brain astrocytes, renal tubules and podocytes, pancreatic islet cells, bile duct and intestinal epithelial cells, and the seminiferous ducts of the testis, all of which SARS-CoV-2 can infect, not just the lungs. SARS-CoV-2 infects a cell as follows: SARS-CoV-2 Spike undergoes a conformational change where the S1 trimers flip up and extend, locking onto ACE2 bound to the surface of a cell. TMPRSS2, or transmembrane protease serine 2, comes along and cuts off the heads of the Spike, exposing the S2 stalk-shaped subunit inside. The remainder of the Spike undergoes a conformational change that causes it to unfold like an extension ladder, embedding itself in the cell membrane. Then, it folds back upon itself, pulling the viral membrane and the cell membrane together. The two membranes fuse, with the virus’s proteins migrating out onto the surface of the cell. The SARS-CoV-2 nucleocapsid enters the cell, disgorging its genetic material and beginning the viral replication process, hijacking the cell’s own structures to produce more virus. SARS-CoV-2 Spike proteins embedded in a cell can actually cause human cells to fuse together, forming syncytia/MGCs (multinuclear giant cells). They also have other pathogenic, harmful effects. SARS-CoV- 2’s viroporins, such as its Envelope protein, act as calcium ion channels, introducing calcium into infected cells. The virus suppresses the natural interferon response, resulting in delayed inflammation. SARS-CoV-2 N protein can also directly activate the NLRP3 inflammasome. Also, it suppresses the Nrf2 antioxidant pathway. The suppression of ACE2 by binding with Spike causes a buildup of bradykinin that would otherwise be broken down by ACE2. This constant calcium influx into the cells results in (or is accompanied by) noticeable hypocalcemia, or low blood calcium, especially in people with Vitamin D deficiencies and pre-existing endothelial dysfunction. Bradykinin upregulates cAMP, cGMP, COX, and Phospholipase C activity. This results in prostaglandin release and vastly increased intracellular calcium signaling, which promotes highly aggressive ROS release and ATP depletion. NADPH oxidase releases superoxide into the extracellular space. Superoxide radicals react with nitric oxide to form peroxynitrite. Peroxynitrite reacts with the tetrahydrobiopterin cofactor needed by endothelial nitric oxide synthase, destroying it and “uncoupling” the enzymes, causing nitric oxide synthase to synthesize more superoxide instead. This proceeds in a positive feedback loop until nitric oxide bioavailability in the circulatory system is depleted. Dissolved nitric oxide gas produced constantly by eNOS serves many important functions, but it is also antiviral against SARS-like coronaviruses, preventing the palmitoylation of the viral Spike protein and making it harder for it to bind to host receptors. The loss of NO allows the virus to begin replicating with impunity in the body. Those with endothelial dysfunction (i.e. hypertension, diabetes, obesity, old age, African-American race) have redox equilibrium issues to begin with, giving the virus an advantage. Due to the extreme cytokine release triggered by these processes, the body summons a great deal of neutrophils and monocyte-derived alveolar macrophages to the lungs. Cells of the innate immune system are the first-line defenders against pathogens. They work by engulfing invaders and trying to attack them with enzymes that produce powerful oxidants, like SOD and MPO. Superoxide dismutase takes superoxide and makes hydrogen peroxide, and myeloperoxidase takes hydrogen peroxide and chlorine ions and makes hypochlorous acid, which is many, many times more reactive than sodium hypochlorite bleach. Neutrophils have a nasty trick. They can also eject these enzymes into the extracellular space, where they will continuously spit out peroxide and bleach into the bloodstream. This is called neutrophil extracellular trap formation, or, when it becomes pathogenic and counterproductive, NETosis. In severe and critical COVID-19, there is actually rather severe NETosis. Hypochlorous acid building up in the bloodstream begins to bleach the iron out of heme and compete for O2 binding sites. Red blood cells lose the ability to transport oxygen, causing the sufferer to turn blue in the face. Unliganded iron, hydrogen peroxide, and superoxide in the bloodstream undergo the Haber- Weiss and Fenton reactions, producing extremely reactive hydroxyl radicals that violently strip electrons from surrounding fats and DNA, oxidizing them severely. This condition is not unknown to medical science. The actual name for all of this is acute sepsis. We know this is happening in COVID-19 because people who have died of the disease have noticeable ferroptosis signatures in their tissues, as well as various other oxidative stress markers such as nitrotyrosine, 4-HNE, and malondialdehyde. When you intubate someone with this condition, you are setting off a free radical bomb by supplying the cells with O2. It’s a catch-22, because we need oxygen to make Adenosine Triphosphate (that is, to live), but O2 is also the precursor of all these damaging radicals that lead to lipid peroxidation. The correct treatment for severe COVID-19 related sepsis is non-invasive ventilation, steroids, and antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any benefit whatsoever in rescuing critically-ill COVID-19 patients are antioxidants. N-acetylcysteine, melatonin, fluvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants. Indomethacin prevents iron- driven oxidation of arachidonic acid to isoprostanes. There are powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore oxygenation to the tissues. Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known or surmised much of this since March 2020. In April 2020, Swiss scientists confirmed that COVID-19 was a vascular endotheliitis. By late 2020, experts had already concluded that COVID-19 causes a form of viral sepsis. They also know that sepsis can be effectively treated with antioxidants. None of this information is particularly new, and yet, for the most part, it has not been acted upon. Doctors continue to use damaging intubation techniques with high PEEP settings despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients with medical malpractice. Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford’s ludicrous RECOVERY study, the intervention is too late to have any positive effect. The clinical course of COVID-19 is such that by the time most people seek medical attention for hypoxia, their viral load has already tapered off to almost nothing. If someone is about 10 days post-exposure and has already been symptomatic for five days, there is hardly any virus left in their bodies, only cellular damage and derangement that has initiated a hyperinflammatory response. It is from this group that the clinical trials for antivirals have recruited, pretty much exclusively. In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a delayed hyperinflammatory response, and then absurdly claim that antivirals have no utility in treating or preventing COVID-19. These clinical trials do not recruit people who are pre-symptomatic. They do not test pre-exposure or post-exposure prophylaxis. This is like using a defibrillator to shock only flatline, and then absurdly claiming that defibrillators have no medical utility whatsoever when the patients refuse to rise from the dead. The intervention is too late. These trials for antivirals show systematic, egregious selection bias. They are providing a treatment that is futile to the specific cohort they are enrolling. India went against the instructions of the WHO and mandated the prophylactic usage of Ivermectin. They have almost completely eradicated COVID-19. The Indian Bar Association of Mumbai has brought criminal charges against WHO Chief Scientist Dr. Soumya Swaminathan for recommending against the use of Ivermectin. Ivermectin is not “horse dewormer”. Yes, it is sold in veterinary paste form as a dewormer for animals. It has also been available in pill form for humans for decades, as an antiparasitic drug. The media have disingenuously claimed that because Ivermectin is an antiparasitic drug, it has no utility as an antivirus. This is incorrect. Ivermectin has utility as an antiviral. It blocks importin, preventing nuclear import, effectively inhibiting viral access to cell nuclei. Many drugs currently on the market have multiple modes of action. Ivermectin is one such drug. It is both antiparasitic and antiviral. In Bangladesh, Ivermectin costs $1.80 for an entire 5-day course. Remdesivir, which is toxic to the liver, costs $3,120 for a 5-day course of the drug. Billions of dollars of utterly useless Remdesivir were sold to our governments on the taxpayer’s dime, and it ended up being totally useless for treating hyperinflammatory COVID-19. The media has hardly even covered this at all. The opposition to the use of generic Ivermectin is not based in science. It is purely financially and politically-motivated. An effective non-vaccine intervention would jeopardize the rushed FDA approval of patented vaccines and medicines for which the pharmaceutical industry stands to rake in billions upon billions of dollars in sales on an ongoing basis. The majority of the public are scientifically illiterate and cannot grasp what any of this even means, thanks to a pathetic educational system that has miseducated them. You would be lucky to find 1 in 100 people who have even the faintest clue what any of this actually means. COVID-19 Transmission: COVID-19 is airborne. The WHO carried water for China by claiming that the virus was only droplet- borne. Our own CDC absurdly claimed that it was mostly transmitted by fomite-to-face contact, which, given its rapid spread from Wuhan to the rest of the world, would have been physically impossible. The ridiculous belief in fomite-to-face being a primary mode of transmission led to the use of surface disinfection protocols that wasted time, energy, productivity, and disinfectant. The 6-foot guidelines are absolutely useless. The minimum safe distance to protect oneself from an aerosolized virus is to be 15+ feet away from an infected person, no closer. Realistically, no public transit is safe. Surgical masks do not protect you from aerosols. The virus is too small and the filter media has too large of gaps to filter it out. They may catch respiratory droplets and keep the virus from being expelled by someone who is sick, but they do not filter a cloud of infectious aerosols if someone were to walk into said cloud. The minimum level of protection against this virus is quite literally a P100 respirator, a PAPR/CAPR, or a 40mm NATO CBRN respirator, ideally paired with a full-body tyvek or tychem suit, gloves, and booties, with all the holes and gaps taped. Live SARS-CoV-2 may potentially be detected in sewage outflows, and there may be oral-fecal transmission. During the SARS outbreak in 2003, in the Amoy Gardens incident, hundreds of people were infected by aerosolized fecal matter rising from floor drains in their apartments. COVID-19 Vaccine Dangers: The vaccines for COVID-19 are not sterilizing and do not prevent infection or transmission. They are “leaky” vaccines. This means they remove the evolutionary pressure on the virus to become less lethal. It also means that the vaccinated are perfect carriers. In other words, those who are vaccinated are a threat to the unvaccinated, not the other way around. All of the COVID-19 vaccines currently in use have undergone minimal testing, with highly accelerated clinical trials. Though they appear to limit severe illness, the long-term safety profile of these vaccines remains unknown. Some of these so-called “vaccines” utilize an untested new technology that has never been used in vaccines before. Traditional vaccines use weakened or killed virus to stimulate an immune response. The Moderna and Pfizer-BioNTech vaccines do not. They are purported to consist of an intramuscular shot containing a suspension of lipid nanoparticles filled with messenger RNA. The way they generate an immune response is by fusing with cells in a vaccine recipient’s shoulder, undergoing endocytosis, releasing their mRNA cargo into those cells, and then utilizing the ribosomes in those cells to synthesize modified SARS-CoV-2 Spike proteins in-situ. These modified Spike proteins then migrate to the surface of the cell, where they are anchored in place by a transmembrane domain. The adaptive immune system detects the non-human viral protein being expressed by these cells, and then forms antibodies against that protein. This is purported to confer protection against the virus, by training the adaptive immune system to recognize and produce antibodies against the Spike on the actual virus. The J&J and AstraZeneca vaccines do something similar, but use an adenovirus vector for genetic material delivery instead of a lipid nanoparticle. These vaccines were produced or validated with the aid of fetal cell lines HEK-293 and PER.C6, which people with certain religious convictions may object strongly to. SARS-CoV-2 Spike is a highly pathogenic protein on its own. It is impossible to overstate the danger presented by introducing this protein into the human body. It is claimed by vaccine manufacturers that the vaccine remains in cells in the shoulder, and that SARS- CoV-2 Spike produced and expressed by these cells from the vaccine’s genetic material is harmless and inert, thanks to the insertion of prolines in the Spike sequence to stabilize it in the prefusion conformation, preventing the Spike from becoming active and fusing with other cells. However, a pharmacokinetic study from Japan showed that the lipid nanoparticles and mRNA from the Pfizer vaccine did not stay in the shoulder, and in fact bioaccumulated in many different organs, including the reproductive organs and adrenal glands, meaning that modified Spike is being expressed quite literally all over the place. These lipid nanoparticles may trigger anaphylaxis in an unlucky few, but far more concerning is the unregulated expression of Spike in various somatic cell lines far from the injection site and the unknown consequences of that. Messenger RNA is normally consumed right after it is produced in the body, being translated into a protein by a ribosome. COVID-19 vaccine mRNA is produced outside the body, long before a ribosome translates it. In the meantime, it could accumulate damage if inadequately preserved. When a ribosome attempts to translate a damaged strand of mRNA, it can become stalled. When this happens, the ribosome becomes useless for translating proteins because it now has a piece of mRNA stuck in it, like a lace card in an old punch card reader. The whole thing has to be cleaned up and new ribosomes synthesized to replace it. In cells with low ribosome turnover, like nerve cells, this can lead to reduced protein synthesis, cytopathic effects, and neuropathies. Certain proteins, including SARS-CoV-2 Spike, have proteolytic cleavage sites that are basically like little dotted lines that say “cut here”, which attract a living organism’s own proteases (essentially, molecular scissors) to cut them. There is a possibility that S1 may be proteolytically cleaved from S2, causing active S1 to float away into the bloodstream while leaving the S2 “stalk” embedded in the membrane of the cell that expressed the protein. SARS-CoV-2 Spike has a Superantigenic region (SAg), which may promote extreme inflammation. Anti-Spike antibodies were found in one study to function as autoantibodies and attack the body’s own cells. Those who have been immunized with COVID-19 vaccines have developed blood clots, myocarditis, Guillain-Barre Syndrome, Bell’s Palsy, and multiple sclerosis flares, indicating that the vaccine promotes autoimmune reactions against healthy tissue. SARS-CoV-2 Spike does not only bind to ACE2. It was suspected to have regions that bind to basigin, integrins, neuropilin-1, and bacterial lipopolysaccharides as well. SARS-CoV-2 Spike, on its own, can potentially bind any of these things and act as a ligand for them, triggering unspecified and likely highly inflammatory cellular activity. SARS-CoV-2 Spike contains an unusual PRRA insert that forms a furin cleavage site. Furin is a ubiquitous human protease, making this an ideal property for the Spike to have, giving it a high degree of cell tropism. No wild-type SARS-like coronaviruses related to SARS-CoV-2 possess this feature, making it highly suspicious, and perhaps a sign of human tampering. SARS-CoV-2 Spike has a prion-like domain that enhances its infectiousness. The Spike S1 RBD may bind to heparin-binding proteins and promote amyloid aggregation. In humans, this could lead to Parkinson’s, Lewy Body Dementia, premature Alzheimer’s, or various other neurodegenerative diseases. This is very concerning because SARS-CoV-2 S1 is capable of injuring and penetrating the blood-brain barrier and entering the brain. It is also capable of increasing the permeability of the blood-brain barrier to other molecules. SARS-CoV-2, like other betacoronaviruses, may have Dengue-like ADE, or antibody-dependent enhancement of disease. For those who aren’t aware, some viruses, including betacoronaviruses, have a feature called ADE. There is also something called Original Antigenic Sin, which is the observation that the body prefers to produce antibodies based on previously-encountered strains of a virus over newly- encountered ones. In ADE, antibodies from a previous infection become non-neutralizing due to mutations in the virus’s proteins. These non-neutralizing antibodies then act as trojan horses, allowing live, active virus to be pulled into macrophages through their Fc receptor pathways, allowing the virus to infect immune cells that it would not have been able to infect before. This has been known to happen with Dengue Fever; when someone gets sick with Dengue, recovers, and then contracts a different strain, they can get very, very ill. If someone is vaccinated with mRNA based on the Spike from the initial Wuhan strain of SARS-CoV-2, and then they become infected with a future, mutated strain of the virus, they may become severely ill. In other words, it is possible for vaccines to sensitize someone to disease. There is a precedent for this in recent history. Sanofi’s Dengvaxia vaccine for Dengue failed because it caused immune sensitization in people whose immune systems were Dengue-naive. In mice immunized against SARS-CoV and challenged with the virus, a close relative of SARS-CoV-2, they developed immune sensitization, Th2 immunopathology, and eosinophil infiltration in their lungs. We have been told that SARS-CoV-2 mRNA vaccines cannot be integrated into the human genome, because messenger RNA cannot be turned back into DNA. This is false. There are elements in human cells called LINE-1 retrotransposons, which can indeed integrate mRNA into a human genome by endogenous reverse transcription. Because the mRNA used in the vaccines is stabilized, it hangs around in cells longer, increasing the chances for this to happen. If the gene for SARS-CoV-2 Spike is integrated into a portion of the genome that is not silent and actually expresses a protein, it is possible that people who take this vaccine may continuously express SARS-CoV-2 Spike from their somatic cells for the rest of their lives. By inoculating people with a vaccine that causes their bodies to produce Spike in-situ, they are being inoculated with a pathogenic protein. A toxin that may cause long-term inflammation, heart problems, and a raised risk of cancers. In the long-term, it may also potentially lead to premature neurodegenerative disease. Absolutely nobody should be compelled to take this vaccine under any circumstances, and in actual fact, the vaccination campaign must be stopped immediately. COVID-19 Criminal Conspiracy: The vaccine and the virus were made by the same people. In 2014, there was a moratorium on SARS gain-of-function research that lasted until 2017. This research was not halted. Instead, it was outsourced, with the federal grants being laundered through NGOs. Ralph Baric is a virologist and SARS expert at UNC Chapel Hill in North Carolina. This is who Anthony Fauci was referring to when he insisted, before Congress, that if any gain-of-function research was being conducted, it was being conducted in North Carolina. This was a lie. Anthony Fauci lied before Congress. A felony. Ralph Baric and Shi Zhengli are colleagues and have co-written papers together. Ralph Baric mentored Shi Zhengli in his gain-of-function manipulation techniques, particularly serial passage, which results in a virus that appears as if it originated naturally. In other words, deniable bioweapons. Serial passage in humanized hACE2 mice may have produced something like SARS-CoV-2. The funding for the gain-of-function research being conducted at the Wuhan Institute of Virology came from Peter Daszak. Peter Daszak runs an NGO called EcoHealth Alliance. EcoHealth Alliance received millions of dollars in grant money from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (that is, Anthony Fauci), the Defense Threat Reduction Agency (part of the US Department of Defense), and the United States Agency for International Development. NIH/NIAID contributed a few million dollars, and DTRA and USAID each contributed tens of millions of dollars towards this research. Altogether, it was over a hundred million dollars. EcoHealth Alliance subcontracted these grants to the Wuhan Institute of Virology, a lab in China with a very questionable safety record and poorly trained staff, so that they could conduct gain-of-function research, not in their fancy P4 lab, but in a level-2 lab where technicians wore nothing more sophisticated than perhaps a hairnet, latex gloves, and a surgical mask, instead of the bubble suits used when working with dangerous viruses. Chinese scientists in Wuhan reported being routinely bitten and urinated on by laboratory animals. Why anyone would outsource this dangerous and delicate work to the People’s Republic of China, a country infamous for industrial accidents and massive explosions that have claimed hundreds of lives, is completely beyond me, unless the aim was to start a pandemic on purpose. In November of 2019, three technicians at the Wuhan Institute of Virology developed symptoms consistent with a flu-like illness. Anthony Fauci, Peter Daszak, and Ralph Baric knew at once what had happened, because back channels exist between this laboratory and our scientists and officials. December 12th, 2019, Ralph Baric signed a Material Transfer Agreement (essentially, an NDA) to receive Coronavirus mRNA vaccine-related materials co-owned by Moderna and NIH. It wasn’t until a whole month later, on January 11th, 2020, that China allegedly sent us the sequence to what would become known as SARS-CoV-2. Moderna claims, rather absurdly, that they developed a working vaccine from this sequence in under 48 hours. Stephane Bancel, the current CEO of Moderna, was formerly the CEO of bioMerieux, a French multinational corporation specializing in medical diagnostic tech, founded by one Alain Merieux. Alain Merieux was one of the individuals who was instrumental in the construction of the Wuhan Institute of Virology’s P4 lab. The sequence given as the closest relative to SARS-CoV-2, RaTG13, is not a real virus. It is a forgery. It was made by entering a gene sequence by hand into a database, to create a cover story for the existence of SARS-CoV-2, which is very likely a gain-of-function chimera produced at the Wuhan Institute of Virology and was either leaked by accident or intentionally released. The animal reservoir of SARS-CoV-2 has never been found. This is not a conspiracy “theory”. It is an actual criminal conspiracy, in which people connected to the development of Moderna’s mRNA-1273 are directly connected to the Wuhan Institute of Virology and their gain-of-function research by very few degrees of separation, if any. The paper trail is well- established. The lab-leak theory has been suppressed because pulling that thread leads one to inevitably conclude that there is enough circumstantial evidence to link Moderna, the NIH, the WIV, and both the vaccine and the virus’s creation together. In a sane country, this would have immediately led to the world’s biggest RICO and mass murder case. Anthony Fauci, Peter Daszak, Ralph Baric, Shi Zhengli, and Stephane Bancel, and their accomplices, would have been indicted and prosecuted to the fullest extent of the law. Instead, billions of our tax dollars were awarded to the perpetrators. The FBI raided Allure Medical in Shelby Township north of Detroit for billing insurance for “fraudulent COVID-19 cures”. The treatment they were using? Intravenous Vitamin C. An antioxidant. Which, as described above, is an entirely valid treatment for COVID-19-induced sepsis, and indeed, is now part of the MATH+ protocol advanced by Dr. Paul E. Marik. The FDA banned ranitidine (Zantac) due to supposed NDMA (N-nitrosodimethylamine) contamination. Ranitidine is not only an H2 blocker used as antacid, but also has a powerful antioxidant effect, scavenging hydroxyl radicals. This gives it utility in treating COVID-19. The FDA also attempted to take N-acetylcysteine, a harmless amino acid supplement and antioxidant, off the shelves, compelling Amazon to remove it from their online storefront. This leaves us with a chilling question: did the FDA knowingly suppress antioxidants useful for treating COVID-19 sepsis as part of a criminal conspiracy against the American public? The establishment is cooperating with, and facilitating, the worst criminals in human history, and are actively suppressing non-vaccine treatments and therapies in order to compel us to inject these criminals’ products into our bodies. This is absolutely unacceptable. COVID-19 Vaccine Development and Links to Transhumanism: This section deals with some more speculative aspects of the pandemic and the medical and scientific establishment’s reaction to it, as well as the disturbing links between scientists involved in vaccine research and scientists whose work involved merging nanotechnology with living cells. On June 9th, 2020, Charles Lieber, a Harvard nanotechnology researcher with decades of experience, was indicted by the DOJ for fraud. Charles Lieber received millions of dollars in grant money from the US Department of Defense, specifically the military think tanks DARPA, AFOSR, and ONR, as well as NIH and MITRE. His specialty is the use of silicon nanowires in lieu of patch clamp electrodes to monitor and modulate intracellular activity, something he has been working on at Harvard for the past twenty years. He was claimed to have been working on silicon nanowire batteries in China, but none of his colleagues can recall him ever having worked on battery technology in his life; all of his research deals with bionanotechnology, or the blending of nanotech with living cells. The indictment was over his collaboration with the Wuhan University of Technology. He had double- dipped, against the terms of his DOD grants, and taken money from the PRC’s Thousand Talents plan, a program which the Chinese government uses to bribe Western scientists into sharing proprietary R&D information that can be exploited by the PLA for strategic advantage. Charles Lieber’s own papers describe the use of silicon nanowires for brain-computer interfaces, or “neural lace” technology. His papers describe how neurons can endocytose whole silicon nanowires or parts of them, monitoring and even modulating neuronal activity. Charles Lieber was a colleague of Robert Langer. Together, along with Daniel S. Kohane, they worked on a paper describing artificial tissue scaffolds that could be implanted in a human heart to monitor its activity remotely. Robert Langer, an MIT alumnus and expert in nanotech drug delivery, is one of the co-founders of Moderna. His net worth is now $5.1 billion USD thanks to Moderna’s mRNA-1273 vaccine sales. Both Charles Lieber and Robert Langer’s bibliographies describe, essentially, techniques for human enhancement, i.e. transhumanism. Klaus Schwab, the founder of the World Economic Forum and the architect behind the so-called “Great Reset”, has long spoken of the “blending of biology and machinery” in his books. Since these revelations, it has come to the attention of independent researchers that the COVID-19 vaccines may contain reduced graphene oxide nanoparticles. Japanese researchers have also found unexplained contaminants in COVID-19 vaccines. Graphene oxide is an anxiolytic. It has been shown to reduce the anxiety of laboratory mice when injected into their brains. Indeed, given SARS-CoV-2 Spike’s propensity to compromise the blood-brain barrier and increase its permeability, it is the perfect protein for preparing brain tissue for extravasation of nanoparticles from the bloodstream and into the brain. Graphene is also highly conductive and, in some circumstances, paramagnetic. In 2013, under the Obama administration, DARPA launched the BRAIN Initiative; BRAIN is an acronym for Brain Research Through Advancing Innovative Neurotechnologies®. This program involves the development of brain-computer interface technologies for the military, particularly non-invasive, injectable systems that cause minimal damage to brain tissue when removed. Supposedly, this technology would be used for healing wounded soldiers with traumatic brain injuries, the direct brain control of prosthetic limbs, and even new abilities such as controlling drones with one’s mind. Various methods have been proposed for achieving this, including optogenetics, magnetogenetics, ultrasound, implanted electrodes, and transcranial electromagnetic stimulation. In all instances, the goal is to obtain read or read-write capability over neurons, either by stimulating and probing them, or by rendering them especially sensitive to stimulation and probing. However, the notion of the widespread use of BCI technology, such as Elon Musk’s Neuralink device, raises many concerns over privacy and personal autonomy. Reading from neurons is problematic enough on its own. Wireless brain-computer interfaces may interact with current or future wireless GSM infrastructure, creating neurological data security concerns. A hacker or other malicious actor may compromise such networks to obtain people’s brain data, and then exploit it for nefarious purposes. However, a device capable of writing to human neurons, not just reading from them, presents another, even more serious set of ethical concerns. A BCI that is capable of altering the contents of one’s mind for innocuous purposes, such as projecting a heads-up display onto their brain’s visual center or sending audio into one’s auditory cortex, would also theoretically be capable of altering mood and personality, or perhaps even subjugating someone’s very will, rendering them utterly obedient to authority. This technology would be a tyrant’s wet dream. Imagine soldiers who would shoot their own countrymen without hesitation, or helpless serfs who are satisfied to live in literal dog kennels. BCIs could be used to unscrupulously alter perceptions of basic things such as emotions and values, changing people’s thresholds of satiety, happiness, anger, disgust, and so forth. This is not inconsequential. Someone’s entire regime of behaviors could be altered by a BCI, including such things as suppressing their appetite or desire for virtually anything on Maslow’s Hierarchy of Needs. Anything is possible when you have direct access to someone’s brain and its contents. Someone who is obese could be made to feel disgust at the sight of food. Someone who is involuntarily celibate could have their libido disabled so they don’t even desire sex to begin with. Someone who is racist could be forced to feel delight over cohabiting with people of other races. Someone who is violent could be forced to be meek and submissive. These things might sound good to you if you are a tyrant, but to normal people, the idea of personal autonomy being overridden to such a degree is appalling. For the wealthy, neural laces would be an unequaled boon, giving them the opportunity to enhance their intelligence with neuroprosthetics (i.e. an “exocortex”), and to deliver irresistible commands directly into the minds of their BCI-augmented servants, even physically or sexually abusive commands that they would normally refuse. If the vaccine is a method to surreptitiously introduce an injectable BCI into millions of people without their knowledge or consent, then what we are witnessing is the rise of a tyrannical regime unlike anything ever seen before on the face of this planet, one that fully intends to strip every man, woman, and child of our free will. Our flaws are what make us human. A utopia arrived at by removing people’s free will is not a utopia at all. It is a monomaniacal nightmare. Furthermore, the people who rule over us are Dark Triad types who cannot be trusted with such power. Imagine being beaten and sexually assaulted by a wealthy and powerful psychopath and being forced to smile and laugh over it because your neural lace gives you no choice but to obey your master. The Elites are forging ahead with this technology without giving people any room to question the social or ethical ramifications, or to establish regulatory frameworks that ensure that our personal agency and autonomy will not be overridden by these devices. They do this because they secretly dream of a future where they can treat you worse than an animal and you cannot even fight back. If this evil plan is allowed to continue, it will spell the end of humanity as we know it. Conclusions: The current pandemic was produced and perpetuated by the establishment, through the use of a virus engineered in a PLA-connected Chinese biowarfare laboratory, with the aid of American taxpayer dollars and French expertise. This research was conducted under the absolutely ridiculous euphemism of “gain-of-function” research, which is supposedly carried out in order to determine which viruses have the highest potential for zoonotic spillover and preemptively vaccinate or guard against them. Gain-of-function/gain-of-threat research, a.k.a. “Dual-Use Research of Concern”, or DURC, is bioweapon research by another, friendlier-sounding name, simply to avoid the taboo of calling it what it actually is. It has always been bioweapon research. The people who are conducting this research fully understand that they are taking wild pathogens that are not infectious in humans and making them more infectious, often taking grants from military think tanks encouraging them to do so. These virologists conducting this type of research are enemies of their fellow man, like pyromaniac firefighters. GOF research has never protected anyone from any pandemic. In fact, it has now started one, meaning its utility for preventing pandemics is actually negative. It should have been banned globally, and the lunatics performing it should have been put in straitjackets long ago. Either through a leak or an intentional release from the Wuhan Institute of Virology, a deadly SARS strain is now endemic across the globe, after the WHO and CDC and public officials first downplayed the risks, and then intentionally incited a panic and lockdowns that jeopardized people’s health and their livelihoods. This was then used by the utterly depraved and psychopathic aristocratic class who rule over us as an excuse to coerce people into accepting an injected poison which may be a depopulation agent, a mind control/pacification agent in the form of injectable “smart dust”, or both in one. They believe they can get away with this by weaponizing the social stigma of vaccine refusal. They are incorrect. Their motives are clear and obvious to anyone who has been paying attention. These megalomaniacs have raided the pension funds of the free world. Wall Street is insolvent and has had an ongoing liquidity crisis since the end of 2019. The aim now is to exert total, full-spectrum physical, mental, and financial control over humanity before we realize just how badly we’ve been extorted by these maniacs. The pandemic and its response served multiple purposes for the Elite: Concealing a depression brought on by the usurious plunder of our economies conducted by rentier-capitalists and absentee owners who produce absolutely nothing of any value to society whatsoever. Instead of us having a very predictable Occupy Wall Street Part II, the Elites and their stooges got to stand up on television and paint themselves as wise and all-powerful saviors instead of the marauding cabal of despicable land pirates that they are. Destroying small businesses and eroding the middle class. Transferring trillions of dollars of wealth from the American public and into the pockets of billionaires and special interests. Engaging in insider trading, buying stock in biotech companies and shorting brick-and-mortar businesses and travel companies, with the aim of collapsing face-to-face commerce and tourism and replacing it with e-commerce and servitization. Creating a casus belli for war with China, encouraging us to attack them, wasting American lives and treasure and driving us to the brink of nuclear armageddon. Establishing technological and biosecurity frameworks for population control and technocratic- socialist “smart cities” where everyone’s movements are despotically tracked, all in anticipation of widespread automation, joblessness, and food shortages, by using the false guise of a vaccine to compel cooperation. Any one of these things would constitute a vicious rape of Western society. Taken together, they beggar belief; they are a complete inversion of our most treasured values. What is the purpose of all of this? One can only speculate as to the perpetrators’ motives, however, we have some theories. The Elites are trying to pull up the ladder, erase upward mobility for large segments of the population, cull political opponents and other “undesirables”, and put the remainder of humanity on a tight leash, rationing our access to certain goods and services that they have deemed “high-impact”, such as automobile use, tourism, meat consumption, and so on. Naturally, they will continue to have their own luxuries, as part of a strict caste system akin to feudalism. Why are they doing this? Simple. The Elites are Neo-Malthusians and believe that we are overpopulated and that resource depletion will collapse civilization in a matter of a few short decades. They are not necessarily incorrect in this belief. We are overpopulated, and we are consuming too many resources. However, orchestrating such a gruesome and murderous power grab in response to a looming crisis demonstrates that they have nothing but the utmost contempt for their fellow man. To those who are participating in this disgusting farce without any understanding of what they are doing, we have one word for you. Stop. You are causing irreparable harm to your country and to your fellow citizens. To those who may be reading this warning and have full knowledge and understanding of what they are doing and how it will unjustly harm millions of innocent people, we have a few more words. Damn you to hell. You will not destroy America and the Free World, and you will not have your New World Order. We will make certain of that. *  *  * This PDF document contains 14 pages, followed by another 17 pages of references. For those, please visit the original PDF file at Covid19 – The Spartacus Letter. *  *  * We try to run the Automatic Earth on donations. Since ad revenue has collapsed, you are now not just a reader, but an integral part of the process that builds this site. Thank you for your support. Support the Automatic Earth in virustime. Donate with Paypal, Bitcoin and Patreon. Tyler Durden Mon, 09/27/2021 - 00:00.....»»

Category: dealsSource: nyt3 hr. 15 min. ago

Morgan Stanley: We Are Approaching An Inflection Point In China Policy Easing

Morgan Stanley: We Are Approaching An Inflection Point In China Policy Easing By Chetan Ahya, Chief Economist and Global Head of Economics at Morgan Stanley The past two months have seen successive waves of headlines from China, first on the broad regulatory reset and then this week’s focus on property developers facing near-term funding pressures. The policy goals of these measures are first to ensure social stability and second to make economic growth more sustainable by reducing income inequality and addressing imbalances and excesses. However, they have raised concerns about a potential rise in systemic risks and a sharper slowdown in growth. Investors’ focus has shifted from tech to the property sector, which faces challenges on two fronts. First, property developers are required to adhere to the “three red lines” – maintaining healthy liabilities-to-assets, net gearing and cash-to-short-term debt ratios – which were announced in August 2020. What we are experiencing now is a direct effect of that regulatory action, which aimed to reduce systemic risks with benchmarks to curb excessive property sector borrowing. In addition, property demand in China has slowed in the last two months, as the front-loading of mortgage lending quotas in the first half of the year has weighed on property sales, increasing headwinds for property developers. As things stand, most property developers are on track to comply with the three red lines, but a number face challenges in meeting the mandated ratios. Our China property analyst estimates that the total debt exposure of property developers is around Rmb 18.4 trillion, which is now similar to annual sales. This indicates that leverage in aggregate is manageable – hence, so is the deleveraging process. Nonetheless, the pressure to reduce leverage means that defaults in China's property sector are likely to increase. From past experience, policy-makers have mechanisms in place to prevent systemic risks. For instance, debt restructuring will take place at the holding company level of property developers in default, while operating companies remain in business and construction projects move forward. Credit committees will oversee this process, with representation from the financial regulators, the central bank and local governments. Vis-à-vis the banking system, the property risk exposure of China's banks appears manageable. Development loans totaled 6.9% of banks' total loan balances, and individual developers' loan balances are limited to 0.3% of banks' total loan balance or less. NPL formation has also dropped to multi-year lows in 1H21. In addition, the risks related to peer-to-peer consumer loans and shadow banking credits have largely been addressed over the last three years. Hence, our China financials analyst sees ample room for the domestic banking system to deal with property sector risks this year. The exposure of global investors to the China property sector as holders of the debt or global banks as lenders to the sector is relatively small, which reduces the potential for global systemic risks. While we expect the restructuring process and immediate spillovers to the financial system to be orderly, we are mindful of potential knock-on effects in the broader economy. Although inventory levels are low, the economy will see some downside pressure from weaker housing starts in the near term. The property and adjacent sectors – residential property investment, related services and downstream goods consumption – account for ~15% of China’s GDP. Our chief China economist Robin Xing estimates that a 10pp slowdown in residential property activity could exert a ~1pp drag on GDP growth. Further spillovers could take the form of a negative wealth effect: reduced private consumption, the decline in property investment weighing on fixed asset investment in other upstream manufacturing sectors, and the impact on property sector employment exacerbating weaker consumption. These spillover effects are creating downward pressure on growth at the same time that production cuts to meet energy intensity targets are weighing on growth, the regulatory reset is weighing on corporate sentiment and consumption is softening because of intermittent Covid-related restrictions. We therefore see a risk that spillovers from the property sector would keep 4Q21 growth below 5% on a 2Y CAGR basis. This is a low starting point relative to next year’s growth target of 5.5%. Moreover, a sharper growth slowdown could increase the risk of a material impact on the labour market, which would run counter to the policy objective of ensuring social stability. It is in this context that we expect policy-makers to manage the process and pace of adjustment while providing meaningful countercyclical easing, just as they did in 2H15, 4Q18 and 2H19. Indeed, we think that we are approaching an inflection point in policy easing. Further measures in the pipeline include: faster fiscal spending to support infrastructure projects in September-December; another 50bp RRR cut in mid-to-late October; some easing of mortgage quotas and fine-tuning of production cuts to meet energy intensity targets in 4Q21; and front-loading of loan quotas and local government special bonds in January-February 2022. In the coming weeks, we will be watching for (1) communication from policy-makers on the details of the restructuring plan for property developers, and (2) policy easing signals and announcements. Tyler Durden Sun, 09/26/2021 - 22:00.....»»

Category: personnelSource: nyt5 hr. 31 min. ago

The Importance Of Dune, Part 2: The Jihad

The Importance Of Dune, Part 2: The Jihad Authored by Tom Luongo via Gold, Goats, 'n Guns blog, Read Part 1 here In 2020 I wrote a pair of editorials for the Gold Goats ‘n Guns Newsletter in sympathy to the movie’s original release for last December. This one appeared in November after the (s)election of Joe Biden as U.S. president. I’ve written a lot about the ideas contained in this essay but I felt it appropriate to revisit it now that we’re in the window of seeing our story play out on the big screen, where art still has the possibility of moving us to action. The Jihad “We Fremen have a saying: God created Arrakis to train the faithful. One cannot go against the word of God.” — FRANK HERBERT In my last editorial I talked about why Frank Herbert’s Dune was even more relevant today than when it was published in 1965.  As we approached the election, after re-reading Dune, I made it into Herbert’s sequel, Dune Messiah. And having not read it in thirty years I was amazed at how good it was.  The whole book is about a moment in time that Paul, who can see into the future, cannot see beyond.  The 2020 election felt exactly that way to me. That moment was a singularity, a point we pass through without knowing what lies on the other side.  The parallels were simply too deep for me to ignore.  The trope Herbert used in Dune Messiah has been copied a hundred times since then, but its metaphoric power remains the same. A moment like that turns everything on its head when it happens.  It shattered Paul’s life and ushered in the next period of chaos far deadlier than the last. Dune left us knowing that with the victory over the entrenched, sclerotic power structure of the great houses there would be a religious jihad by the Fremen which would sweep across the galaxy like a plague of killer locusts. That jihad occurred and Paul was powerless to stop it. And, like Paul, this is what I fear is coming. The results of the election confirm for me that what comes next will be a terrible thing.  The Davos Crowd think they have won the war, that they have been successful in defeating the insurgent Trump and his Deplorable sand rats.  They think there are only a few of us vocally leading a loose contingent of conspiracy theorists on the fringe of society who can be easily controlled and marginalized. This was the mistake the establishment made in Dune, thinking the Fremen numbered in the thousands.  In reality, they numbered in the tens of millions and were viciously angry, self-sufficient and disciplined; ready to remake the world and shut off the source of the power, the spice. When Dune was written the spice was a metaphor for oil.  Today information is the currency of the realm, and Davos thinks that by controlling all information flow they can control everything else. But they don’t control the information anymore, even if it looks that way. Because by cheating and creating false value throughout the society, by degrading the quality of the information, they have raised the value of producing real things with real labor to the point of it being existential to their power. And when you marginalize the tens of millions of people who produce the goods which sustain their false reality, when you remove their ability to speak their mind and make their voices heard, when you insult them, berate them, hector them and beat them then you will bear the consequences when the sleeper awakens, in Herbert’s words. This isn’t a threat or an open invitation to violence.  This is an observation of what always comes next.  These people know that they have been lied to, their children spiritually separated from them.  The election was a cruel joke meant to rub our noses in their complete power over us.  You can see it every day on Twitter. What comes next will be nothing short of a Fremen-esque jihad by the 70+ million people who voted for Donald Trump.  If his allies prove the systematic thievery of the election, it will fuel what is now a simmering anger to a violent boiling rage with a near-religious frenzy. They will be fully justified. I get that anger.  I feel it building in me.  Paul saw this coming in Dune and failed in his attempt to control it.  And I can see it coming today. Their Jihad will be joined by the people who didn’t want to win by cheating.  There are millions of them, too.  They voted against Trump but don’t view their neighbors as enemies. The alternative to it is worse, acquiescence and vassalage to a corrupt system.  And that’s why today it’s clear to me this only ends in violence.  The elites had a choice.  They chose poorly. They have their own religious zealots, suffused with the righteous anger at a corrupt system but blaming it on the wrong people, their neighbors.  The people have a choice, stand their ground or be ground into paste.  This is why I feel the only option for Davos when faced with the coming jihad against them will be to unleash a response to it orders of magnitude deadlier than COVID-19.  That’s a moment I, frankly, don’t want to see beyond. *  *  * I think it’s quite clear now that we’re in the middle of that next response. The ‘Jihad’ of angry Trump voters hasn’t quite materialized yet, but it has in other parts of the world. The descent into random violence with brutal Harkonnen police and embedded Sardaukar mercenaries putting down protests in Melbourne, Australia is not only deeply disturbing but, sadly, wholly predictable. The Fremen were trained by Arrakis through privation and extreme thrift imposed on them by the desert to find meaning and beauty in the simplest things. We’re not there yet. But by now brutally imposing vaccination mandates through a terror campaign people have woken up quickly. Because they already saw the problem if they didn’t want to believe it would ever come to this. The sleeper will awaken here in the U.S. The more they take away from us the more it will feed the burning inside. Davos’ Sardaukar are sustained through blood sacrifice and dehumanization, the Harkonnens through good ol’ payola. They serve this system not because they believe in it but because they are fed by it. Australians will begin imposing costs on them that outweigh their comfort and they will collapse. It’s already happening in France. It will happen in Germany this fall. And when the U.S. joins the jihad that’s when the violence gets real. Fat, roid-freaks running around beating old women and unarmed men with gang tactics will turn into massacres, but not for us, for them. They have told us they are no longer negotiating with us. Become subservient or be destroyed. Their call isn’t a bluff but it ultimately is. We have reached that moment today where the choice is clear. Get hard, get in shape, get tough-mined and become #ungovernable or be extinguished. You are not alone. Moments like this take generations to build to. Welcome to Arrakis. *  *  * Join my Patreon if you can see The Jihad forming BTC: 3GSkAe8PhENyMWQb7orjtnJK9VX8mMf7Zf BCH: qq9pvwq26d8fjfk0f6k5mmnn09vzkmeh3sffxd6ryt DCR: DsV2x4kJ4gWCPSpHmS4czbLz2fJNqms78oE LTC: MWWdCHbMmn1yuyMSZX55ENJnQo8DXCFg5k DASH: XjWQKXJuxYzaNV6WMC4zhuQ43uBw8mN4Va WAVES: 3PF58yzAghxPJad5rM44ZpH5fUZJug4kBSa ETH: 0x1dd2e6cddb02e3839700b33e9dd45859344c9edc DGB: SXygreEdaAWESbgW6mG15dgfH6qVUE5FSE Tyler Durden Sun, 09/26/2021 - 20:00.....»»

Category: dealsSource: nyt7 hr. 15 min. ago

Goldman Raises Year-End Oil Price Target To $90

Goldman Raises Year-End Oil Price Target To $90 Just days after Goldman's head commodity analyst Jeff Currie told Bloomberg TV that the bank anticipates oil spiking to $90 if the winter is colder than usual, on Sunday afternoon Goldman went ahead and made that its base case and in a note from energy strategist Damien Courvalin, he writes that with Brent prices reaching new highs since October 2018, the bank now forecasts that this rally will continue, "with our year-end Brent forecast of $90/bbl vs. $80/bbl previously." What tipped the scales is that while Goldman has long held a bullish oil view, "the current global oil supply-demand deficit is larger than we expected, with the recovery in global demand from the Delta impact even faster than our above consensus forecast and with global supply remaining short of our below consensus forecasts." Among the supply factors cited by Goldman is hurricane Ida - the "most bullish hurricane in US history" - which more than offset the ramp-up in OPEC+ production since July with non-OPEC+ non-shale production continuing to disappoint. Meanwhile, as noted above, on the demand side Goldman cited low hospitalization rates which are leading more countries to re-open, including to international travel in particularly COVID-averse countries in Asia. Finally, from a seasonal standpoint, Courvalin sees winter demand risks as "further now squarely skewed to the upside" as the global gas shortage will increase oil fired power generation. From a fundamental standpoint, the current c.4.5 mb/d observable inventory draws are the largest on record, including for global SPRs and oil on water, and follow the longest deficit on record, started in June 2020. For the oil bears, Goldman does not see this deficit as reversing in coming months as its scale will overwhelm both the willingness and ability for OPEC+ to ramp up, with the shale supply response just starting. This sets the stage for inventories to fall to their lowest level since 2013 by year-end (after adjusting for pipeline fill), supporting further backwardation in the oil forward curve where positioning remains low. But what about a production response? While Goldman does expect short-cycle production to respond by 2022 at the bank's higher price forecast, from core-OPEC, Russia and shale, this according to Goldman, will only lay bare the structural nature of the oil market repricing. To be sure, there will likely be a time to be tactically bearish in 2022, especially if a US-Iran deal is eventually reached. The bank's base-case assumption is for such an agreement to be reached in April, leading the bank to then trim its price target to an $80/bbl price forecast in 2Q22-4Q22 (vs. its 4Q21-1Q22 $85/bbl quarterly average forecast). This would, however, remain a tactical call and a likely timespread trade according to Courvalin, with long-dated oil prices poised to reset higher from current levels, especially as the hedging momentum shifts from US producer selling to airline buying (a move which Goldman says to position for with a long Dec-22 Brent and short Dec-22 Brent put trade recommendations).   Meanwhile, the lack of long-cycle capex response - here you can thank the green crazy sweeping the world - the quickly diminishing OPEC spare capacity (Goldman expects normalization by early 2022), the inability for shale producers to sustain production growth (given their low reinvestment rate targets) and oil service and carbon cost inflation will all instead point to the need for sustainably higher long-dated oil prices. Remarkably, Goldman now expects the market to return to a structural deficit by 2H23, which leads it to raise its 2023 oil price forecast from $65/bbl to $85/bbl, and the mid-cycle valuation oil price used by Goldman's equity analysts to $70/bbl. Translation: expect a slew of price hikes on energy stocks in the coming days from Goldman. Finally, where could Goldman's forecast - which would infuriate the white house as gasoline prices are about to explode higher - be wrong? For what it's worth, the bank sees the greatest risk on the timeline of its bullish view. On the demand side, it would take a potentially new variant that renders vaccine ineffective. Beyond that, however, the bank expects limited downside risk from China, with its economists not expecting a hard landing and with our demand growth forecast driven by DMs and other EMs instead. This leaves near-term risks having to come from the supply side, most notably OPEC+, which next meets on October 4. And while an aggressively faster ramp-up in production by year-end would soften (but not derail) our projected deficit, it would only further delay the shale rebound, which would reinforce the structural nature of the next rally given binding under-investment in oil services by 2023. In addition, a large ramp-up in OPEC+ production would simply fast-forward the decline in global spare capacity to historically low levels, replacing a cyclical tight market with a structural one. The full report as usual available to pro subscribers in the usual place. Tyler Durden Sun, 09/26/2021 - 20:36.....»»

Category: dealsSource: nyt7 hr. 15 min. ago

30 Facts You Need To Know: A COVID Cribsheet

30 Facts You Need To Know: A COVID Cribsheet Authored by Kit Knightly via Off-Guardian.org, You asked for it, so we made it. A collection of all the arguments you’ll ever need. We get a lot of e-mails and private messages along these lines “do you have a source for X?” or “can you point me to mask studies?” or “I know I saw a graph for mortality, but I can’t find it anymore”. And we understand, it’s been a long 18 months, and there are so many statistics and numbers to try and keep straight in your head. So, to deal with all these requests, we decided to make a bullet-pointed and sourced list for all the key points. A one-stop-shop. Here are key facts and sources about the alleged “pandemic”, that will help you get a grasp on what has happened to the world since January 2020, and help you enlighten any of your friends who might be still trapped in the New Normal fog: “Covid deaths” – Lockdowns – PCR Tests – “asymptomatic infection” – Ventilators – Masks – Vaccines – Deception & Foreknowledge *  *  * PART I: “COVID DEATHS” & MORTALITY 1. The survival rate of “Covid” is over 99%. Government medical experts went out of their way to underline, from the beginning of the pandemic, that the vast majority of the population are not in any danger from Covid. Almost all studies on the infection-fatality ratio (IFR) of Covid have returned results between 0.04% and 0.5%. Meaning Covid’s survival rate is at least 99.5%. * 2. There has been NO unusual excess mortality. The press has called 2020 the UK’s “deadliest year since world war two”, but this is misleading because it ignores the massive increase in the population since that time. A more reasonable statistical measure of mortality is Age-Standardised Mortality Rate (ASMR): By this measure, 2020 isn’t even the worst year for mortality since 2000, In fact since 1943 only 9 years have been better than 2020. Similarly, in the US the ASMR for 2020 is only at 2004 levels: For a detailed breakdown of how Covid affected mortality across Western Europe and the US click here. What increases in mortality we have seen could be attributable to non-Covid causes [facts 7, 9 & 19]. * 3. “Covid death” counts are artificially inflated. Countries around the globe have been defining a “Covid death” as a “death by any cause within 28/30/60 days of a positive test”. Healthcare officials from Italy, Germany, the UK, US, Northern Ireland and others have all admitted to this practice: Removing any distinction between dying of Covid, and dying of something else after testing positive for Covid will naturally lead to over-counting of “Covid deaths”. British pathologist Dr John Lee was warning of this “substantial over-estimate” as early as last spring. Other mainstream sources have reported it, too. Considering the huge percentage of “asymptomatic” Covid infections [14], the well-known prevalence of serious comorbidities [fact 4] and the potential for false-positive tests [fact 18], this renders the Covid death numbers an extremely unreliable statistic. * 4. The vast majority of covid deaths have serious comorbidities. In March 2020, the Italian government published statistics showing 99.2% of their “Covid deaths” had at least one serious comorbidity. These included cancer, heart disease, dementia, Alzheimer’s, kidney failure and diabetes (among others). Over 50% of them had three or more serious pre-existing conditions. This pattern has held up in all other countries over the course of the “pandemic”. An October 2020 FOIA request to the UK’s ONS revealed less than 10% of the official “Covid death” count at that time had Covid as the sole cause of death. * 5. Average age of “Covid death” is greater than the average life expectancy. The average age of a “Covid death” in the UK is 82.5 years. In Italy it’s 86. Germany, 83. Switzerland, 86. Canada, 86. The US, 78, Australia, 82. In almost all cases the median age of a “Covid death” is higher than the national life expectancy. As such, for most of the world, the “pandemic” has had little-to-no impact on life expectancy. Contrast this with the Spanish flu, which saw a 28% drop in life expectancy in the US in just over a year. [source] * 6. Covid mortality exactly mirrors the natural mortality curve. Statistical studies from the UK and India have shown that the curve for “Covid death” follows the curve for expected mortality almost exactly: The risk of death “from Covid” follows, almost exactly, your background risk of death in general. The small increase for some of the older age groups can be accounted for by other factors.[facts 7, 9 & 19] * 7. There has been a massive increase in the use of “unlawful” DNRs. Watchdogs and government agencies have reported huge increases in the use of Do Not Resuscitate Orders (DNRs) over the last twenty months. In the US, hospitals considered “universal DNRs” for any patient who tested positive for Covid, and whistleblowing nurses have admitted the DNR system was abused in New York. In the UK there was an “unprecdented” rise in “illegal” DNRs for disabled people, GP surgeries sent out letters to non-terminal patients recommending they sign DNR orders, whilst other doctors signed “blanket DNRs” for entire nursing homes. A study done by Sheffield Univerisity found over one-third of all “suspected” Covid patients had a DNR attached to their file within 24 hours of hospital admission. Blanket use of coerced or illegal DNR orders could account for any increases in mortality in 2020/21.[Facts 2 & 6] *  *  * PART II: LOCKDOWNS 8. Lockdowns do not prevent the spread of disease. There is little to no evidence lockdowns have any impact on limiting “Covid deaths”. If you compare regions that locked down to regions that did not, you can see no pattern at all. “Covid deaths” in Florida (no lockdown) vs California (lockdown) “Covid deaths” in Sweden (no lockdown) vs UK (lockdown) * 9. Lockdowns kill people. There is strong evidence that lockdowns – through social, economic and other public health damage – are deadlier than the “virus”. Dr David Nabarro, World Health Organization special envoy for Covid-19 described lockdowns as a “global catastrophe” in October 2020: We in the World Health Organization do not advocate lockdowns as the primary means of control of the virus[…] it seems we may have a doubling of world poverty by next year. We may well have at least a doubling of child malnutrition […] This is a terrible, ghastly global catastrophe.” A UN report from April 2020 warned of 100,000s of children being killed by the economic impact of lockdowns, while tens of millions more face possible poverty and famine. Unemployment, poverty, suicide, alcoholism, drug use and other social/mental health crises are spiking all over the world. While missed and delayed surgeries and screenings are going to see increased mortality from heart disease, cancer et al. in the near future. The impact of lockdown would account for the small increases in excess mortality [Facts 2 & 6] * 10. Hospitals were never unusually over-burdened. the main argument used to defend lockdowns is that “flattening the curve” would prevent a rapid influx of cases and protect healthcare systems from collapse. But most healthcare systems were never close to collapse at all. In March 2020 it was reported that hospitals in Spain and Italy were over-flowing with patients, but this happens every flu season. In 2017 Spanish hospitals were at 200% capacity, and 2015 saw patients sleeping in corridors. A paper JAMA paper from March 2020 found that Italian hospitals “typically run at 85-90% capacity in the winter months”. In the UK, the NHS is regularly stretched to breaking point over the winter. As part of their Covid policy, the NHS announced in Spring of 2020 that they would be “re-organizing hospital capacity in new ways to treat Covid and non-Covid patients separately” and that “as result hospitals will experience capacity pressures at lower overall occupancy rates than would previously have been the case.” This means they removed thousands of beds. During an alleged deadly pandemic, they reduced the maximum occupancy of hospitals. Despite this, the NHS never felt pressure beyond your typical flu season, and at times actually had 4x more empty beds than normal. In both the UK and US millions were spent on temporary emergency hospitals that were never used. *  *  * PART III: PCR TESTS 11. PCR tests were not designed to diagnose illness. The Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) test is described in the media as the “gold standard” for Covid diagnosis. But the Nobel Prize-winning inventor of the process never intended it to be used as a diagnostic tool, and said so publicly: PCR is just a process that allows you to make a whole lot of something out of something. It doesn’t tell you that you are sick, or that the thing that you ended up with was going to hurt you or anything like that.” * 12. PCR Tests have a history of being inaccurate and unreliable. The “gold standard” PCR tests for Covid are known to produce a lot of false-positive results, by reacting to DNA material that is not specific to Sars-Cov-2. A Chinese study found the same patient could get two different results from the same test on the same day. In Germany, tests are known to have reacted to common cold viruses. A 2006 study found PCR tests for one virus responded to other viruses too. In 2007, a reliance on PCR tests resulted in an “outbreak” of Whooping Cough that never actually existed. Some tests in the US even reacted to the negative control sample. The late President of Tanzania, John Magufuli, submitted samples goat, pawpaw and motor oil for PCR testing, all came back positive for the virus. As early as February of 2020 experts were admitting the test was unreliable. Dr Wang Cheng, president of the Chinese Academy of Medical Sciences told Chinese state television “The accuracy of the tests is only 30-50%”. The Australian government’s own website claimed “There is limited evidence available to assess the accuracy and clinical utility of available COVID-19 tests.” And a Portuguese court ruled that PCR tests were “unreliable” and should not be used for diagnosis. You can read detailed breakdowns of the failings of PCR tests here, here and here. * 13. The CT values of the PCR tests are too high. PCR tests are run in cycles, the number of cycles you use to get your result is known as your “cycle threshold” or CT value. Kary Mullis said: “If you have to go more than 40 cycles[…]there is something seriously wrong with your PCR.” The MIQE PCR guidelines agree, stating: “[CT] values higher than 40 are suspect because of the implied low efficiency and generally should not be reported,” Dr Fauci himself even admitted anything over 35 cycles is almost never culturable. Dr Juliet Morrison, virologist at the University of California, Riverside, told the New York Times: Any test with a cycle threshold above 35 is too sensitive…I’m shocked that people would think that 40 [cycles] could represent a positive…A more reasonable cutoff would be 30 to 35″. In the same article Dr Michael Mina, of the Harvard School of Public Health, said the limit should be 30, and the author goes on to point out that reducing the CT from 40 to 30 would have reduced “covid cases” in some states by as much as 90%. The CDC’s own data suggests no sample over 33 cycles could be cultured, and Germany’s Robert Koch Institute says nothing over 30 cycles is likely to be infectious. Despite this, it is known almost all the labs in the US are running their tests at least 37 cycles and sometimes as high as 45. The NHS “standard operating procedure” for PCR tests rules set the limit at 40 cycles. Based on what we know about the CT values, the majority of PCR test results are at best questionable. * 14. The World Health Organization (Twice) Admitted PCR tests produced false positives. In December 2020 WHO put out a briefing memo on the PCR process instructing labs to be wary of high CT values causing false positive results: when specimens return a high Ct value, it means that many cycles were required to detect virus. In some circumstances, the distinction between background noise and actual presence of the target virus is difficult to ascertain. Then, in January 2021, the WHO released another memo, this time warning that “asymptomatic” positive PCR tests should be re-tested because they might be false positives: Where test results do not correspond with the clinical presentation, a new specimen should be taken and retested using the same or different NAT technology. * 15. The scientific basis for Covid tests is questionable. The genome of the Sars-Cov-2 virus was supposedly sequenced by Chinese scientists in December 2019, then published on January 10th 2020. Less than two weeks later, German virologists (Christian Drosten et al.) had allegedly used the genome to create assays for PCR tests. They wrote a paper, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, which was submitted for publication on January 21st 2020, and then accepted on January 22nd. Meaning the paper was allegedly “peer-reviewed” in less than 24 hours. A process that typically takes weeks. Since then, a consortium of over forty life scientists has petitioned for the withdrawal of the paper, writing a lengthy report detailing 10 major errors in the paper’s methodology. They have also requested the release of the journal’s peer-review report, to prove the paper really did pass through the peer-review process. The journal has yet to comply. The Corman-Drosten assays are the root of every Covid PCR test in the world. If the paper is questionable, every PCR test is also questionable. *  *  * PART IV: “ASYMPTOMATIC INFECTION” 16. The majority of Covid infections are “asymptomatic”. From as early as March 2020, studies done in Italy were suggesting 50-75% of positive Covid tests had no symptoms. Another UK study from August 2020 found as much as 86% of “Covid patients” experienced no viral symptoms at all. It is literally impossible to tell the difference between an “asymptomatic case” and a false-positive test result. * 17. There is very little evidence supporting the alleged danger of “asymptomatic transmission”. In June 2020, Dr Maria Van Kerkhove, head of the WHO’s emerging diseases and zoonosis unit, said: From the data we have, it still seems to be rare that an asymptomatic person actually transmits onward to a secondary individual,” A meta-analysis of Covid studies, published by Journal of the American Medical Association (JAMA) in December 2020, found that asymptomatic carriers had a less than 1% chance of infecting people within their household. Another study, done on influenza in 2009, found: …limited evidence to suggest the importance of [asymptomatic] transmission. The role of asymptomatic or presymptomatic influenza-infected individuals in disease transmission may have been overestimated…” Given the known flaws of the PCR tests, many “asymptomatic cases” may be false positives.[fact 14] *  *  * PART V: VENTILATORS 18. Ventilation is NOT a treatment for respiratory viruses. Mechanical ventilation is not, and never has been, recommended treatment for respiratory infection of any kind. In the early days of the pandemic, many doctors came forward questioning the use of ventilators to treat “Covid”. Writing in The Spectator, Dr Matt Strauss stated: Ventilators do not cure any disease. They can fill your lungs with air when you find yourself unable to do so yourself. They are associated with lung diseases in the public’s consciousness, but this is not in fact their most common or most appropriate application. German Pulmonologist Dr Thomas Voshaar, chairman of Association of Pneumatological Clinics said: When we read the first studies and reports from China and Italy, we immediately asked ourselves why intubation was so common there. This contradicted our clinical experience with viral pneumonia. Despite this, the WHO, CDC, ECDC and NHS all “recommended” Covid patients be ventilated instead of using non-invasive methods. This was not a medical policy designed to best treat the patients, but rather to reduce the hypothetical spread of Covid by preventing patients from exhaling aerosol droplets. * 19. Ventilators killed people. Putting someone who is suffering from influenza, pneumonia, chronic obstructive pulmonary disease, or any other condition which restricts breathing or affects the lungs, will not alleviate any of those symptoms. In fact, it will almost certainly make it worse, and will kill many of them. Intubation tubes are a source of potential a infection known as “ventilator-associated pneumonia”, which studies show affects up to 28% of all people put on ventilators, and kills 20-55% of those infected. Mechanical ventilation is also damaging to the physical structure of the lungs, resulting in “ventilator-induced lung injury”, which can dramatically impact quality of life, and even result in death. Experts estimate 40-50% of ventilated patients die, regardless of their disease. Around the world, between 66 and 86% of all “Covid patients” put on ventilators died. According to the “undercover nurse”, ventilators were being used so improperly in New York, they were destroying patients’ lungs: This policy was negligence at best, and potentially deliberate murder at worst. This misuse of ventilators could account for any increase in mortality in 2020/21 [Facts 2 & 6] *  *  * PART VI: MASKS 20. Masks don’t work. At least a dozen scientific studies have shown that masks do nothing to stop the spread of respiratory viruses. One meta-analysis published by the CDC in May 2020 found “no significant reduction in influenza transmission with the use of face masks”. Another study with over 8000 subjects found masks “did not seem to be effective against laboratory-confirmed viral respiratory infections nor against clinical respiratory infection.” There are literally too many to quote them all, but you can read them: [1][2][3][4][5][6][7][8][9][10] Or read a summary by SPR here. While some studies have been done claiming to show mask do work for Covid, they are all seriously flawed. One relied on self-reported surveys as data. Another was so badly designed a panel of experts demand it be withdrawn. A third was withdrawn after its predictions proved entirely incorrect. The WHO commissioned their own meta-analysis in the Lancet, but that study looked only at N95 masks and only in hospitals. [For full run down on the bad data in this study click here.] Aside from scientific evidence, there’s plenty of real-world evidence that masks do nothing to halt the spread of disease. For example, North Dakota and South Dakota had near-identical case figures, despite one having a mask-mandate and the other not: In Kansas, counties without mask mandates actually had fewer Covid “cases” than counties with mask mandates. And despite masks being very common in Japan, they had their worst flu outbreak in decades in 2019. * 21. Masks are bad for your health. Wearing a mask for long periods, wearing the same mask more than once, and other aspects of cloth masks can be bad for your health. A long study on the detrimental effects of mask-wearing was recently published by the International Journal of Environmental Research and Public Health Dr. James Meehan reported in August 2020 he was seeing increases in bacterial pneumonia, fungal infections, facial rashes . Masks are also known to contain plastic microfibers, which damage the lungs when inhaled and may be potentially carcinogenic. Childen wearing masks encourages mouth-breathing, which results in facial deformities. People around the world have passed out due to CO2 poisoning while wearing their masks, and some children in China even suffered sudden cardiac arrest. * 22. Masks are bad for the planet. Millions upon millions of disposable masks have been used per month for over a year. A report from the UN found the Covid19 pandemic will likely result in plastic waste more than doubling in the next few years., and the vast majority of that is face masks. The report goes on to warn these masks (and other medical waste) will clog sewage and irrigation systems, which will have knock on effects on public health, irrigation and agriculture. A study from the University of Swansea found “heavy metals and plastic fibres were released when throw-away masks were submerged in water.” These materials are toxic to both people and wildlife. *  *  * PART VII: VACCINES 23. Covid “vaccines” are totally unprecedented. Before 2020 no successful vaccine against a human coronavirus had ever been developed. Since then we have allegedly made 20 of them in 18 months. Scientists have been trying to develop a SARS and MERS vaccine for years with little success. Some of the failed SARS vaccines actually caused hypersensitivity to the SARS virus. Meaning that vaccinated mice could potentially get the disease more severely than unvaccinated mice. Another attempt caused liver damage in ferrets. While traditional vaccines work by exposing the body to a weakened strain of the microorganism responsible for causing the disease, these new Covid vaccines are mRNA vaccines. mRNA (messenger ribonucleic acid) vaccines theoretically work by injecting viral mRNA into the body, where it replicates inside your cells and encourages your body to recognise, and make antigens for, the “spike proteins” of the virus. They have been the subject of research since the 1990s, but before 2020 no mRNA vaccine was ever approved for use. * 24. Vaccines do not confer immunity or prevent transmission. It is readily admitted that Covid “vaccines” do not confer immunity from infection and do not prevent you from passing the disease onto others. Indeed, an article in the British Medical Journal highlighted that the vaccine studies were not designed to even try and assess if the “vaccines” limited transmission. The vaccine manufacturers themselves, upon releasing the untested mRNA gene therapies, were quite clear their product’s “efficacy” was based on “reducing the severity of symptoms”. * 25. The vaccines were rushed and have unknown longterm effects. Vaccine development is a slow, laborious process. Usually, from development through testing and finally being approved for public use takes many years. The various vaccines for Covid were all developed and approved in less than a year. Obviously there can be no long-term safety data on chemicals which are less than a year old. Pfizer even admit this is true in the leaked supply contract between the pharmaceutical giant, and the government of Albania: the long-term effects and efficacy of the Vaccine are not currently known and that there may be adverse effects of the Vaccine that are not currently known Further, none of the vaccines have been subject to proper trials. Many of them skipped early-stage trials entirely, and the late-stage human trials have either not been peer-reviewed, have not released their data, will not finish until 2023 or were abandoned after “severe adverse effects”. * 26. Vaccine manufacturers have been granted legal indemnity should they cause harm. The USA’s Public Readiness and Emergency Preparedness Act (PREP) grants immunity until at least 2024. The EU’s product licensing law does the same, and there are reports of confidential liability clauses in the contracts the EU signed with vaccine manufacturers. The UK went even further, granting permanent legal indemnity to the government, and any employees thereof, for any harm done when a patient is being treated for Covid19 or “suspected Covid19”. Again, the leaked Albanian contract suggests that Pfizer, at least, made this indemnity a standard demand of supplying Covid vaccines: Purchaser hereby agrees to indemnify, defend and hold harmless Pfizer […] from and against any and all suits, claims, actions, demands, losses, damages, liabilities, settlements, penalties, fines, costs and expenses *  *  * PART VIII: DECEPTION & FOREKNOWLEDGE 27. The EU was preparing “vaccine passports” at least a YEAR before the pandemic began. Proposed COVID countermeasures, presented to the public as improvised emergency measures, have existed since before the emergence of the disease. Two EU documents published in 2018, the “2018 State of Vaccine Confidence” and a technical report titled “Designing and implementing an immunisation information system” discussed the plausibility of an EU-wide vaccination monitoring system. These documents were combined into the 2019 “Vaccination Roadmap”, which (among other things) established a “feasibility study” on vaccine passports to begin in 2019 and finish in 2021: This report’s final conclusions were released to the public in September 2019, just a month before Event 201 (below). * 28. A “training exercise” predicted the pandemic just weeks before it started. In October 2019 the World Economic Forum and Johns Hopkins University held Event 201. This was a training exercise based on a zoonotic coronavirus starting a worldwide pandemic. The exercise was sponsored by the Bill and Melinda Gates Foundation and GAVI the vaccine alliance. The exercise published its findings and recommendations in November 2019 as a “call to action”. One month later, China recorded their first case of “Covid”. * 29. Since the beginning of 2020, the Flu has “disappeared”. In the United States, since Februart 2020, influenza cases have allegedly dropped by over 98%. It’s not just the US either, globally flu has apparently almost completely disappeared. Meanwhile, a new disease called “Covid”, which has identical symptoms and a similar mortality rate to influenza, is supposedly sweeping the globe. * 30. The elite have made fortunes during the pandemic. Since the beginning of lockdown the wealthiest people have become significantly wealthier. Forbes reported that 40 new billionaires have been created “fighting the coronavirus”, with 9 of them being vaccine manufacturers. Business Insider reported that “billionaires saw their net worth increase by half a trillion dollars” by October 2020. Clearly that number will be even bigger by now. *  *  * These are the vital facts of the pandemic, presented here as a resource to help formulate and support your arguments with friends or strangers. Thanks to all the researchers who have collated and collected this information over the last twenty months, especially Swiss Policy Research. Tyler Durden Sun, 09/26/2021 - 07:00.....»»

Category: personnelSource: nyt19 hr. 3 min. ago

"A More Difficult Backdrop Is Emerging": 5 Reasons Why Goldman Is Starting To Turn Bearish

"A More Difficult Backdrop Is Emerging": 5 Reasons Why Goldman Is Starting To Turn Bearish Last week's remarkable bounce in stocks from Monday's lows which, as a reminder, prompted the first outflow from equities in 2021... ... has sparked many questions among Wall Street's elite where even some of the biggest bulls are puzzled by the market's violent reversal (which, however, was predicted correctly by flow-tracking quants like Nomura's Charlie McElligott). And it's not just the market's relentless ability to internalize any adverse market action and come out on top as a wave of BTFDers rushes in: as Goldman's strategist Chris Hussey wrote late on Friday, "one thing that is increasingly drawing our attention and was 'front and center' this week is how the economy, policy, and earnings growth appear to be rapidly transitioning away from the initial post-pandemic explosion of accommodation and activity and towards a slower pace as the brakes are pressed on a variety of key parts of the growth machine." As Hussey further notes, growth is fine for now and even robust, with Goldman's economists forecasting over 4.5% GDP growth forecast to extend into 2022, but as he cautions "a developed economy like the US cannot grow at a 9% pace for very long --even as it catches up out of a pandemic." Meanwhile, as he delineates below, a series of pieces may be falling into place to 'tap the brakes' on some of the torrid growth we have been seeing since vaccines were distributed earlier this year. Among these Goldman focuses on the impact of fading stimulus, supply chains, the virus, China, and even stock valuations which are "coalescing to create a more difficult backdrop for earnings growth and multiple expansion in the months, or at least years ahead." Here are a few observations on all 5 of these potentially "braking" factors: 1. Stimulus. The FOMC indicated that tapering ‘may soon be warranted’ at this week’s meeting and on the back of the statement, yields on 10-year Treasuries have risen 15 bp to 1.45% while front-end rates have reset notably higher as shown in the chart below. Interestingly, stocks also rose on the back of the Fed statement, consolidating the rebound from Monday's sell-off. And while the Fed has not done anything yet -- only suggested it is about to -- the wheels do seem to now be in place to wind down the central bank's latest QE program and to eventually start raising rates -- as soon as one year from now. Adding to this point, BofA's Michael Hartnett notes that global tapering has begun (ECB, BoE, BoC, RBA, Fed) which will see a sharp drop in global central liquidity which was $8.5 trillion in 2020, shrinks to $2.1trillion in 2021, and will be just $0.1 in 2022 (putting this in context, since the COVID outbreak central banks have bought $800MM of assets every hour, a number which shrinks to.....»»

Category: smallbizSource: nytSep 25th, 2021

"Immunity As A Service" - The Snake-Oil Salesmen & The COVID-Zero Con

"Immunity As A Service" - The Snake-Oil Salesmen & The COVID-Zero Con Authored by Julius Ruechel via Julius Ruechel.com, The Snake-Oil Salesmen and the COVID-Zero Con: A Classic Bait-And-Switch for a Lifetime of Booster Shots (Immunity as a Service) If a plumber with a lifetime of experience were to tell you that water runs uphill, you would know he is lying and that the lie is not accidental. It is a lie with a purpose. If you can also demonstrate that the plumber knows in advance that the product he is promoting with that lie is snake oil, you have evidence for a deliberate con. And once you understand what's really inside that bottle of snake oil, you will begin to understand the purpose of the con. One of the most common reasons given for mass COVID vaccinations is the idea that if we reach herd immunity through vaccination, we can starve the virus out of existence and get our lives back. It's the COVID-Zero strategy or some variant of it. By now it is abundantly clear from the epidemiological data that the vaccinated are able to both catch and spread the disease. Clearly vaccination isn't going to make this virus disappear. Only a mind that has lost its grasp on reality can fail to see how ridiculous all this has become.  But a tour through pre-COVID science demonstrates that, from day one, long before you and I had even heard of this virus, it was 100% inevitable and 100% predictable that these vaccines would never be capable of eradicating this coronavirus and would never lead to any kind of lasting herd immunity. Even worse, lockdowns and mass vaccination have created a dangerous set of circumstances that interferes with our immune system's ability to protect us against other respiratory viruses. They also risk driving the evolution of this virus towards mutations that are more dangerous to both the vaccinated and the unvaccinated alike. Lockdowns, mass vaccinations, and mass booster shots were never capable of delivering on any of the promises that were made to the public.  And yet, vaccination has been successfully used to control measles and even to eradicate smallpox. So, why not COVID? Immunity is immunity, and a virus is a virus is a virus, right? Wrong! Reality is far more complicated... and more interesting. This Deep Dive exposes why, from day one, the promise of COVID-Zero can only ever have been a deliberately dishonest shell game designed to prey on a lack of public understanding of how our immune systems work and on how most respiratory viruses differ from other viruses that we routinely vaccinate against. We have been sold a fantasy designed to rope us into a pharmaceutical dependency as a deceitful trade-off for access to our lives. Variant by variant. For as long as the public is willing to go along for the ride.  Exposing this story does not require incriminating emails or whistleblower testimony. The story tells itself by diving into the long-established science that every single virologist, immunologist, evolutionary biologist, vaccine developer, and public health official had access to long before COVID began. As is so often the case, the devil is hidden in the details. As this story unfolds it will become clear that the one-two punch of lockdowns and the promise of vaccines as an exit strategy began as a cynical marketing ploy to coerce us into a never-ending regimen of annual booster shots intentionally designed to replace the natural "antivirus security updates" against respiratory viruses that come from hugs and handshakes and from children laughing together at school. We are being played for fools.  This is not to say that there aren't plenty of other opportunists taking advantage of this crisis to pursue other agendas and to tip society into a full-blown police state. One thing quickly morphs into another. But this essay demonstrates that never-ending boosters were the initial motive for this global social-engineering shell game ― the subscription-based business model, adapted for the pharmaceutical industry. "Immunity as a service".  So, let's dive into the fascinating world of immune systems, viruses, and vaccines, layer by layer, to dispel the myths and false expectations that have been created by deceitful public health officials, pharmaceutical lobbyists, and media manipulators. What emerges as the lies are peeled apart is both surprising and more than a little alarming. “Once you eliminate the impossible, whatever remains, no matter how improbable, must be the truth.” - Sherlock Homes”  - Sir Arthur Conan Doyle Table of Contents:     Viral Reservoirs: The Fantasy of Eradication     SARS: The Exception to the Rule?     Fast Mutations: The Fantasy of Control through Herd Immunity     Blind Faith in Central Planning: The Fantasy of Timely Doses     Spiked: The Fantasy of Preventing Infection     Antibodies, B-Cells, and T-Cells: Why Immunity to Respiratory Viruses Fades So Quickly     Manufacturing Dangerous Variants: Virus Mutations Under Lockdown Conditions — Lessons from the 1918 Spanish Flu     Leaky Vaccines, Antibody-Dependent Enhancement, and the Marek Effect     Anti-Virus Security Updates: Cross-Reactive Immunity Through Repeated Exposure     The Not-So-Novel Novel Virus: The Diamond Princess Cruise Ship Outbreak Proved We Have Cross-Reactive Immunity     Mother Knows Best: Vitamin D, Playing in Puddles, and Sweaters     The Paradox: Why COVID-Zero Makes People More Vulnerable to Other Viruses     Introducing Immunity as a Service - A Subscription-Based Business Model for the Pharmaceutical Industry (It was always about the money!)     The Path Forward: Neutralizing the Threat and Bullet-Proofing Society to Prevent This Ever Happening Again. *  *  * Viral Reservoirs: The Fantasy of Eradication Eradication of a killer virus sounds like a noble goal. In some cases it is, such as in the case of the smallpox virus. By 1980 we stopped vaccinating against smallpox because, thanks to widespread immunization, we starved the virus of available hosts for so long that it died out. No-one will need to risk their life on the side effects of a smallpox vaccination ever again because the virus is gone. It is a public health success story. Polio will hopefully be next ― we're getting close.  But smallpox is one of only two viruses (along with rinderpest) that have been eradicated thanks to vaccination. Very few diseases meet the necessary criteria. Eradication is hard and only appropriate for very specific families of viruses. Smallpox made sense for eradication because it was a uniquely human virus ― there was no animal reservoir. By contrast, most respiratory viruses including SARS-CoV-2 (a.k.a. COVID) come from animal reservoirs: swine, birds, bats, etc. As long as there are bats in caves, birds in ponds, pigs in mud baths, and deer living in forests, respiratory viruses are only controllable through individual immunity, but it is not possible to eradicate them. There will always be a near-identical cousin brewing in the wings. Even the current strain of COVID is already cheerfully jumping onwards across species boundaries. According to both National Geographic and Nature magazine, 40% of wild deer tested positive for COVID antibodies in a study conducted in Michigan, Illinois, New York, and Pennsylvania. It has also been documented in wild mink and has already made the species jump to other captive animals including dogs, cats, otters, leopards, tigers, and gorillas. A lot of viruses are not fussy. They happily adapt to new opportunities. Specialists, like smallpox, eventually go extinct. Generalists, like most respiratory viruses, never run out of hosts to keep the infection cycle going, forever. As long as we share this planet with other animals, it is extremely deceitful to give anyone the impression that we can pursue any scorched earth policy that can put this genie back in the bottle. With an outbreak on this global scale, it was clear that we were always going to have to live with this virus. There are over 200 other endemic respiratory viruses that cause colds and flus, many of which circulate freely between humans and other animals. Now there are 201. They will be with us forever, whether we like it or not. SARS: The Exception to the Rule? This all sounds well and good, but the original SARS virus did disappear, with public health measures like contact tracing and strict quarantine measures taking the credit. However, SARS was the exception to the rule. When it made the species jump to humans, it was so poorly adapted to its new human hosts that it had terrible difficulty spreading. This very poor level of adaptation gave SARS a rather unique combination of properties: SARS was extremely difficult to catch (it was never very contagious) SARS made people extremely sick. SARS did not have pre-symptomatic spread. These three conditions made the SARS outbreak easy to control through contact tracing and through the quarantine of symptomatic individuals. SARS therefore never reached the point where it circulated widely among asymptomatic community members.  By contrast, by January/February of 2020 it was clear from experiences in China, Italy, and the outbreak on the Diamond Princess cruise ship (more on that story later) that the unique combination of conditions that made SARS controllable were not going to be the case with COVID. COVID was quite contagious (its rapid spread showed that COVID was already well adapted to spreading easily among its new human hosts), most people would have mild or no symptoms from COVID (making containment impossible), and that it was spreading by aerosols produced by both symptomatic and pre-symptomatic people (making contact tracing a joke). In other words, it was clear by January/February 2020 that this pandemic would follow the normal rules of a readily transmissible respiratory epidemic, which cannot be reined in the way SARS was. Thus, by January/February of 2020, giving the public the impression that the SARS experience could be replicated for COVID was a deliberate lie - this genie was never going back inside the bottle. Fast Mutations: The Fantasy of Control through Herd Immunity Once a reasonably contagious respiratory virus begins circulating widely in a community, herd immunity can never be maintained for very long. RNA respiratory viruses (such as influenza viruses, respiratory syncytial virus (RSV), rhinoviruses, and coronaviruses) all mutate extremely fast compared to viruses like smallpox, measles, or polio. Understanding the difference between something like measles and a virus like COVID is key to understanding the con that is being perpetrated by our health institutions. Bear with me here, I promise not to get too technical. All viruses survive by creating copies of themselves. And there are always a lot of "imperfect copies" — mutations — produced by the copying process itself. Among RNA respiratory viruses these mutations stack up so quickly that there is rapid genetic drift, which continually produces new strains. Variants are normal. Variants are expected. Variants make it virtually impossible to build the impenetrable wall of long-lasting herd immunity required to starve these respiratory viruses out of existence. That's one of several reasons why flu vaccines don't provide long-lasting immunity and have to be repeated annually ― our immune system constantly needs to be updated to keep pace with the inevitable evolution of countless unnamed "variants."  This never-ending conveyor belt of mutations means that everyone's immunity to COVID was always only going to be temporary and only offer partial cross-reactive protection against future re-infections. Thus, from day one, COVID vaccination was always doomed to the same fate as the flu vaccine ― a lifelong regimen of annual booster shots to try to keep pace with "variants" for those unwilling to expose themselves to the risk of a natural infection. And the hope that by the time the vaccines (and their booster shots) roll off the production line, they won't already be out of date when confronted by the current generation of virus mutations.  Genetic drift caused by mutations is much slower in viruses like measles, polio, or smallpox, which is why herd immunity can be used to control these other viruses (or even eradicate them as in the case of smallpox or polio). The reason the common respiratory viruses have such rapid genetic drift compared to these other viruses has much less to do with how many errors are produced during the copying process and much more to do with how many of those "imperfect" copies are actually able to survive and produce more copies.  A simple virus with an uncomplicated attack strategy for taking over host cells can tolerate a lot more mutations than a complex virus with a complicated attack strategy. Complexity and specialization put limits on how many of those imperfect copies have a chance at becoming successful mutations. Simple machinery doesn't break down as easily if there is an imperfection in the mechanical parts. Complicated high-tech machinery will simply not work if there are even minor flaws in precision parts. For example, before a virus can hijack the DNA of a host cell to begin making copies of itself, the virus needs to unlock the cell wall to gain entry. Cellular walls are made of proteins and are coated by sugars; viruses need to find a way to create a doorway through that protein wall. A virus like influenza uses a very simple strategy to get inside ― it locks onto one of the sugars on the outside of the cell wall in order to piggyback a ride as the sugar is absorbed into the cell (cells use sugar as their energy source). It's such a simple strategy that it allows the influenza virus to go through lots of mutations without losing its ability to gain entry to the cell. Influenza's simplicity makes it very adaptable and allows many different types of mutations to thrive as long as they all use the same piggyback entry strategy to get inside host cells. By contrast, something like the measles virus uses a highly specialized and very complicated strategy to gain entry to a host cell. It relies on very specialized surface proteins to break open a doorway into the host cell. It's a very rigid and complex system that doesn't leave a lot of room for errors in the copying process. Even minor mutations to the measles virus will cause changes to its surface proteins, leaving it unable to gain access to a host cell to make more copies of itself. Thus, even if there are lots of mutations, those mutations are almost all evolutionary dead ends, thus preventing genetic drift. That's one of several reasons why both a natural infection and vaccination against measles creates lifetime immunity ― immunity lasts because new variations don't change much over time.  Most RNA respiratory viruses have a high rate of genetic drift because they all rely on relatively simple attack strategies to gain entry to host cells. This allows mutations to stack up quickly without becoming evolutionary dead ends because they avoid the evolutionary trap of complexity.  Coronaviruses use a different strategy than influenza to gain access to host cells. They have proteins on the virus surface (the infamous S-spike protein, the same one that is mimicked by the vaccine injection), which latches onto a receptor on the cell surface (the ACE2 receptor) ― a kind of key to unlock the door. This attack strategy is a little bit more complicated than the system used by influenza, which is probably why genetic drift in coronaviruses is slightly slower than in influenza, but it is still a much much simpler and much less specialized system than the one used by measles. Coronaviruses, like other respiratory viruses, are therefore constantly producing a never-ending conveyor belt of "variants" that make long-lasting herd immunity impossible. Variants are normal. The alarm raised by our public health authorities about "variants" and the feigned compassion of pharmaceutical companies as they rush to develop fresh boosters capable of fighting variants is a charade, much like expressing surprise about the sun rising in the East. Once you got immunity to smallpox, measles, or polio, you had full protection for a few decades and were protected against severe illness or death for the rest of your life. But for fast-mutating respiratory viruses, including coronaviruses, within a few months they are sufficiently different that your previously acquired immunity will only ever offer partial protection against your next exposure. The fast rate of mutation ensures that you never catch the exact same cold or flu twice, just their closely related constantly evolving cousins. What keeps you from feeling the full brunt of each new infection is cross-reactive immunity, which is another part of the story of how you are being conned, which I will come back to shortly.  Blind Faith in Central Planning: The Fantasy of Timely Doses But let's pretend for a moment that a miraculous vaccine could be developed that could give us all 100% sterilizing immunity today. The length of time it takes to manufacture and ship 8 billion doses (and then make vaccination appointments for 8 billion people) ensures that by the time the last person gets their last dose, the never-ending conveyor belt of mutations will have already rendered the vaccine partially ineffective. True sterilizing immunity simply won't ever happen with coronaviruses. The logistics of rolling out vaccines to 8 billion people meant that none of our vaccine makers or public health authorities ever could have genuinely believed that vaccines would create lasting herd immunity against COVID. So, for a multitude of reasons, it was a deliberate lie to give the public the impression that if enough people take the vaccine, it would create lasting herd immunity. It was 100% certain, from day one, that by the time the last dose is administered, the rapid evolution of the virus would ensure that it would already be time to start thinking about booster shots. Exactly like the flu shot. Exactly the opposite of a measles vaccine. Vaccines against respiratory viruses can never provide anything more than a temporary cross-reactive immunity "update" ― they are merely a synthetic replacement for your annual natural exposure to the smorgasbord of cold and flu viruses. Immunity as a service, imposed on society by trickery. The only question was always, how long between booster shots? Weeks, months, years?  Feeling conned yet? Spiked: The Fantasy of Preventing Infection The current crop of COVID vaccines was never designed to provide sterilizing immunity - that's not how they work. They are merely a tool designed to teach the immune system to attack the S-spike protein, thereby priming the immune system to reduce the severity of infection in preparation for your inevitable future encounter with the real virus. They were never capable of preventing infection, nor of preventing spread. They were merely designed to reduce your chance of being hospitalized or dying if you are infected. As former FDA commissioner Scott Gottlieb, who is on Pfizer’s board, said: "the original premise behind these vaccines were [sic] that they would substantially reduce the risk of death and severe disease and hospitalization. And that was the data that came out of the initial clinical trials.” Every first-year medical student knows that you cannot get herd immunity from a vaccine that does not stop infection.  In other words, by their design, these vaccines can neither stop you from catching an infection nor stop you from transmitting the infection to someone else. They were never capable of creating herd immunity. They were designed to protect individuals against severe outcomes if they choose to take them - a tool to provide temporary focused protection for the vulnerable, just like the flu vaccine. Pushing for mass vaccination was a con from day one. And the idea of using vaccine passports to separate the vaccinated from the unvaccinated was also a con from day one. The only impact these vaccine passports have on the pandemic is as a coercive tool to get you to roll up your sleeve. Nothing more. Antibodies, B-Cells, and T-Cells: Why Immunity to Respiratory Viruses Fades So Quickly There are multiple interconnected parts to why immunity to COVID, or any other respiratory virus, is always only temporary. Not only is the virus constantly mutating but immunity itself fades over time, not unlike the way our brains start forgetting how to do complicated math problems unless they keep practicing. This is true for both immunity acquired through natural infection and immunity acquired through vaccination. Our immune systems have a kind of immunological memory ― basically, how long does your immune system remember how to launch an attack against a specific kind of threat. That memory fades over time. For some vaccines, like diphtheria and tetanus, that immunological memory fades very slowly. The measles vaccine protects for life. But for others, like the flu vaccine, that immunological memory fades very quickly. On average, the flu vaccine is only about 40% effective to begin with. And it begins to fade almost immediately after vaccination. By about 150 days (5 months), it reaches zero. Fading immunity after flu shot (Science, April 18th, 2019) The solution to this strange phenomenon lies in the different types of immune system responses that are triggered by a vaccine (or by exposure to the real thing through a natural infection). This has big implications for coronavirus vaccines, but I'll get to that in a moment. First a little background information... A good analogy is to think of our immune system like a medieval army. The first layer of protection began with generalists - guys armed with clubs that would take a swing at everything - they were good for keeping robbers and brigands at bay and for conducting small skirmishes. But if the attack was bigger, then these generalists were quickly overwhelmed, serving as arrow fodder to blunt the attack on the more specialized troops coming up behind them. Spearmen, swordsmen, archers, cavalry, catapult operators, siege tower engineers, and so on. Each additional layer of defense has a more expensive kit and takes ever greater amounts of time to train (an English longbowman took years to build up the necessary skill and strength to become effective). The more specialized a troop is, the more you want to hold them back from the fight unless it's absolutely necessary because they are expensive to train, expensive to deploy, and make a bigger mess when they fight that needs to be cleaned up afterwards. Always keep your powder dry. Send in the arrow fodder first and slowly ramp up your efforts from there. Our immune system relies on a similar kind of layered system of defense. In addition to various non-specific rapid response layers that take out the brigands, like natural killer cells, macrophages, mast cells, and so on, we also have many adaptive (specialized) layers of antibodies (i.e. IgA, IgG, IgM immunoglobulin) and various types of highly specialized white blood cells, like B-cells and T-cells. Some antibodies are released by regular B-cells. Others are released by blood plasma. Then there are memory B-cells, which are capable of remembering previous threats and creating new antibodies long after the original antibodies fade away. And there are various types of T-cells (again with various degrees of immunological memory), like natural killer T-cells, killer T-cells, and helper T-cells, all of which play various roles in detecting and neutralizing invaders. In short, the greater the threat, the more troops are called into the fight. This is clearly a gross oversimplification of all the different interconnected parts of our immune system, but the point is that a mild infection doesn't trigger as many layers whereas a severe infection enlists the help of deeper layers, which are slower to respond but are much more specialized in their attack capabilities. And if those deeper adaptive layers get involved, they are capable of retaining a memory of the threat in order to be able to mount a quicker attack if a repeat attack is recognized in the future. That's why someone who was infected by the dangerous Spanish Flu in 1918 might still have measurable T-cell immunity a century later but the mild bout of winter flu you had a couple of years ago might not have triggered T-cell immunity, even though both may have been caused by versions of the same H1N1 influenza virus. As a rule of thumb, the broader the immune response, the longer immunological memory will last. Antibodies fade in a matter of months, whereas B-cell and T-cell immunity can last a lifetime. Another rule of thumb is that a higher viral load puts more strain on your immune defenses, thus overwhelming the rapid response layers and forcing the immune system to enlist the deeper adaptive layers. That's why nursing homes and hospitals are more dangerous places for vulnerable people than backyard barbeques. That's why feedlot cattle are more vulnerable to viral diseases than cattle on pasture. Viral load matters a lot to how easily the generalist layers are overwhelmed and how much effort your immune system has to make to neutralize a threat. Where the infection happens in the body also matters. For example, an infection in the upper respiratory tract triggers much less involvement from your adaptive immune system than when it reaches your lungs. Part of this is because your upper respiratory tract is already heavily preloaded with large numbers of generalist immunological cells that are designed to attack germs as they enter, which is why most colds and flus never make it deeper into the lungs. The guys with the clubs are capable of handling most of the threats that try to make through the gate. Most of the specialized troops hold back unless they are needed. Catching a dangerous disease like measles produces lifetime immunity because an infection triggers all the deep layers that will retain a memory of how to fight off future encounters with the virus. So does the measles vaccine. Catching a cold or mild flu generally does not.  From an evolutionary point of view, this actually makes a lot of sense. Why waste valuable resources developing long-lasting immunity (i.e. training archers and building catapults) to defend against a virus that did not put you in mortal danger. A far better evolutionary strategy is to evolve a narrower generalist immune response to mild infections (i.e. most cold and flu viruses), which fades quickly once the threat is conquered, but invest in deep long-term broad-based immunity to dangerous infections, which lasts a very long time in case that threat is ever spotted on the horizon again. Considering the huge number of threats our immune systems face, this strategy avoids the trap of spreading immunological memory too thin. Our immunological memory resources are not limitless - long-term survival requires prioritizing our immunological resources. The take-home lesson is that vaccines will, at best, only last as long as immunity acquired through natural infection and will often fade much faster because the vaccine is often only able to trigger a partial immune response compared to the actual infection. So, if the disease itself doesn't produce a broad-based immune response leading to long-lasting immunity, neither will the vaccine. And in most cases, immunity acquired through vaccination will begin to fade much sooner than immunity acquired through a natural infection. Every vaccine maker and public health official knows this despite bizarrely claiming that the COVID vaccines (based on re-creating the S-protein spike instead of using a whole virus) would somehow become the exception to the rule. That was a lie, and they knew it from day one. That should set your alarm bells ringing at full throttle. So, with this little bit of background knowledge under our belts, let's look at what our public health officials and vaccine makers would have known in advance about coronaviruses and coronavirus vaccines when they told us back in the early Spring of 2020 that COVID vaccines were the path back to normality. From a 2003 study [my emphasis]: "Until SARS appeared, human coronaviruses were known as the cause of 15–30% of colds... Colds are generally mild, self-limited infections, and significant increases in neutralizing antibody titer are found in nasal secretions and serum after infection. Nevertheless, some unlucky individuals can be reinfected with the same coronavirus soon after recovery and get symptoms again." In other words, the coronaviruses involved in colds (there were four human coronaviruses before SARS, MERS, and COVID) all trigger such a weak immune response that they do not lead to any long-lasting immunity whatsoever. And why would they if, for most of us, the threat is so minimal that the generalists are perfectly capable of neutralizing the attack. We also know that immunity against coronaviruses is not durable in other animals either. As any farmer knows well, cycles of reinfection with coronaviruses are the rule rather than the exception among their livestock (for example, coronaviruses are a common cause of pneumonia and various types of diarrheal diseases like scours, shipping fever, and winter dysentery in cattle). Annual farm vaccination schedules are therefore designed accordingly. The lack of long-term immunity to coronaviruses is well documented in veterinary research among cattle, poultry, deer, water buffalo, etc. Furthermore, although animal coronavirus vaccines have been on the market for many years, it is well known that "none are completely efficacious in animals". So, like the fading flu vaccine profile I showed you earlier, none of the animal coronavirus vaccines are capable of providing sterilizing immunity (none were capable of stopping 100% of infections, without which you can never achieve herd immunity) and the partial immunity they offered is well known to fade rather quickly. What about immunity to COVID's close cousin, the deadly SARS coronavirus, which had an 11% case fatality rate during the 2003 outbreak? From a 2007 study: "SARS-specific antibodies were maintained for an average of 2 years... SARS patients might be susceptible to reinfection >3 years after initial exposure."  (Bear in mind that, as with all diseases, re-infection does not mean you are necessarily going to get full-blown SARS; fading immunity after a natural infection tends to offer at least some level of partial protection against severe outcomes for a considerable amount of time after you can already be reinfected and spread it to others - more on that later.) And what about MERS, the deadliest coronavirus to date, which made the jump from camels in 2012 and had a fatality rate of around 35%? It triggered the broadest immune response (due to its severity) and also appears to trigger the longest lasting immunity as a result (> 6yrs) Thus, to pretend that there was any chance that herd immunity to COVID would be anything but short-lived was dishonest at best. For most people, immunity was always going to fade quickly. Just like what happens after most other respiratory virus infections. By February 2020, the epidemiological data showed clearly that for most people COVID was a mild coronavirus (nowhere near as severe than SARS or MERS), so it was virtually a certainty that even the immunity from a natural infection would fade within months, not years. It was also a certainty that vaccination was therefore, at best, only ever going to provide partial protection and that this protection would be temporary, lasting on the order of months. This is a case of false and misleading advertising if there ever was one. If I can allow my farming roots to shine through for a moment, I'd like to explain the implications of what was known about animal coronaviruses vaccines. Baby calves are often vaccinated against bovine coronaviral diarrhea shortly after birth if they are born in the spring mud and slush season, but not if they are born in midsummer on lush pastures where the risk of infection is lower. Likewise, bovine coronavirus vaccines are used to protect cattle before they face stressful conditions during shipping, in a feedlot, or in winter feed pens. Animal coronavirus vaccines are thus used as tools to provide a temporary boost in immunity, in very specific conditions, and only for very specific vulnerable categories of animals. After everything I've laid out so far in this text, the targeted use of bovine coronavirus vaccines should surprise no-one. Pretending that our human coronavirus vaccines would be different was nonsense.  The only rational reason why the WHO and public health officials would withhold all that contextual information from the public as they rolled out lockdowns and held forth vaccines as an exit strategy was to whip the public into irrational fear in order to be able to make a dishonest case for mass vaccination when they should have, at most, been focused on providing focused vaccination of the most vulnerable only. That deception was the Trojan Horse to introduce endless mass booster shots as immunity inevitably fades and as new variants replace old ones.  Now, as all the inevitable limitations and problems with these vaccines become apparent (i.e. fading of vaccine-induced immunity, vaccines proving to only be partially effective, the rise of new variants, and the vaccinated population demonstrably catching and spreading the virus ― a.k.a. the leaky vaccine phenomenon), the surprise that our health authorities are showing simply isn't credible. As I have shown you, all this was 100% to be expected. They intentionally weaponized fear and false expectations to unleash a fraudulent bait-and-switch racket of global proportions. Immunity on demand, forever. Manufacturing Dangerous Variants: Virus Mutations Under Lockdown Conditions — Lessons from the 1918 Spanish Flu At this point you may be wondering, if there is no lasting immunity from infection or vaccination, then are public health officials right to roll out booster shots to protect us from severe outcomes even if their dishonest methods to get us to accept them were unethical? Do we need a lifetime regimen of booster shots to keep us safe from a beast to which we cannot develop durable long-term immunity? The short answer is no.  Contrary to what you might think, the rapid evolution of RNA respiratory viruses actually has several important benefits for us as their involuntary hosts, which protects us without the benefit of broad lifelong immunity. One of those benefits has to do with the natural evolution of the virus towards less dangerous variants. The other is the cross-reactive immunity that comes from frequent re-exposure to closely related "cousins". I'm going to peel apart both of these topics in order to show you the remarkable system that nature designed to keep us safe... and to show you how the policies being forced on us by our public health authorities are knowingly interfering with this system. They are creating a dangerous situation that increases our risk to other respiratory viruses (not just to COVID) and may even push the COVID virus to evolve to become more dangerous to both the unvaccinated and the vaccinated. There are growing signs that this nightmare scenario has already begun.  “In this present crisis, government is not the solution to our problem; government is the problem."  - President Ronald Reagan in 1981. Let's start with the evolutionary pressures that normally drive viruses towards becoming less dangerous over time. A virus depends on its host to spread it. A lively host is more useful than a bedridden or dead one because a lively host can spread the virus further and will still be around to catch future mutations. Viruses risk becoming evolutionary dead ends if they kill or immobilize their hosts. Plagues came, killed, and then were starved out of existence because their surviving hosts had all acquired herd immunity. Colds come and go every year because their hosts are lively, easily spread the viruses around, and never acquire long-lasting immunity so that last year's hosts can also serve as next year's hosts ― only those who have weak immune systems have much to worry about. In other words, under normal conditions, mutations that are more contagious but less deadly have a survival advantage over less contagious and more deadly variations. From the virus' point of view, the evolutionary golden mean is reached when it can easily infect as many hosts as possible without reducing their mobility and without triggering long-term immunity in most of their hosts. That's the ticket to setting up a sustainable cycle of reinfection, forever. Viruses with slow genetic drift and highly specialized reproductive strategies, like polio or measles, can take centuries or longer to become less deadly and more contagious; some may never reach the relatively harmless status of a cold or mild flu virus (by harmless I mean harmless to the majority of the population despite being extremely dangerous to those with weak or compromised immune systems). But for viruses with fast genetic drift, like respiratory viruses, even a few months can make a dramatic difference. Rapid genetic drift is one of the reasons why the Spanish Flu stopped being a monster disease, but polio and measles haven't. And anyone with training in virology or immunology understands this!  We often speak of evolutionary pressure as though it forces an organism to adapt. In reality, a simple organism like a virus is utterly blind to its environment — all it does is blindly produce genetic copies of itself. "Evolutionary pressure" is actually just a fancy way of saying that environmental conditions will determine which of those millions of copies survives long enough to produce even more copies of itself.  A human adapts to its environment by altering its behaviour (that's one type of adaptation). But the behaviour of a single viral particle never changes. A virus "adapts" over time because some genetic copies with one set of mutations survive and spread faster than other copies with a different set of mutations. Adaptation in viruses has to be seen exclusively through the lens of changes from one generation of virus to the next based on which mutations have a competitive edge over others. And that competitive edge will vary depending on the kinds of environmental conditions a virus encounters. So, fear mongering about the Delta variant being even more contagious leaves out the fact that this is exactly what you would expect as a respiratory virus adapts to its new host species. We would expect new variants to be more contagious but less deadly as the virus fades to become just like the other 200+ respiratory viruses that cause common colds and flus.  That's also why the decision to lock down the healthy population is so sinister. Lockdowns, border closures, and social distancing rules reduced spread among the healthy population, thus creating a situation where mutations produced among the healthy would become sufficiently rare that they might be outnumbered by mutations circulating among the bedridden. Mutations circulating among the healthy are, by definition, going to be the least dangerous mutations since they did not make their hosts s.....»»

Category: blogSource: zerohedgeSep 25th, 2021

The 6 best treadmills of 2021

An at-home treadmill allows you to improve your cardio, keep fit, and stay healthy. Here are the best treadmills we've tested this year. Table of Contents: Masthead Sticky Treadmills offer an excellent way to increase or maintain your routine cardio and keep fit. The most important qualities to look for in a treadmill are its power, reliability, and run comfort. Our top pick, the ProForm Pro 2000, features iFit workouts, has a cushioned tread, and easily folds up. Few exercise machines have endured the changing landscape of at-home fitness like the treadmill. Not only do they work well for anyone maintaining cardio fitness but they also help runners prepare for things like 5Ks or half marathons. They can even complement a weekly workout routine, especially for those who don't have time to run outside.Treadmills are also simple to use. You simply run or walk on the belt and a motor moves it under your feet at whatever speed you select. Some offer high-tech features like touchscreen displays and live-streamed classes, while others offer a more basic, just-hop-on-and-run experience.As a frequent gym-goer and the Insider Reviews fitness editor, I've run more miles than I can count on treadmills advanced, basic, or otherwise. For every mile logged on something like NordicTrack's Commercial 2950 or ProForm's Pro 2000, I've logged an equal amount (if not many more) on the standard treadmills found at a local gym - i.e. one without an interactive screen attached to it.I leaned on this experience to comb through and test a number of high-quality treadmills currently available. The following guide features a range of treadmill types at various price points in hopes of helping you find the best option for your fitness needs.You'll also find answers to a selection of treadmill FAQs, as well as some insight into how I tested treadmills featured in this guide. Here are the best treadmills 0f 2021 Best overall: ProForm Pro 2000 TreadmillBest smart treadmill: NordicTrack Commercial 2950Best on a budget: Horizon Fitness T101-04 TreadmillBest upright folding model: LifeSpan TR3000i Folding TreadmillBest compact: Cubii ProBest for quiet workouts: 3G Cardio Elite Runner Treadmill How I test treadmills Alyssa Powell/Business Insider Each treadmill featured in this guide went through a series of extensive tests (i.e. I ran on them a lot) to see how well they compared across these four categories: Performance, features, quality, and value. Here's how the categories specifically factored into which treadmills made the cut:Performance: How a treadmill performs comes down to a few basic aspects, including how comfortable it is to run on (and how shock absorbing it is), if it's able to avoid sounding like you're loudly pounding the ground with each step, what its tread feels like underfoot, and how wide the running area is. Though not all treadmills reliably check each of these boxes, a healthy combination of at least three of those often translates to high quality. Features: Some modern treadmills, like those from NordicTrack or ProForm, feature a built-in interactive screen that streams workouts, tracks output metrics, and improves the treadmill's performance. For models that don't have a screen, I looked at how intuitive it was to increase and decrease the treadmill's speed and whether it offered an incline or decline mode. Even those that aren't decked out with the ability to stream workouts are still feature-heavy enough to warrant a spot in your home gym.Quality: If used often, treadmills can take a consistent beating, mostly due to a runner pounding on it step after step after step. This means the best treadmills should feature a sturdy and durable tread, a high-quality design that won't become compromised even after a full year or more of use, and that features an interface or series of buttons and dials that can avoid popping off or being unusable. Value: The value of a treadmill is less about its sticker price and more so the combination of the three categories above compared to its initial (and sometimes recurring) investment. I factored in everything when selecting treadmills across each featured category and often feel that it's worth it to spend a little more money on a product that's designed to last than to spend less, more often on something inferior.  The best treadmill overall ProForm The ProForm Pro 2000 Treadmill is a race-trainers dream that's versatile enough for the casual runner, too. Pros: Good motor, large running belt of 22 by 60 inches, includes both an incline and a decline setting, offers good interval training features, has access to iFit workoutsCons: Customer service may be disappointing if you have problems, very heavy treadmillRunners looking for a treadmill with good all-around training capabilities and a host of useful features will like the reasonably-priced ProForm Pro 2000 Treadmill. It has a 3.5-horsepower motor, which allows it to stand up to daily use, and it boasts a belt deck that measures 22 by 60 inches, which is perfect for most runners. When you're training for races with hills, you'll appreciate this treadmill's ability to reach a 15% incline and a 3% decline, which better simulates hills than most other treadmills — it's easy to adjust it both up and down, too, even while running. The ProForm Pro 2000 also has a number of tech features, including a 7-inch screen that streams iFit's interactive workouts, a music port for iPods, and a built-in fan that works well to keep you (somewhat) cool as you run. Its tread features what the brand calls ProShox Cushioning, which is designed to lessen the impact on your feet and knees while running. Though a true, long-term test of this would better judge its viability, even a handful of runs on it showed that this made a difference (even if it was minimal). What truly makes this treadmill stand out is its inclusion of the above-mentioned iFit workouts. Not only are these excellent ways to keep motivated, but the platform offers some genuinely unique workouts. One day you could be running through France and the next through Vietnam. The globe-spanning locales add a level of quality to the workouts you'd have a hard time finding elsewhere.Another perk of the iFit workouts is how the trainers leading the runs entirely control the incline, decline, and speed, allowing you to focus strictly on running. This is something that's incredibly welcome as fumbling with a treadmill's controls while in a full stride isn't always the most fun (and can easily mess with your cadence). The ProForm Pro 2000 comes with one free year of iFit, too, so you won't have to worry about shelling out a monthly payment for at least 12 months.Its price is also in the range of what you'd expect to pay for a full-featured treadmill. Most interactive workout machines run in the $2,000 range, and the fact this undercuts that average by a few hundred dollars makes it an appealing choice for anyone looking to add a treadmill to their home gym. The best smart treadmill NordicTrack NordicTrack's Commercial 2950 is a highly versatile treadmill that offers automatic incline control, an HD 22-inch touchscreen, and a deep library of interactive classes from iFit. Pros: Now features automatically adjusting resistance and speed, the iFit library offers a wide range of in-studio classes and runs through real-world locales, offers Bluetooth connectivity and WiFi supportCons: ExpensiveThe Commercial 2950 treadmill from NordicTrack is one of the most full-featured machines I've tested, coming with everything from automatic incline control and Bluetooth connectivity to Google Maps integration and personalized workout stats. My favorite feature, however, is its access to iFit's expansive library of interactive workouts. With iFit, you're able to run essentially anywhere, yet still from the comfort of your home. The service's roster of trainers offers a wide range of run types that aren't just confined to a studio or their home (where they do film some of the classes). Rather, you could be running through real-world locales that offer a breath of fresh air from standard treadmill routines. I found this to be a welcome deviation from the tediousness of normal running. Though iFit does cost $39 per month, a free year of the service comes standard with the purchase of all new treadmills.In addition to those workouts, the rest of the 2950 is a premium. The automatically adjusting resistance feature mentioned above is a game-changer, and, as the name suggests, allows the trainers to fully control the incline, decline, and speed of the treadmill as you run along. All you have to worry about is just running — which does well to keep you focused and motivated instead of worrying about fumbling with controls. One nitpick could be that the iFit interface can be a little clunky and slow to use sometimes, and the service occasionally crashed mid-workout (though did tend to load right back up in the exact same spot I was running). This didn't happen enough to be concerning, nor did it detract from my overall experience. What holds the 2950 back from nabbing the top spot in this guide is its price, which is roughly double the cost of the ProForm Pro 200. It's hard for treadmills that have as much as the 2950 in terms of features and available workouts to cost much less than $2,500, so this is still a worthwhile investment for anyone who  certainly isn't cheap but few treadmills with this much to offer both in terms of features and available workouts will necessarily be "affordable." Still, it's worth the investment for those who want access to a huge library of interactive classes and a premium-built treadmill.  The best budget treadmill Horizon Fitness Compared to other budget fold-up treadmills, the Horizon Fitness T101-04 Treadmill has nice features and good performance.Pros: Very good price point for an entry-level treadmill, will save space with a fold-up design, runs quieter than most budget-priced treadmills, works better for walkers and light runnersCons: Only a 55-inch belt length, not really made for high-end running workouts, longevity is questionableSaving space with a fold-up treadmill is a great idea for a lot of people. However, most fold-up treadmills don't offer a lot of power.With those natural limitations of fold-up treadmills in mind, you'll like the Horizon Fitness T101-04 Treadmill, which works well for walkers and anyone on a budget (and isn't really made for runners looking for high-end workouts). Think of it as like an entry-level treadmill, or something that can be a complement to a wider range of at-home equipment. It has a 55-inch belt length, a maximum 10 mph speed, and a 2.25-horsepower motor. The T101-04 treadmill is easy to fold up for storage, which is great for anyone with minimal space in their home or apartment.You can't beat the value, too. If you want something simple, straightforward, and cost-effective that has the basic features necessary for just running and walking, the T101-04 from Horizon Fitness is the treadmill you need. The best upright folding treadmill LifeSpan The LifeSpan TR3000i uses an extensive shock absorption system to take some pressure off your joints while running.Pros: Good price for a mid-range treadmill, unit folds up to save storage space, extensive shock absorption system, good feature set versus other models in this price rangeCons: Not really designed for high-end workouts, build quality of treadmill is questionableSome people dislike working out on a treadmill because of the pressure it places on their joints. The LifeSpan TR3000i attempts to alleviate some of this pressure by using a shock absorption system in the treadmill's deck.It has a 20 x 56-inch running surface, 15 incline levels, and a 6-inch LCD screen that shows your time, calories, distance covered, steps, heart rate, speed, and incline. The eight shock absorber elements in the deck ensure that it remains both stable and comfortable to run on. As mentioned on other models, long-term testing would be a better indicator of just how well the shock-absorbing works, but it's easy to notice the difference in the TR3000i compared to others. If you at all have foot, knee, or joint issues, you'll want to at least consider this one when shopping.Beyond its shock-absorbing capabilities, the TR3000i has a number of fun features to give you variety in your workouts, too, including a tablet holder, a USB charging port, and compatibility with iPods. It also has built-in speakers, folds up for easy storage, and physical console buttons that are sometimes easier to use when making adjustments than only relying on the touchscreen. The best compact treadmill Cubii The Cubii Pro is an easy-to-use, under desk exercise machine that's more of an elliptical than a treadmill but still allows you to log some quality cardio no matter if you're sitting down for lunch or powering through a backlog of emails. Pros: Small, easy-to-use machine that delivers an effective cardio workout, has up to eight different resistance settings, offers companion app supportCons: Not strictly a treadmill, might not be as intense for hardcore fitness buffsThough the Cubii Pro isn't exactly a treadmill in the traditional sense (and is more of an elliptical style machine than anything else), its unobtrusive nature makes it a convenient addition to anyone's home gym. The machine simply sits on the floor, be it under a desk, next to a coffee table, or literally anywhere around the house, and lets you pedal away for as long as you like. The machine delivers low-impact cardio that may benefit those unable to run on a treadmill due to sore joints, and its quiet operation even allows it to be used while watching TV, talking on the phone, or listening to music. With eight different levels of resistance, it affords as easy or as difficult a workout as you like, too. A companion smartphone application lets you keep track of all your logged workouts and lets you set weekly and monthly goals or share your progress with friends. The app is also compatible with services like Fitbit or Apple HealthKit, so if you prefer the interface of those, all workout data can easily sync to them.At $349, it's certainly not a drop in the bucket but it is far cheaper than even the budget model on this list. For convenient, low-impact cardio exercise, the Cubii Pro is as versatile and easy to use as it gets.  The best treadmill for quiet workouts 3G Cardio The 3G Cardio Elite Runner Treadmill delivers excellent performance and runs quieter than most treadmills.Pros: Strong steel frame that will support a lot of weight, unit runs quieter than most treadmills, large treadmill belt area for tall runners, includes a large motor to compare favorably to gym treadmillsCons: Extremely high price point, very heavy equipment that is difficult to move aroundFew treadmills made for use at home will deliver the kind of quiet performance that the 3G Cardio Elite Runner Treadmill delivers. It's made for tall or heavy runners looking for a tough workout, but you'll pay more than $3,000 for the kind of quality that this 3G Cardio unit delivers.It has an Ortho Flex Shock suspension system to minimize the stress of impact for runners, and the 22 by 62-inch platform is perfect for running.The 3G Cardio comes with many pre-programmed workouts and a fitness level test. You have access to speed and elevation settings, heart rate control, and workout customization.  This treadmill also has a 4.0 horsepower motor and 3-inch rollers for great performance.As you would expect with a treadmill with such a high price point, the 3G Cardio Elite consists of thick steel tubing in the frame. It's also rather expensive, so this is really only for serious runners who want a treadmill that will last a lifetime. What treadmills I'm testing next Technogym MyRun ($2,980): Technogym's lineup of cardio machines offers a quality experience on par with the likes of NordicTrack and ProForm, though instead of having iFit workouts, it has its own streaming platform called Technogym Live. The classes on the MyRun tread allow users to run with a trainer, take to a digital beach, or develop a set of goals to work toward. Its full-color display not only streams the content in high-definition but also supplies helpful analytic data that inform how well the workout is going. Matrix Fitness Treadmill TF30 XR ($2,999): A premium-priced treadmill, Matrix Fitness' Treadmill TF30 XR is the entry-level version of the TF30 lineup, but it still offers a quality run experience. This model comes with a built-in screen, speeds up to 12.5 miles per hour, and an incline up to 15%. It also folds up to nearly 90-degrees, making it easy to store. Since I live in a small Brooklyn apartment, this one is very intriguing. Sole Fitness F80 Treadmill ($1,599): Sole's F80 tread looks like some sort of Swiss Army Knife of treadmills, as it has a number of visible bells and whistles. There's an on-board screen that tracks distance run and calories burned (among other stats), handle grips for heart rate monitoring, and a tablet holder (for when you'd rather stream Netflix than watch your mileage slowly tick up). This is close to the kinds of treadmills you'd find at your local gym, so I'm curious as to how it'd function as an at-home option.  FAQs What types of treadmills are there?Basic: The most basic type of treadmill only works for walkers. They will have simple tracking features, such as speed, distance, and time. Most basic units will have a short bed that works better for a walker's stride than for running.And you'll find limited shock absorption features here, which isn't great for runners. Such treadmills will fold up for easy storage (although some more expensive treadmills also can fold up for storage).Mid-range: These treadmills will work for walkers or runners. For walkers, a mid-range treadmill should have longer support arms, allowing you to balance yourself easier. The belt bed will be a bit longer than the basic treadmill but those with longer running strides may still struggle.You'll see better tech features in this price range, including a heart rate monitor worn on the chest or pre-set training programs.Top-end: The highest quality of treadmills will contain long belt beds with good shock absorption, making them perfect for runners. To gain these features, such treadmills rarely will fold up for storage, meaning they require a lot of free space. They will deliver greater maximum speed levels and greater levels of incline, too.These treadmills consist of the highest-quality materials. You'll receive Wi-Fi connectivity and extensive pre-set exercise programs with these models.What are some key treadmill features?Interactive exercise programs: Treadmills may have pre-programmed workouts that can help you with weight loss, cardiovascular performance, speed workouts, or hills training. These programs will allow you to set the length of exercise time, but they will automatically change the speed of the treadmill and the incline to match the parameters of the pre-programmed workout.The ability to incline, decline, and adjust the speed: To help with training for running on hills or for additional calorie burn, the treadmill needs to offer an incline. Most treadmills can reach at least a 12% incline grade. Some treadmills even give you a simulation of running downhill with a decline grade of around 3%.You should be able to adjust the incline, speed, and program in use through the touchscreen monitor. The screen also gives you information on the time elapsed, calories burned, distance traveled, your heart rate, and more. Are there different size treadmill belts?Yes, there are, and it differs for what runners need versus walkers. Runners need a treadmill belt bed of roughly 55-60 inches long, while walkers can use one closer to 45-50 inches long. Taller people will need an even longer belt bed. Remember that the length of the treadmill isn't the same as the length of the bed.The treadmill length (and width, for that matter) must accommodate the base portion of the unit that doesn't move, as well as the bed's motor housing at the front of the unit.A treadmill belt bed should be at least 22 inches wide for runners which provides plenty of space in case you have a misstep. Walkers can successfully use a narrower bed than runners, such as 18 or 20 inches.Are treadmills safe? Many treadmills contain a safety line that hooks into the unit and clips to your shirt. Should you stumble, the safety line disconnects from the treadmill, causing it to shut down immediately. This is a helpful safety feature and it prevents situations where the person using the treadmill falls and gets launched into a wall. It's also recommended that you unplug your treadmill when not in use for added safety. This assures it won't accidentally turn on if a child or pet is around it. Do treadmills have a weight limit? Based on the size of the motor and the shock absorption capabilities, a treadmill may give you a maximum user weight recommendation. You should be able to find this listed in its online user's manual or listed on its specifications sheet.  Read the original article on Business Insider.....»»

Category: worldSource: nytSep 24th, 2021

How to watch college football without cable - the 2021 season continues with new matchups on September 25

The 2021 NCAA college football season is in full swing. We rounded up the best streaming services for catching all the action without cable. When you buy through our links, Insider may earn an affiliate commission. Learn more. Notre Dame's college football team faces off against Wisconsin on September 25. Michael Hickey/Getty Images The 2021 NCAA college football season began on August 28 and runs through December. Games are broadcast on local stations, national networks, and college sports channels. You can watch select college football matches without cable via live TV streaming services like Sling TV. Table of Contents: Masthead StickyThe 2021 NCAA college football season kicked off in late August and will continue through December. Playoffs occur after the regular season ends, and the championship game is currently scheduled for January 10.As we enter Week Four, several exciting matchups are set for September 25. Most notably, Notre Dame faces Wisconsin at 12 p.m. ET on Fox, and Texas A&M takes on Arkansas at 3:30 p.m. ET on CBS.College football games are primarily broadcast in one of three ways: on local channels, on cable networks, or on college sports networks. Select games will also be available to stream via ESPN+.Below, we broke down some of the best ways to watch college football without cable, so you can stay up to date with your favorite teams.How to watch college football without cableYou can watch local college football games for free by using an HDTV antenna. In order to watch games that are broadcast on pay-TV or college sports networks, you need a subscription to a streaming service like Sling TV, Hulu with Live TV, or YouTube TV.The core local channels with access to college football games are ABC, CBS, Fox, and NBC. National stations like ESPN, Fox Sports 1 (FS1), and CBSSN broadcast select college football games. Additional games are available through college sports networks such as the ACC Network, Big Ten Network, and SEC Network.The number of channels that broadcast college football games can be a little overwhelming, so we put together a list featuring some of the best ways to stream games without a cable subscription.Here's a roundup of services you can use to watch college football without cable: HDTV Antenna StackSocial TV Antenna (small)If your main concern is rooting for your local college football team, an HDTV antenna is one of the most affordable options. A one-time purchase of an inexpensive antenna unlocks access to over-the-air (OTA) signals near you, and allows you to stream any available local affiliates of ABC, CBS, Fox, or NBC. An HDTV antenna is a great, budget-friendly option for streaming local games and does not require any monthly subscription. The major downside is that it doesn't give you access to games broadcast on cable channels like ESPN or out-of-market games.What college football channels you can get: ABCCBSFoxNBC Sling TV Antonio Villas-Boas/Business Insider TV (small)Sling TV is one of the most affordable live TV streaming services with access to college football games. Sling's two core plans, Orange and Blue, start at just $35 a month. If you want to watch games broadcast on ESPN and ESPN2, then Sling Orange is a great choice. Looking for the college football games airing on FS1 and NBC? Then Sling Blue is the best plan for you. Sling also offers a bundle option that combines all the channels from the Orange and Blue plan for just $50 a month. New customers to Sling TV currently receive $25 off their first month of service to the Orange or Blue plans, and $30 off their first month of the combined plan.For an extra $11 a month, you can add access to college sports channels like the Big Ten Network and the SEC Network with the Sports Plus add-on package.What college football channels you can get: Sling Orange:ESPNESPN 2StadiumACC Network*ACC Network Extra*ESPNU*SEC Network*SEC Network+*Pac-12 Network*Sling Blue:NBCFoxFS1StadiumPac-12 Network*Big Ten Network**Available as an add-on channel Hulu with Live TV Ahmad Danial Zulhilmi/Shutterstock + Live TV (small)If you want to get access to a vast library of movies, TV shows, and originals with your live TV subscription service, Hulu + Live TV could be a great fit for your needs. A subscription to Hulu + Live TV starts at $65 a month. With Hulu + Live TV, you get access to available local affiliate channels, like ABC, CBS, NBC, and Fox. You also unlock many important broadcast channels for watching nationally televised college football games such as ESPN, ESPN2, FS1, and more. Unlike Sling TV, Hulu + Live TV includes access to the SEC Network and ESPNU in their basic subscription plan.What college football channels you can get: ABCCBSNBCFoxCBSSNESPNESPN2ESPNUFS1ACC NetworkBig Ten NetworkSEC Network YouTube TV YouTube TV TV (small)As a live TV streaming service, YouTube TV includes many of the same features as Hulu + Live TV without the vast catalog of on-demand entertainment. A subscription to YouTube TV starts at $65 a month.The channels available with a YouTube TV subscription closely mirror what is offered through Hulu + Live TV. You get access to local affiliates and all the important cable channels like ESPN, FS1, and CBSSN. Similar to Hulu + Live TV, college sports channels, such as the SEC Network, Big Ten Network, and ESPNU are included as part of the base plan for YouTube TV. The one main difference between the two services is that you can purchase a Sports Plus add-on for YouTube TV that costs $11 a month and includes the Stadium College Sports channel.What college football channels you can get: ABCCBSNBCFoxCBSSNESPNESPN2ESPNUFS1ACC NetworkBig Ten NetworkSEC Network FuboTV Reuters/Carlo Allegri TV (Starter Plan) (small)FuboTV is another quality live TV streaming service with access to college football games. Starting at $65 a month, the streaming service has the same basic rate as Hulu + Live TV and YouTube TV.You can watch games that air on local affiliate channels and core broadcast channels with FuboTV. The streaming service offers certain college sports channels in its base plan, like the Big Ten Network and CBS Sports Network, but the options are more limited than what is offered through Hulu + Live TV or YouTube TV.Certain channels with college football games, such as the ACC Network, SEC Network, and ESPNU, are available in add-on packages for FuboTV.What college football channels you can get: ABCCBSNBCFoxCBSSNESPNESPN2ESPNU*FS1ACC Network*Big Ten NetworkSEC Network*Pac-12 Network*Stadium**Available as an add-on channel Paramount Plus Paramount + Essential Monthly Plan (ad-supported) (small)If your main concern is watching the SEC football games airing on CBS, then Paramount Plus is a great streaming service for you. Plans for Paramount Plus start at $5 a month and include access to the college football games broadcast on CBS.You also get thousands of hours of on-demand movies, TV shows, and original content with a subscription to Paramount Plus.  ESPN+ ESPN+ Monthly Subscription Service (small)ESPN+ doesn't give you access to the ESPN channel, but for $7 a month, you can live stream select college football games from the MVFC, Ohio Valley, Southern Conference, and more. This is a great supplemental streaming service if you want to watch more niche college football games that are often not nationally broadcast. Read the original article on Business Insider.....»»

Category: worldSource: nytSep 24th, 2021

We need to protect communities hit "first and worst" by climate change, state lawmakers say

The climate-change, racial-justice, environmental-justice, and economic-justice crises intersect, and a holistic solution is needed to solve them all. Insider "The challenge is that we've got a limited timeframe to get this right," US Rep. A. Donald McEachin, a Democrat from Virginia, said during Climate Week NYC Thursday. REUTERS/Carlo Allegri We need holistic environmental-justice solutions, state lawmakers said at Climate Week NYC Thursday. Communities impacted most by climate change also face other challenges that need to be considered. One step forward is the Environmental Justice for All Act, which addresses disproportionate effects. Subscribe to our weekly newsletter, Insider Sustainability. Low-income and indigenous communities as well as communities of color are hit "first and worst" by climate change, whether it's destructive hurricanes, droughts, or extreme heat, policymaker panelists said during a Climate Week NYC event Thursday - and holistic environmental-justice solutions are needed. The session, titled "Building a Just Climate Future: Centering Equity in Climate Solutions," focused on how the climate-change, racial-justice, environmental-justice, and economic-justice crises intersect, and panelists discussed some of the Biden administration's and other initiatives created to solve the problems. The panel was sponsored by environmental law organization Earthjustice and moderated by Jill Tauber, the group's vice president of litigation for climate and energy."The challenge is that we've got a limited timeframe to get this right," US Rep. A. Donald McEachin, a Democrat from Virginia, said during the session. "If we're going to pass on a cleaner earth, we've got to take some action and take it now. The challenge really is that Congress is not set up to move that quickly."Along with the climate crisis, the country is dealing with the pandemic and systemic racism, and "we must look at how we address all of them in totality, making sure we leave no one behind," Michele L. Roberts, a member of the White House Environmental Justice Advisory Council (WHEJAC) and national co-coordinator for the Environmental Justice Health Alliance, said. WHEJAC and the White House Environmental Justice Interagency Council were created to prioritize environmental justice and address current and historical environmental injustices. While a solution likely won't be found overnight, Roberts said the Biden administration's initiatives to address climate change and end environmental racism offer hope."The first part is admitting the problem," she said. "Then, we can begin to build from there."Through the Justice40 Initiative, President Biden set a goal of providing 40% of the benefits of federal investments in climate and clean energy to disadvantaged communities. The president signed an executive order adding environmental justice to the mission of each federal agency by instructing them to create programs, policies, and activities to address the disproportionate health, environmental, economic, and climate effects on disadvantaged communities.In the current divisive political climate, Harold Mitchell Jr., a WHEJAC member and executive director of the ReGenesis Project, a South Carolina-based environmental-justice organization, told the panel that the council is helping groups in some red-leaning states identify and overcome any barriers that local governments could put in place to prevent the programs from succeeding. "We have to be real and understand that what is promised may not hit the ground into those disadvantaged pockets unless we're strategic," he said.The councils include members of the communities most affected by climate change and environmental justice, giving them a voice in the decision-making process, Roberts said.In March, McEachin and Rep. Raul Grijalva, an Arizona Democrat, introduced the Environmental Justice for All Act, which would create several environmental-justice requirements, advisory groups, and programs to address the disproportionate health and environmental effects on communities of color, low-income groups, and indigenous communities. McEachin said the bill was written by the people directly affected by these problems."Environmental-justice communities are different communities with different sets of problems and we have different solutions," he said. "The act says let's go to the people, let them come up with solutions. Let's make sure that we give them sufficient funding and get out of their way."Many of these communities have been affected by environmental justice for decades, and to prioritize the groups going forward, Roberts said, "We need to make sure when we talk about green energy that it is clean, equitable, and just - all three words, not just one."McEachin said everyone, not just those affected by environmental justice, needs to get engaged, organize on a grassroots level, contact their lawmakers, and urge others to do the same."You may not be able to get it done your way, but let's pass some compromise and get something positive done, because, you know, as I wake up in the morning, we're one day closer to the climate catastrophe that we're all trying to avoid," he said. "We needed to take action yesterday. We need to take action today. And we're going to need to take action tomorrow."Read the original article on Business Insider.....»»

Category: worldSource: nytSep 24th, 2021

“The Housing Market Is Almost Frozen" - An Even Bigger Problem Emerges For China

“The Housing Market Is Almost Frozen" - An Even Bigger Problem Emerges For China With Wall Street's fascination with risk associated with Evergrande's default fading fast, and the sellside pumping out charts such as this one showing that the contagion in China junk bond market is unlikely to spillover globally... ... the smartest men in the room are once again missing the forest for the trees because as we explained in detail over the weekend, and again reminded earlier this week... Remember: for China this is not about Evergrande, it's about preserving confidence in the property sector — zerohedge (@zerohedge) September 22, 2021 ... for Beijing the real risk is not whether foreign creditors are impacted - in fact Evergrande's willingness to default on offshore bondholders while preserving operational cash flow and continuing to build homes shows just how much China "cares" about Blackrock's P&L - but how an Evergrande crisis could impact China's massive, $60 trillion, property sector, something which CCB International, the Chinese investment bank, touched on in a recent research note in which it said that Evergrande "contagion risk has spread from financing to land sales, property sales, project deliveries and home prices." And indeed, as the FT reports this morning, some very ominous cracks in China's property market - which according to Goldman is the largest asset class globally - are starting to emerge. In a letter to the Shaoxing municipal government in eastern Zhejiang province, the local office of developer Sunac China appealed for “policy assistance” as it was struggling through what it called a "turning point in China’s real estate industry." "We have never experienced such a radical change in the external environment," Sunac’s Shaoxing office said, pointing to a 60% year-on-year fall in home sales over the summer. "The market is almost frozen," it added in the letter, which was first reported by the Financial Times. “The radical change in policy and environment has seriously disrupted our business and made it very difficult to maintain normal operations.” The sudden, sharp collapse in China's property market is shown in the charts below which reveal that the amount of actual land transactions was not only well below the land supply in recent weeks, an unprecedented divergence, but that volumes were 65% below year-ago levels as potential buyers are suddenly terrified of investing in real estate as the Evergrande fate remains in limbo, with some worried that some of the 65 million empty apartments could hit the market and lead to a crash in property values. While the plunge in transactions is demand-induced, there are also concerns that an Evergrande insolvency and eventual collapse could lead to a supply crunch. As reported earlier, in July a Chinese city halted sales at two Evergrande projects alleging the troubled developer misappropriated funds by only depositing a portion of the proceeds from housing sales into the escrow accounts, according to a local government statement.  To ensure Evergrande doesn’t divert these funds, the housing bureau in Nansha district created an escrow account under its own name this month to take in proceeds from Evergrande homebuyers, cutting off the developer’s direct access to the money. A lack of funds has already led to a construction halt on some unfinished housing properties, sparking social unrest among buyers. In Guangzhou, buyers surrounded a local housing bureau earlier this month to demand Evergrande restart construction. As we discussed over the weekend, one of the most troubling downstream consequences from chaos in the property sector would be social unrest, and as we noted, maintaining social order has always been a key priority for the Communist Party, which has no tolerance for protests of any kind. In Guangzhou, homebuyers surrounded a local housing bureau last week to demand Evergrande restart stalled construction. Disgruntled retail investors have gathered at the companys Shenzhen headquarters for at least three straight days this week, and videos of protests against the developer in other parts of China have been shared widely online. Without a social safety net and with limited places to put their money, Chinese savers have for years been encouraged to buy homes whose prices were only ever supposed to go up (similar to the US before 2007 when even idiots like Ben Bernanke said that the US housing market never goes down). Today, buying a house (or two) is a cultural touchstone. And while housing affordability has become a hot topic in the West, many Chinese are more likely to protest falling home prices than spiking ones. Which brings us to a must read report from Goldman's Kinger Lau published overnight and focusing entirely on China's property sector - instead of just Evergrande - where it addresses a glaring dilemma: Beijing's desire to regulate and deleverage the housing sector even as it keeps property prices rising, a dynamic we summarized concisely earlier this week inside a tweet: Markets used to focus on China's "impossible trinity" but it's time to shift to China's "impossible dilemma": you can't have deleveraging/tightening/"3 red lines" AND rising home prices at the same time. China wants both, will have to pick one — zerohedge (@zerohedge) September 22, 2021 In his must read report (available for professional subscribers in the usual place) Goldman's Lau explains that what is going on with Evergrande, and in fact the turmoil gripping China's broader property sector is largely self-inflicted as "regulatory actions in China Internet have resulted in more than US$1tn market cap loss on the tech sector since mid-Feb, but in the past two weeks, investor focus has shifted to the US$60tn China property market which is linked to ~20% of Chinese GDP and represents 62% of household wealth." Specifically, Goldman notes that more than 400 new property regulations (shown in the appendix) that are largely tightening in nature have been announced ytd to restrain housing market activity, spanning supply, demand, funding, leverage, to price control measures. It is these measures that have contributed to a 14% year-on-year fall in property sales and $90 billion of market-cap losses among developer stocks in 3Q alone. In his attempt to summarize the critical linkages between China's all-important property sector and the broader economy (something we first tried to do back in 2017 in "Why The Fate Of The World Economy Is In The Hands Of China's Housing Bubble"), Goldman first focuses on the immediate catalyst behind the current crisis, which according to the bank has to do with the unprecedented regulatory tightening "in the largest asset class globally." Or, as Goldman puts it succinctly, "Property is everywhere in China" Some explanatory notes on the chart above: The regulatory cycle keeps evolving: The ongoing regulatory tightening cycle, which is unprecedented in terms of its duration, intensity, scope, and velocity (of new regulation announcement) as suggested by our POE regulation proxy, has so far provoked significant concerns among investors in and have resulted in more than US$1tn market cap loss on China Tech. From Tech to Social Sector, and then to Property: According to Centaline, more than 400 new property regulations have been unveiled ytd across the central and local governments to address the issues of rising property prices and imbalanced supply/demand in certain areas, over-reliance on property for economic growth and fiscal revenues, and potential speculation in the real estate market where 22% of property could be vacant and ~60% of recent-year purchases were driven by investment demand. Property market tightening isn’t a new feature in the Chinese policy cycle over the past decade, but the severity of the measures, the scope of tightening, and the determination of policy implementation (e.g. the 3 Red Lines) are arguably unprecedented. China property is big: Almost two years ago, Goldman took a deep dive into the US$40tn Chinese residential housing market and analyzed its impacts on macro and asset markets. Since then, the market has grown to US$60tn in notional value including inventory, likely the largest asset class in the world on current prices. It has also registered Rmb26tn (US$4tn) of home sales with more than 3bn sqm of GFA being sold, almost 3x the size of HK SAR. Additionally, it is well-documented that Chinese households have a strong investment and allocation bias towards real assets for different economic and cultural reasons—as of Aug 2021, property accounted for around 62% of household assets in both the total and net terms, vs. 23% in the US and 36% in Japan, where stocks are the dominant household assets. Property is ubiquitous in China, fundamentally and financially: Goldman economists estimate that the housing sector contributes to around 20% of GDP via direct and indirect channels such as property FAI, property construction supply chain, consumption, and wealth effect. In the financial markets, 15% of aggregate market earnings (i.e. ~US$150bn out of US$1tn in 2020) could be exposed to ‘property demand’ in the extended housing construction-to-sale cycle which typically spans over three years, and that property-related loans (developer loans, mortgages, shadow banking)/ developer bonds represent 35%/23% of banks’ loan books/the outstanding balance of the offshore USD credit (IG + HY) market,respectively. And visually: While a full-blown property crisis would impact virtually every aspect of the Chinese economy, starting with capital markets, shadow banks, and social stability, the most immediate one for global investors is of course, the equity market. Here are Goldman's key observations on this topic: The regulation headwinds have resulted in a noticeable slowdown in property activities in recent months: nationwide property sales have fallen 14% yoy in3Q21 alongside stable prices in the primary market but large declines of transactions in the secondary market; property FAI and new starts have fallend rastically, although completion growth momentum has remained strong largely on favorable base effects. At the macro level, Goldman economists have laid out 3 scenarios to model the contagion impacts from reduced property impulse on macro growth. Overall, they see 2022 GDP growth hit ranging from 1.4% to 4.1% depending on the magnitude/severity of the property market slowdown and the tightening of financial conditions domestically, although their scenario analysis does not take into consideration potential monetary and fiscal policy easing in response to the property market declines. While listed developers only account for 4% of earnings in the aggregate listed universe, the housing market could be linked, directly and indirectly, to ~15% of corporate earnings, and every 10pp growth deceleration in housing activity could reduce profit growth of the housing market by ~2pp, all else equal. Broadly, Goldman lists five key transmission mechanisms along the extended property market food chain: Property developers and management companies (4% of equity market earnings): Developers’ earnings are highly sensitive to the property market fundamentals. However, given the time lag between transaction (pre-sales) and revenue recognition (accrual-based accounting), reported earnings usually lag sales by around 2 years, meaning that their current- and next-year earnings may not fully reflect the latest situation in the physical market. For property management companies, their near-term earnings profile is more sensitive to completions than sales but slowing property sales could dampen their future growth prospect. Financial institutions (54% of equity market earnings): Developer loans and mortgage loans account for 35% of commercial banks’ aggregate loan book. Goldman's banks analysts see the potential for mortgage NPLs to rise (at 0.3% now, 1% increase in mortgage NPL ratio translates into 18.7% drop in net profits per their bear case) although their risk exposures to property-related WMPs have fallen substantially since 2016. For insurers, Goldman's team believes the listed insurers’ exposure to the property sector is low, but the potential indirect wealth effect could pose a bigger fundamental challenge. While not directly linked to the housing market, equity brokers’ earnings cycles have been negatively correlated with property sales, likely reflecting the asset allocation decisions/flows from Chinese households between the two asset classes. Construction (2% of equity market earnings): From new property FAI start to completion, the construction cycle for commodity housing typically lasts 20-30 months in China. It drives demand for construction materials (China is the largest consumer of copper, iron ore and steel), although the focus of materials and their consumption intensity varies in different parts of the cycle. The process also directly impacts construction-related equipment, with excavators, heavy-duty trucks, bulldozers, cranes, and loaders all exhibiting reasonably high demand correlation with land sales. Consumption: (3% of equity market earnings): Whether property purchase is considered consumption (at least for first time buyer) remains an open-ended debate, but the housing market is undoubtedly a key demand driver for a wide range of consumption items, including white goods,consumer durables like furniture equipment, and certain electronic products(e.g. Audio devices and air conditioners). Goldman's study shows that housing completion usually leads the sales and earnings in these sectors by 6-9months. Wealth effect (1% of equity market earnings): At the micro level, capital appreciation (or depreciation) in the housing market could have short-term material impact on discretionary spending given the potential wealth creation from the US$60tn asset market, especially considering the relatively high investment ratios there. Industries that are sensitive to this channel encompass the Autos (luxury), Macau gaming, HK retailers and travel-related companies (before the pandemic), which tend to lag property sales by around two quarters, although these relationships may be also reflective of the broader macro dynamics including liquidity easing. A snapshot of the various top-down impact of the Chinese property cycle on corporate earnings is shown below: In sum, mapping Goldman' base case assumptions on GDP growth and property activities for 2022 onto corporate earnings via these channels,the bank lowers its 2022E EPS growth for MSCI China from 13% to 7%, but as the bank warns "the earnings downside (delta) could be much more significant (-28pp) if their bear cases prevail." And should more companies warn that "the market is almost frozen" as a result of the Evergrande crisis, the bear case is virtually assured. We conclude with Goldman's observations on the contagion risks which according to the bank - and contrary to the market - "are building", even if systemic risks can still be avoided. While the restrictive policies have cooled the market, it has put highly-geared developers, notably Evergrande, in the spotlight as their deleveraging path becomes increasingly challenging. On one hand, Goldman agrees with us, and says that on a standalone basis, Evergrande should not be a serious systemic threat given that its total liability of Rmb1.9tn accounts for 0.6% of China’s outstanding TSF, its bank loans of Rmb572bn represent 0.3% of systemwide loan book, and its market share in nationwide commodity housing sales stood at 4% by 1H21. However, the real risks emerges in the context of the slowing property market: indeed, as in other systemic/crisis episodes, investors are concerned about specific weak links which could spread to the broader system via fundamental and financial channels in the case of disorderly default, and therefore the financial condition tightening risk could be much more significant than the Rmb1.9tn liability would suggest, according to Goldman. How much risk is priced in? This is a popular question from investors but also a difficult one to answer given the fluidity of the situation. However, the following analyses lead Goldman to believe that the market may have priced in some degrees of degradation in macro/corporate fundamentals and possibly policy response from the authorities (i.e. a “muddle-through” scenario), but not a harsh scenario that is systemic and global in nature Episodic analysis: Historical physical property market downturns were short-lived and shallow, but if we focus on episodes where developer equities traded at depressed valuations to proxy for property-related concerns (eg.2H11, early 2015, and late 2018), prevailing NAV discounts of listed developers(-60%) are roughly in-line with those difficult times. At the index level, MSCI China bottomed at around 10-11x fwd P/E and 10% ERP in those periods, vs. 13xand 9% at present respectively. Fair PE targets: The MSCI China index is currently trading on 13x fP/E, having already de-rated from 19.6x at the peak in mid-Feb. Applying Goldman's three scenarios to its top-down macro PE model, the bank estimates that the index fair PE could fall to 12.5x in the base case, and 11.0x in their most bearish case. Correlation analysis: Intra- and inter-sector, and cross-asset correlations with regard to Chinese stocks or developer equities have all risen in the past weeks, albeit from a low base. However, compared with previous cases where concerns related to China regulations or trade relations had spooked global markets (e.g. 2015 FX reform, 2018 US-China trade war), the absolute correlation levels are more benign at present, suggesting a global contagious impact is not fully priced in. In light of all this, the good news is that in Goldman's view systemic risks could still be avoided considering: broad liquidity and risk-appetite indicators such as 7d repo, the onshore funding stress index, as well as the A-share market performance/ turnover suggest that the imminent "minsky moment" remains a narrative but far from a reality; the effective leverage (LTV) for the housing market is low, around 40% to 50% per our Banks team’s estimate; the institutional setup in China where the government has strong control over its banking system makes a market-driven collapse less likely to happen than would otherwise be the case; Losses will be realized by stakeholders associated with highly-geared developers, but the liabilities are relatively transparent and are less widely socialized in the financial markets than in previous global financial crises; the potential economic, social, and financial impacts have been well publicized and discussed, and it appears that the authorities are assessing the situation and starting to take actions; and, economists believe there is potential for the authorities to ease policy to prevent a disorderly default of Evergrande from developing into a crisis leading up to the Sixth Plenum in November. Ultimately, timing will be key to a happy ending: Given the outsized market value of China property, and its intricate linkages to the real economy and the financial markets, deleveraging the property market and improving financial stability - two contradictory concepts - could raise systemic concern if policy actions are pursued too aggressively, or without clear coordination among regulators and communication with the market. Importantly, as market concerns over tail risk and spillovers start to build, there is increasing focus on the narrowing window for policymakers to provide the necessary circuit breakers to ring-fence the (collateral) damages and stop the downward spirals. A key risk from continued delayed action would be a bigger snowball effect and more damage on markets and investor (already strained) confidence in Chinese assets. As such, Goldman expects the market to focus on potential actions that could be pursued, such as a combination of debt restructuring (bank loans, WMP, credits), conditional government involvement in working capital bridges and unfinished property projects, and a coordinated plan to divest and cash in assets. Finally, as promised earlier, here is a summary of the key loosing (green) and tightening (red) policies in China's property market.   Tyler Durden Fri, 09/24/2021 - 13:00.....»»

Category: blogSource: zerohedgeSep 24th, 2021

Five Economic Benefits From Bank And Fintech Firm Partnerships

While banking clientele have never been more frustrated than now, the global industry faces a unique opportunity to flip the current system upside down. Q2 2021 hedge fund letters, conferences and more In fact, Capgemini’s World FinTech Report of 2021 details how banks can leverage the new competitive market in depth. Just as we watched […] While banking clientele have never been more frustrated than now, the global industry faces a unique opportunity to flip the current system upside down. if (typeof jQuery == 'undefined') { document.write(''); } .first{clear:both;margin-left:0}.one-third{width:31.034482758621%;float:left;margin-left:3.448275862069%}.two-thirds{width:65.51724137931%;float:left}form.ebook-styles .af-element input{border:0;border-radius:0;padding:8px}form.ebook-styles .af-element{width:220px;float:left}form.ebook-styles .af-element.buttonContainer{width:115px;float:left;margin-left: 6px;}form.ebook-styles .af-element.buttonContainer input.submit{width:115px;padding:10px 6px 8px;text-transform:uppercase;border-radius:0;border:0;font-size:15px}form.ebook-styles .af-body.af-standards input.submit{width:115px}form.ebook-styles .af-element.privacyPolicy{width:100%;font-size:12px;margin:10px auto 0}form.ebook-styles .af-element.privacyPolicy p{font-size:11px;margin-bottom:0}form.ebook-styles .af-body input.text{height:40px;padding:2px 10px !important} form.ebook-styles .error, form.ebook-styles #error { color:#d00; } form.ebook-styles .formfields h1, form.ebook-styles .formfields #mg-logo, form.ebook-styles .formfields #mg-footer { display: none; } form.ebook-styles .formfields { font-size: 12px; } form.ebook-styles .formfields p { margin: 4px 0; } Get Our Activist Investing Case Study! Get the entire 10-part series on our in-depth study on activist investing in PDF. Save it to your desktop, read it on your tablet, or print it out to read anywhere! Sign up below! (function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';}(jQuery));var $mcj = jQuery.noConflict(true); Q2 2021 hedge fund letters, conferences and more In fact, Capgemini’s World FinTech Report of 2021 details how banks can leverage the new competitive market in depth. Just as we watched large and small businesses alike drastically adapt to the digital demands of Covid in 2020, banks are facing the same reality this year. The competitive threats no longer urge, but rather require, banks to implement a digital-only approach to subsidiaries in order to stay afloat during the dawn of FinTech. Traditional banks are taking to collaboration versus competition in order to boost engagement and interaction with innovative, forward-thinking FinTech firms. The Benefits Of The Partnership Between Banks And FinTech Companies No one can deny the value of both entities, however, they’re also stronger together than apart. That’s what we’re looking at here, and the union is mutually beneficial. Here’s how. Increase In Trust From Modern Customers The connection between banks and FinTech companies means heightened trust backed by better tech, stronger security and less room for errors as a result of automation. This should be welcome for any customer in need of reliable and secure financial banking services, and especially in an age where people are uneasy about the state of their finances. According to a recent survey conducted by CreditDonkey, for instance, only a third of people under the age of 40 expressed a high level of confidence in their financial future. Another survey from April 2020 showed that just 14% of consumers sought their bank’s council when in need of financial direction following a major life event. This has definitely not been great news for the banking industry. However, it also isn’t shocking. Consumers often do not seek guidance from traditional financial sectors due to a lack of trust. This could very well be due to the 2008 recession, where 41% of the population that were surveyed stated that they were scared, and 53% were mad. Client confidence in banks has grown over the years but still, today, only equates to nearly one-third of clientele. On the other hand, trust in tech companies is a starkly different story. According to The Verge Tech Survey 2020, Americans hail Google, Amazon, Apple, Microsoft, Netflix, and YouTube as leaders in positively affecting society. Specifically, 75% of survey respondents trust Microsoft, with Amazon following at 73% and Facebook at 41%. Tech Makes Banking Accessible, Safer, Smarter And More Efficient Combining tech with banking means more ease of use with user’s smartphones. GSMA real-time intelligence data shows that there are 5.28 billion people using mobile devices in the world as of September 2021. Making banking mobile-friendly is a no brainer and boosts connection with clientele. People just don’t want to drive to their bank or ATM anymore. They want instant mobile access and complete visibility from the comfort of their homes. Users are looking for smarter ways to handle business and finances. That means being able to seamlessly switch between desktop, mobile device or tablets. Fortunately, the cloud solves this completely. Banking customers can get to their banking accounts from virtually anywhere and access their updated information in real time. The cloud has paved the way for quicker transactions, greater visibility and increased accuracy. Stronger Brand Reputation As A Result Of Partnership Partnering with a highly regarded FinTech company looks very good for a lesser known bank. More users are going to be interested in downloading a mobile app from a reputable tech company. A credible partnership gives customers more faith that their interests are held at the highest priority. To further the first point of mobile access, even greater than that is the consumer's ability to complete multiple actions digitally that just years ago they would have had to drive to the bank for. This includes, but is not limited to, money transfers, financial planning, transaction tracking, investments, check deposits, special perks and banking fee management. FinTech companies help users have an abundance of options and services right at their fingertips. This, in turn, creates greater business for banks. Security Remember when we mentioned trust earlier? Security plays a massive role in this. FinTech companies lend banks the know-how and resources to protect customers’ data from vulnerabilities. Specific steps include relying on SASE (Secure Access Service Edge) networks, utilizing AI-based fraud detection systems and, as mentioned previously, storing customer data on the cloud rather than with on-premise databases. Customers want to know that their life savings are going to be there when they wake up. Can you blame them? And it’s worth noting while customers should feel safe knowing their funds are held securely with fintech services, none of this is to say that they shouldn’t be investing in other financial safeguards as well. Building up a diversified investment and retirement portfolio, setting aside at least three months worth of expenses into an emergency fund, and investing into a comprehensive insurance policy to help cover their financial assets in the event of the family’s income provider becoming deceased or disabled are all wise strategies anyone should take to prepare for the worst. Scalability FinTech and bank partnerships can be quickly scaled up or down in order to tailor to customer response and needs. These consumer “pain points” present themselves uniquely over the course of the journey and collaboration grants both sectors more solutions to offer. Scalability is the key to sustainability. Together, FinTech and banks can wreak widespread disruption to the market. Providing the best possible products together in an ascendable way helps both teams cut through the noise of the financial industry. Conclusion At the end of the day, it’s not enough for banks to just do things the way they’ve always done with excellence. Banks must remain futuristic with tech-forward, collaborative thinking in order to serve their customers best. Banks and financial institutions alike must together keep their efficiency radars going twenty four hours a day, seven days a week in order to stay on top of new trends, startup activity, new developments, and integration opportunities. Updated on Sep 24, 2021, 12:41 pm (function() { var sc = document.createElement("script"); sc.type = "text/javascript"; sc.async = true;sc.src = "//mixi.media/data/js/95481.js"; sc.charset = "utf-8";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(sc, s); }()); window._F20 = window._F20 || []; _F20.push({container: 'F20WidgetContainer', placement: '', count: 3}); _F20.push({finish: true});.....»»

Category: blogSource: valuewalkSep 24th, 2021

PHOTOS: Special operators and airborne soldiers put the US military"s new sniper rifle of choice to the test by jumping out of airplanes with it

The sniper rifle was then checked to make sure it still fired with precision during the post-drop live-fire trials. A Special Operations Sniper exits a C-27 aircraft with his MK-22 Precision Sniper Rifle (PSR) in the “side-mounted” configuration over Laurinburg drop zone, Laurinburg, North Carolina, during the PSR test. Staff Sgt. Nicholas Birkner, U.S. Army Operational Test Command US special operators and airborne soldiers put the new MK-22 sniper rifle to the test recently. They jumped out of airplanes with the rifle and then had the weapons checked to make sure they still worked. The testing is the "final hurdle" before fielding, the Army said in a statement. See more stories on Insider's business page. US Army snipers from the special operations community and the 82nd Airborne Division put the military's newest sniper rifle of choice to the test at Fort Bragg, North Carolina recently.The MK-22 sniper rifle, Barrett Firearms' Multi-Role Adaptive Design (MRAD) rifle, is a three-in-one sniper rifle that soldiers, Marines, and special operators all want, and the testing at Fort Bragg is the "final hurdle" before fielding starts. Mk 22 MRAD sniper rifle US Army Special Operations Command was the first to choose the new rifle, which can be chambered in 7.62 by 51 mm NATO, .300 Norma Magnum, and .338 Norma Magnum ammunition, giving shooters greater flexibility with a single weapon.The Marines and the Army did the same, with the latter selecting the MRAD rifle for its Precision Sniper Rifle program. The rifle will replace all bolt-action rifles for the Corps and the Army's M2010 and M107 rifles.The sniper rifle "can be configured for multi-calibers by the sniper in the field and requires no higher level maintenance to reconfigure," US Army Operational Test Command's Airborne and Special Operations Test Directorate said in a press statement. "It will also extend engagement ranges for both anti-material and anti-personnel target engagements.""The increased engagement range will keep snipers safer and increase the options for the local commander employing these combat multipliers," Sgt. Austin Stevens, an 82nd Airborne Division sniper, said.Weapon testing at Fort Bragg, which was preceded by the extensive training on the new equipment, involved vertical wind tunnel testing, as well as snipers airdropping from a C-27 military transport aircraft carrying the MK-22 rifles. A Special Operations Sniper participating in the MK-22 Precision Sniper Rifle (PSR) test conducts vertical wind tunnel testing with his MK-22 in the “front-mount” configuration. Michael Zigmond, Audio Visual Production Specialist, U.S. Army Operational Test Command A Special Operations Sniper exits a C-27 aircraft with his MK-22 Precision Sniper Rifle (PSR) in the “side-mounted” configuration over Laurinburg drop zone, Laurinburg, North Carolina, during the PSR test. Staff Sgt. Nicholas Birkner, U.S. Army Operational Test Command The rifles were then evaluated afterwards to make sure that the pre-mission zero set by the snipers had not been thrown off by the jump. Special Operations Snipers zero their MK-22 Precision Sniper Rifles (PSR) before military free fall test trials on Range 61, Fort Bragg, North Carolina Barry Fischer, Audio Visual Production Specialist, U.S. Base & Test Support Services contractor A test NCO assigned to the Airborne and Special Operations Test Directorate observes post-drop live-fire test trials of the MK-22 Precision Sniper Rifle (PSR) at Range 61, Fort Bragg, North Carolina James Finney, Audio Visual Production Specialist, Base and Test Support Services contractor The modular aspect of the MK-22 rifle removes the need for troops to deploy with less weaponry, and the foldable stock and removable suppression systems mean a more compact load for paratroopers.With weapons that will be used by airborne troops, though, it is essential that the weapon be tested to ensure that any shock from an airdrop does not impact a shooter's ability to shoot straight and hit an intended target. That was carefully evaluated during recent testing. Technicians assigned to the Base and Test Support Services contractor conduct bore sight collimation on an MK-22 Precision Sniper Rifle (PSR) after a paratrooper airdrop. James Finney, Audio Visual Production Specialist, Base and Test Support Services contractor. The MRAD rifles have generated a lot of excitement among members of the US military sniper community."It's an awesome gun," an experienced Army sniper previously told Insider. "I can tell you I never saw anything on that gun that I didn't like. It shoots phenomenally well. What it does, as far as barrel changes and things like that go, is pretty exceptional."The MK-22 is a "good gun coming at a good time that is going to increase efficiency and capabilities," he said. "We're excited about it."Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 24th, 2021

Futures Slide Alongside Cryptocurrencies Amid China Crackdown

Futures Slide Alongside Cryptocurrencies Amid China Crackdown US futures and European stocks fell amid ongoing nerves over the Evergrande default, while cryptocurrency-linked stocks tumbled after the Chinese central bank said such transactions are illegal. Sovereign bond yields fluctuated after an earlier selloff fueled by the prospect of tighter monetary policy. At 745am ET, S&P 500 e-minis were down 19.5 points, or 0.43%, Nasdaq 100 e-minis were down 88.75 points, or 0.58% and Dow e-minis were down 112 points, or 0.33%. In the biggest overnight news, Evergrande offshore creditors remain in limbo and still haven't received their coupon payment effectively starting the 30-day grace period, while also in China, the State Planner issued a notice on the crackdown of cryptocurrency mining, will strictly prohibit financing for new crypto mining projects and strengthen energy consumption controls of new crypto mining projects. Subsequently, the PBoC issued a notice to further prevent and dispose of the risks from speculating on cryptocurrencies, to strengthen monitoring of risks from crypto trading and such activities are illegal. The news sent the crypto space tumbling as much as 8% while cryptocurrency-exposed stocks slumped in U.S. premarket trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%. Big banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits. Here are some of the biggest U.S. movers today: Helbiz (HLBZ) falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders. Focus Universal (FCUV), an online marketing company that’s been a favorite of retail traders, surged 26% in premarket trading after the stock was cited on Stocktwits in recent days. Vail Resorts (MTN) falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint. GlycoMimetics (GLYC) jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16. VTV Therapeutics (VTVT) surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. Fears about a sooner-than-expected tapering amid signs of stalling U.S. economic growth and concerns over a spillover from China Evergrande’s default had rattled investors in September, putting the benchmark S&P 500 index on course to snap a seven-month winning streak. Elaine Stokes, a portfolio manager at Loomis Sayles & Co., told Bloomberg Television, adding that “what they did is tell us that they feel really good about the economy.” While the bond selloff vindicated Treasury bears who argue yields are too low to reflect fundamentals, others see limits to how high they can go. “We’d expected bond yields to go higher, given the macro situation where growth is still very strong,” Sylvia Sheng, global multi-asset strategist with JPMorgan Asset Management, said on Bloomberg Television. “But we do stress that is a modest view, because we think that upside to yields is still limited from here given that central banks including the Fed are still buying bonds.” Still, Wall Street’s main indexes rallied in the past two session and are set for small weekly gains. European equities dipped at the open but trade off worst levels, with the Euro Stoxx 50 sliding as much as 1.1% before climbing off the lows. France's CAC underperformed at the margin. Retail, financial services are the weakest performers. EQT AB, Europe’s biggest listed private equity firm, fell as much as 8.1% after Sweden’s financial watchdog opened an investigation into suspected market abuse. Here are some of the other biggest European movers today: SMCP shares surge as much as 9.9%, advancing for a 9th session in 10, amid continued hopes the financial troubles of its top shareholder will ultimately lead to a sale TeamViewer climbs much as 4.2% after Bankhaus Metzler initiated coverage with a buy rating, citing the company’s above-market growth AstraZeneca gains as much as 3.6% after its Lynparza drug met the primary endpoint in a prostate cancer trial Darktrace drops as much as 9.2%, paring the stock’s rally over the past few weeks, as a technical pattern triggered a sell signal Adidas and Puma fall as much as 4% and 2.9%, respectively, after U.S. rival Nike’s “large cut” to FY sales guidance, which Jefferies said would “likely hurt” shares of European peers Earlier in the session, Asian stocks rose for a second day, led by rallies in Japan and Taiwan, following U.S. peers higher amid optimism over the Federal Reserve’s bullish economic outlook and fading concerns over widespread contagion from Evergrande. Stocks were muted in China and Hong Kong. India’s S&P BSE Sensex topped the 60,000 level for the first time on Friday on optimism that speedier vaccinations will improve demand for businesses in Asia’s third-largest economy. The MSCI Asia Pacific Index gained as much as 0.7%, with TSMC and Sony the biggest boosts. That trimmed the regional benchmark’s loss for the week to about 1%. Japan’s Nikkei 225 climbed 2.1%, reopening after a holiday, pushing its advance for September to 7.7%, the best among major global gauges. The Asian regional benchmark pared its gain as Hong Kong stocks fell sharply in late afternoon trading amid continued uncertainty, with Evergrande giving no sign of making an interest payment that was due Thursday. Among key upcoming events is the leadership election for Japan’s ruling party next week, which will likely determine the country’s next prime minister. “Investor concerns over the Evergrande issue have retreated a bit for now,” said Hajime Sakai, chief fund manager at Mito Securities Co. in Tokyo. “But investors will have to keep downside risk in the corner of their minds.” Indian stocks rose, pushing the Sensex above 60,000 for the first time ever. Key gauges fell in Singapore, Malaysia and Australia, while the Thai market was closed for a holiday. Treasuries are higher as U.S. trading day begins after rebounding from weekly lows reached during Asia session, adding to Thursday’s losses. The 10-year yield was down 1bp at ~1.42%, just above the 100-DMA breached on Thursday for the first time in three months; it climbed to 1.449% during Asia session, highest since July 6, and remains 5.2bp higher on the week, its fifth straight weekly increase. Several Fed speakers are slated, first since Wednesday’s FOMC commentary set forth a possible taper timeline.  Bunds and gilts recover off cheapest levels, curves bear steepening. USTs bull steepen, richening 1.5bps from the 10y point out. Peripheral spreads are wider. BTP spreads widen 2-3bps to Bunds. In FX, the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as  businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support In commodities, crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal. Looking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan. Market Snapshot S&P 500 futures down 0.3% to 4,423.50 STOXX Europe 600 down 0.7% to 464.18 German 10Y yield fell 8.5 bps to -0.236% Euro little changed at $1.1737 MXAP up 0.4% to 201.25 MXAPJ down 0.5% to 643.20 Nikkei up 2.1% to 30,248.81 Topix up 2.3% to 2,090.75 Hang Seng Index down 1.3% to 24,192.16 Shanghai Composite down 0.8% to 3,613.07 Sensex up 0.2% to 60,031.83 Australia S&P/ASX 200 down 0.4% to 7,342.60 Kospi little changed at 3,125.24 Brent Futures up 0.4% to $77.57/bbl Gold spot up 0.7% to $1,755.38 U.S. Dollar Index little changed at 93.14 Top Overnight News from Bloomberg China Evergrande Group’s unusual silence about a dollar-bond interest payment that was due Thursday has put a focus on what might happen during a 30-day grace period. The Reserve Bank of Australia’s inflation target is increasingly out of step with international counterparts and fails to account for structural changes in the country’s economy over the past 30 years, Westpac Banking Corp.’s Bill Evans said. With central banks from Washington to London this week signaling more alarm over faster inflation, the ultra-stimulative path of the euro zone and some of its neighbors appears lonelier than ever. China’s central bank continued to pump liquidity into the financial system on Friday as policy makers sought to avoid contagion stemming from China Evergrande Group spreading to domestic markets. A more detailed look at global markets courtesy of Newsquawk Asian equity markets traded mixed with the region failing to fully sustain the impetus from the positive performance across global counterparts after the silence from Evergrande and lack of coupon payments for its offshore bonds, stirred uncertainty for the company. ASX 200 (-0.4%) was negative as underperformance in mining names and real estate overshadowed the advances in tech and resilience in financials from the higher yield environment. Nikkei 225 (+2.1%) was the biggest gainer overnight as it played catch up to the prior day’s recovery on return from the Autumnal Equinox holiday in Japan and with exporters cheering the recent risk-conducive currency flows, while KOSPI (-0.1%) was lacklustre amid the record daily COVID-19 infections and after North Korea deemed that it was premature to declare that the Korean War was over. Hang Seng (-1.2%) and Shanghai Comp. (-0.8%) were indecisive after further liquidity efforts by the PBoC were offset by concerns surrounding Evergrande after the Co. failed to make coupon payments due yesterday for offshore bonds but has a 30-day grace period with the Co. remaining quiet on the issue. Finally, 10yr JGBs were lower on spillover selling from global counterparts including the declines in T-notes as the US 10yr yield breached 1.40% for the first time since early-July with the pressure in bonds also stemming from across the Atlantic following a more hawkish BoE, while the presence of the BoJ in the market today for over JPY 1.3tln of government bonds with 1yr-10yr maturities did very little to spur prices. Top Asian News Rivals for Prime Minister Battle on Social Media: Japan Election Asian Stocks Rise for Second Day, Led by Gains in Japan, Taiwan Hong Kong Stocks Still Wagged by Evergrande Tail Hong Kong’s Hang Seng Tech Index Extends Decline to More Than 2% European equities (Stoxx 600 -0.9%) are trading on the back foot in the final trading session of the week amid further advances in global bond yields and a mixed APAC handover. Overnight, saw gains for the Nikkei 225 of 2.1% with the index aided by favourable currency flows, whilst Chinese markets lagged (Shanghai Comp. -0.8%, Hang Seng -1.6%) with further liquidity efforts by the PBoC offset by concerns surrounding Evergrande after the Co. failed to make coupon payments due yesterday for offshore bonds. As context, despite the losses in Europe today, the Stoxx 600 is still higher by some 1.2% on the week. Stateside, futures are also on a softer footing with the ES down by 0.4% ahead of a busy Fed speaker schedule. Back to Europe, sectors are lower across the board with Retail and Personal & Household Goods lagging peers. The former has been hampered by losses in Adidas (-3.0%) following after hours earnings from Nike (-4.2% pre-market) which saw the Co. cut its revenue guidance amid supply chain woes. AstraZeneca (+2.1%) sits at the top of the FTSE 100 after announcing that the Lynparza PROpel trial met its primary endpoint. Daimler’s (+0.1%) Mercedes-Benz has announced that it will take a 33% stake in a battery cell manufacturing JV with Total and Stellantis. EQT (-6.5%) sits at the foot of the Stoxx 600 after the Swedish FSA announced it will open an investigation into the Co. Top European News EQT Investigated by Sweden’s FSA Over Suspected Market Abuse Gazprom Says Claims of Gas Under-supply to Europe Are ‘Absurd’ German Sept. Ifo Business Confidence 98.8; Est. 99 German Business Index at Five-Month Low in Pre-Election Verdict In FX, the rot seems to have stopped for the Buck in terms of its sharp and marked fall from grace amidst post-FOMC reflection and re-positioning in the financial markets on Thursday. Indeed, the Dollar index has regained some poise to hover above the 93.000 level having recoiled from 93.526 to 92.977 over the course of yesterday’s hectic session that saw the DXY register a marginal new w-t-d high and low at either end of the spectrum. Pre-weekend short covering and consolidation may be giving the Greenback a lift, while the risk backdrop is also less upbeat ahead of a raft of Fed speakers flanking US new home sales data. Elsewhere, the Euro remains relatively sidelined and contained against the Buck with little independent inspiration from the latest German Ifo survey as the business climate deteriorated broadly in line with consensus and current conditions were worse than forecast, but business expectations were better than anticipated. Hence, Eur/Usd is still stuck in a rut and only briefly/fractionally outside 1.1750-00 parameters for the entire week, thus far, as hefty option expiry interest continues to keep the headline pair in check. However, there is significantly less support or gravitational pull at the round number today compared to Thursday as ‘only’ 1.3 bn rolls off vs 4.1 bn, and any upside breach could be capped by 1.1 bn between 1.1765-85. CAD/NZD/AUD - Some payback for the non-US Dollars following their revival, with the Loonie waning from 1.2650+ peaks ahead of Canadian budget balances, though still underpinned by crude as WTI hovers around Usd 73.50/brl and not far from decent option expiries (from 1.2655-50 and 1.2625-30 in 1.4 bn each). Similarly, the Kiwi has faded after climbing to within single digits of 0.7100 in wake of NZ trade data overnight revealing a much wider deficit as exports slowed and imports rose, while the Aussie loses grip of the 0.7300 handle and skirts 1.1 bn option expiries at 0.7275. CHF/GBP/JPY - The Franc is fairly flat and restrained following a dovish SNB policy review that left in lagging somewhat yesterday, with Usd/Chf and Eur/Chf straddling 0.9250 and 1.0850 respectively, in contrast to Sterling that is paring some hawkish BoE momentum, as Cable retreats to retest bids circa 1.3700 and Eur/Gbp bounces from sub-0.8550. Elsewhere, the Yen has not been able to fend off further downside through 110.00 even though Japanese participants have returned to the fray after the Autumn Equinox holiday and reports suggest some COVID-19 restrictions may be lifted in 13 prefectures on a trial basis. SCANDI/EM/PM/CRYPTO - A slight change in the pecking order in Scandi-land as the Nok loses some post-Norges Bank hike impetus and the Sek unwinds a bit of its underperformance, but EM currencies are bearing the brunt of the aforementioned downturn in risk sentiment and firmer Usd, with the Zar hit harder than other as Gold is clings to Usd 1750/oz and Try down to deeper post-CBRT rate cut lows after mixed manufacturing sentiment and cap u readings. Meanwhile, Bitcoin is being shackled by the latest Chinese crackdown on mining and efforts to limit risks from what it describes as unlawful speculative crypto currency trading. In commodities, WTI and Brent are set the conclude the week in the green with gains in excess of 2% for WTI at the time of writing; in-spite of the pressure seen in the complex on Monday and the first-half of Tuesday, where a sub USD 69.50/bbl low was printed. Fresh newsflow has, once again, been limited for the complex and continues to focus on the gas situation. More broadly, no update as of yet on the Evergrande interest payment and by all accounts we appear to have entered the 30-day grace period for this and, assuming catalysts remain slim, updates on this will may well dictate the state-of-play. Schedule wise, the session ahead eyes significant amounts of central bank commentary but from a crude perspective the weekly Baker Hughes rig count will draw attention. On the weather front, Storm Sam has been upgraded to a Hurricane and is expected to rapidly intensify but currently remains someway into the mid-Atlantic. Moving to metals, LME copper is pivoting the unchanged mark after a mixed APAC lead while attention is on Glencore’s CSA copper mine, which it has received an offer for; the site in 2020 produced circa. 46k/T of copper which is typically exported to Asia smelters. Elsewhere, spot gold and silver are firmer but have been very contained and remain well-within overnight ranges thus far. Which sees the yellow metal holding just above the USD 1750/oz mark after a brief foray below the level after the US-close. US Event Calendar 10am: Aug. New Home Sales MoM, est. 1.0%, prior 1.0% 10am: Aug. New Home Sales, est. 715,000, prior 708,000 Central Bank Speakers 8:45am: Fed’s Mester Discusses the Economic Outlook 10am: Powell, Clarida and Bowman Host Fed Listens Event 10:05am: Fed’s George Discusses Economic Outlook 12pm: Fed’s Bostic Discusses Equitable Community Development DB's Jim Reid concludes the overnight wrap WFH today is a bonus as it’s time for the annual ritual at home where the latest, sleekest, shiniest iPhone model arrives in the post and i sheepishly try to justify to my wife when I get home why I need an incremental upgrade. This year to save me from the Spanish Inquisition I’m going to intercept the courier and keep quiet. Problem is that such speed at intercepting the delivery will be logistically challenging as I remain on crutches (5 weeks to go) and can’t grip properly with my left hand due to an ongoing trapped nerve. I’m very glad I’m not a racehorse. Although hopefully I can be put out to pasture in front of the Ryder Cup this weekend. The big news of the last 24 hours has been a galloping global yield rise worthy of the finest thoroughbred. A hawkish Fed meeting, with the dots increasing and the end of QE potentially accelerated, didn’t quite have the ability to move markets but the global dam finally broke yesterday with Norway being the highest profile developed country to raise rates this cycle (expected), but more importantly a Bank of England meeting that saw the market reappraise rate hikes. Looking at the specific moves, yields on 10yr Treasuries were up +13.0bps to 1.430% in their biggest daily increase since 25 February, as both higher real rates (+7.9bps) and inflation breakevens (+4.9bps) drove the advance. US 10yr yields had been trading in a c.10bp range for the last month before breaking out higher, though they have been trending higher since dropping as far as 1.17% back in early-August. US 30yr yields rose +13.2bps, which was the biggest one day move in long dated yields since March 17 2020, which was at the onset of the pandemic and just days after the Fed announced it would be starting the current round of QE. The large selloff in US bonds saw the yield curve steepen and the long-end give back roughly half of the FOMC flattening from the day before. The 5y30y curve steepened 3.4bps for a two day move of -3.3bps. However the 2y10y curve steepened +10.5bps, completely reversing the prior day’s flattening (-4.2bps) and leaving the spread at 116bp, the steepest level since first week of July. 10yr gilt yields saw nearly as strong a move (+10.8bps) with those on shorter-dated 2yr gilts (+10.7bps) hitting their highest level (0.386%) since the pandemic began.That came on the back of the BoE’s latest policy decision, which pointed in a hawkish direction, building on the comment in the August statement that “some modest tightening of monetary policy over the forecast period is likely to be necessary” by saying that “some developments during the intervening period appear to have strengthened that case”. The statement pointed out that the rise in gas prices since August represented an upside risks to their inflation projections from next April, and the MPC’s vote also saw 2 members (up from 1 in August) vote to dial back QE. See DB’s Sanjay Raja’s revised rate hike forecasts here. We now expect a 15bps hike in February. The generalised move saw yields in other European countries rise as well, with those on 10yr bunds (+6.6bps), OATs (+6.5bps) and BTPs (+5.7bps) all seeing big moves higher with 10yr bunds seeing their biggest climb since late-February and back to early-July levels as -0.258%. The yield rise didn’t stop equity indices recovering further from Monday’s rout, with the S&P 500 up +1.21% as the index marked its best performance in over 2 months, and its best 2-day performance since May. Despite the mood at the end of the weekend, the S&P now starts Friday in positive territory for the week. The rally yesterday was led by cyclicals for a second straight day with higher commodity prices driving outsized gains for energy (+3.41%) and materials (+1.39%) stocks, and the aforementioned higher yields causing banks (+3.37%) and diversified financials (+2.35%) to outperform. The reopening trade was the other main beneficiary as airlines rose +2.99% and consumer services, which include hotel and cruiseline companies, gained +1.92%. In Europe, the STOXX 600 (+0.93%) witnessed a similarly strong performance, with index led by banks (+2.16%). As a testament to the breadth of yesterday’s rally, the travel and leisure sector (+0.04%) was the worst performing sector on this side of the Atlantic even while registering a small gain and lagging its US counterparts. Before we get onto some of yesterday’s other events, it’s worth noting that this is actually the last EMR before the German election on Sunday, which has long been signposted as one of the more interesting macro events on the 2021 calendar, the results of which will play a key role in not just domestic, but also EU policy. And with Chancellor Merkel stepping down after four terms in office, this means that the country will soon be under new management irrespective of who forms a government afterwards. It’s been a volatile campaign in many respects, with Chancellor Merkel’s CDU/CSU, the Greens and the centre-left SPD all having been in the lead at various points over the last six months. But for the last month Politico’s Poll of Polls has shown the SPD consistently ahead, with their tracker currently putting them on 25%, ahead of the CDU/CSU on 22% and the Greens on 16%. However the latest poll from Forschungsgruppe Wahlen yesterday suggested a tighter race with the SPD at 25, the CDU/CSU at 23% and the Greens at 16.5%. If the actual results are in line with the recent averages, it would certainly mark a sea change in German politics, as it would be the first time that the SPD have won the popular vote since the 2002 election. Furthermore, it would be the CDU/CSU’s worst ever result, and mark the first time in post-war Germany that the two main parties have failed to win a majority of the vote between them, which mirrors the erosion of the traditional big parties in the rest of continental Europe. For the Greens, 15% would be their best ever score, and exceed the 9% they got back in 2017 that left them in 6th place, but it would also be a disappointment relative to their high hopes back in the spring, when they were briefly polling in the mid-20s after Annalena Baerbock was selected as their Chancellor candidate. In terms of when to expect results, the polls close at 17:00 London time, with initial exit polls released immediately afterwards. However, unlike the UK, where a new majority government can immediately come to power the day after the election, the use of proportional representation in Germany means that it could potentially be weeks or months before a new government is formed. Indeed, after the last election in September 2017, it wasn’t until March 2018 that the new grand coalition between the CDU/CSU and the SPD took office, after attempts to reach a “Jamaica” coalition between the CDU/CSU, the FDP and the Greens was unsuccessful. In the meantime, the existing government will act as a caretaker administration. On the policy implications, it will of course depend on what sort of government is actually formed, but our research colleagues in Frankfurt have produced a comprehensive slidepack (link here) running through what the different parties want across a range of policies, and what the likely coalitions would mean for Germany. They also put out another note yesterday (link here) where they point out that there’s still much to play for, with the SPD’s lead inside the margin of error and with an unusually high share of yet undecided voters. Moving on to Asia and markets are mostly higher with the Nikkei (+2.04%), CSI (+0.53%) and India’s Nifty (+0.52%) up while the Hang Seng (-0.03%), Shanghai Comp (-0.07%) and Kospi (-0.10%) have all made small moves lower. Meanwhile, the Evergrande group missed its dollar bond coupon payment yesterday and so far there has been no communication from the group on this. They have a 30-day grace period to make the payment before any event of default can be declared. This follows instructions from China’s Financial regulators yesterday in which they urged the group to take all measures possible to avoid a near-term default on dollar bonds while focusing on completing unfinished properties and repaying individual investors. Yields on Australia and New Zealand’s 10y sovereign bonds are up +14.5bps and +11.3bps respectively this morning after yesterday’s move from their western counterparts. Yields on 10y USTs are also up a further +1.1bps to 1.443%. Elsewhere, futures on the S&P 500 are up +0.04% while those on the Stoxx 50 are down -0.10%. In terms of overnight data, Japan’s August CPI printed at -0.4% yoy (vs. -0.3% yoy expected) while core was unchanged in line with expectations. We also received Japan’s flash PMIs with the services reading at 47.4 (vs. 42.9 last month) while the manufacturing reading came in at 51.2 (vs. 52.7 last month). In pandemic related news, Jiji reported that Japan is planning to conduct trials of easing Covid restrictions, with 13 prefectures indicating they’d like to participate. This is likely contributing to the outperformance of the Nikkei this morning. Back to yesterday now, and one of the main highlights came from the flash PMIs, which showed a continued deceleration in growth momentum across Europe and the US, and also underwhelmed relative to expectations. Running through the headline numbers, the Euro Area composite PMI fell to 56.1 (vs. 58.5 expected), which is the lowest figure since April, as both the manufacturing (58.7 vs 60.3 expected) and services (56.3 vs. 58.5 expected) came in beneath expectations. Over in the US, the composite PMI fell to 54.5 in its 4th consecutive decline, as the index hit its lowest level in a year, while the UK’s composite PMI at 54.1 (vs. 54.6 expected) was the lowest since February when the country was still in a nationwide lockdown. Risk assets seemed unperturbed by the readings, and commodities actually took another leg higher as they rebounded from their losses at the start of the week. The Bloomberg Commodity Spot index rose +1.12% as Brent crude oil (+1.39%) closed at $77.25/bbl, which marked its highest closing level since late 2018, while WTI (+1.07%) rose to $73.30/bbl, so still a bit beneath its recent peak in July. However that is a decent rebound of roughly $11/bbl since its recent low just over a month ago. Elsewhere, gold (-1.44%) took a knock amidst the sharp move higher in yields, while European natural gas prices subsidised for a third day running, with futures now down -8.5% from their intraday peak on Tuesday, although they’re still up by +71.3% since the start of August. US negotiations regarding the upcoming funding bill and raising the debt ceiling are ongoing, with House Speaker Pelosi saying that the former, also called a continuing resolution, will pass “both houses by September 30,” and fund the government through the first part of the fiscal year, starting October 1. Treasury Secretary Yellen has said the US will likely breach the debt ceiling sometime in the next month if Congress does not increase the level, and because Republicans are unwilling to vote to raise the ceiling, Democrats will have to use the once-a-fiscal-year tool of budget reconciliation to do so. However Democrats, are also using that process for the $3.5 trillion dollar economic plan that makes up the bulk of the Biden agenda, and have not been able to get full party support yet. During a joint press conference with Speaker Pelosi, Senate Majority Leader Schumer said that Democrats have a “framework” to pay for the Biden Economic agenda, which would imply that the broad outline of a deal was reached between the House, Senate and the White House. However, no specifics were mentioned yesterday. With Democrats looking to vote on the bipartisan infrastructure bill early next week, negotiations today and this weekend on the potential reconciliation package will be vital. Looking at yesterday’s other data, the weekly initial jobless claims from the US for the week through September 18 unexpectedly rose to 351k (vs. 320k expected), which is the second week running they’ve come in above expectations. Separately, the Chicago Fed’s national activity index fell to 0.29 in August (vs. 0.50 expected), and the Kansas City Fed’s manufacturing activity index also fell more than expected to 22 in September (vs. 25 expected). To the day ahead now, and data highlights include the Ifo’s business climate indicator from Germany for September, along with Italian consumer confidence for September and US new home sales for August. From central banks, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan. Tyler Durden Fri, 09/24/2021 - 08:12.....»»

Category: blogSource: zerohedgeSep 24th, 2021

Brandon Smith: Organizing Patriots In The Face Of Government Informants And False Flags

Brandon Smith: Organizing Patriots In The Face Of Government Informants And False Flags Authored by Brandon Smith via Alt-Market.us, There is a simple fact that must be understood when it comes to the fight for liberty: Such a fight cannot be won by lone individuals. Freedom requires organized resistance and it does not matter how many millions of people stand against an authoritarian regime, if they are completely isolated from each other they WILL lose. It’s a guarantee. This is why a considerable portion of establishment money, energy and propaganda is directed at defusing or sabotaging any semblance of conservative organization. This includes engineering false flag events and creating potential terror attacks from thin air so that they can be blamed on constitutionally minded groups. The strategy is called “4th Generation Warfare” and it is not conspiracy theory, this is conspiracy fact. For example, as we now know according to court documentation, the supposed scheme by a Michigan “militia” made up of anarchists to kidnap Governor Gretchen Whitmer and “try her as a tyrant” was heavily infiltrated by at least a dozen FBI agents and informants. The group was so infiltrated, in fact, that the entire plot for the kidnapping was essentially planned out by the FBI. This is the very definition of a false flag. The corruption and entrapment involved in the operation was so egregious that even the leftist media has reported on it. I recall a very similar situation occurred during the Malheur incident when Ammon Bundy (son of Cliven Bundy) and a group of patriots decided to annex the wildlife refuge and its obscure ranger buildings as a launching point for a revolution. Though I was a supporter of the efforts at Bundy Ranch, I was vehemently against Malheur because the whole situation seemed grossly suspect. The strategy made no sense, the rationale made no sense, the site of the standoff made no sense and the public optics were terrible. It was an anti-Bundy Ranch; a situation in which all of the dynamics were in favor of the feds and against the liberty movement. And, not surprisingly, Malhuer had also been influenced and in some cases was arranged by federal informants and agents. These people were whispering in the ear of Ammon Bundy the entire time while the FBI authorized them to commit criminal acts. There were so many paid employees of the FBI at Malheur that jurors decided to drop all charges against most of the defendants involved. And what about the latest “J6” rally in Washington DC, which was planned by a virtually unknown former Trump aid and was quickly exposed as a potential “honeypot” designed to lure in conservatives? The army of plain clothes undercover feds was so prevalent that riot cops accidentally arrested an armed FBI agent thinking he was a protester. Now, there are many people in the alternative media that are breathing a sigh of relief that almost no one showed up for the J6 protest or “fell into the trap”. In fact, there were far more reporters and feds there than actual activists. However, I think we need to look at the bigger picture of why the government is staging such events in the first place, and it’s not just to entrap a few conservatives . If you think about it, the entire strategy is high cost/minimum reward if we only look at it in terms of actual arrests. If the idea is to catch and prosecute patriots, then they could infiltrate groups and engineer criminal actions for decades and achieve little to nothing. Obviously, this is not the purpose of informants. Rather, the strategy is not to invade groups unnoticed; the strategy is to BE NOTICED, to make sure the whole of the liberty movement believe that if they ever try to organize in any way the feds will be there to set them up. In other words, the primary goal of the FBI is to instill paranoia and fear among patriots and ensure they never effectively organize to resist. When we cheer the “failure” of J6, we need to keep in mind that the establishment does not care. Getting people to show up was not their main intent; making people afraid to show up for any other events in the future is what they want. The issue presents a Catch-22. If conservatives organize there is the chance that some groups will be infiltrated or set up and used to make the entire movement look bad. If we don’t organize, then we have lost the fight. It will be over before it even truly begins (and no, the real fight has not started yet). So what is the solution? I think it’s odd but maybe not surprising that the standoff at Bundy Ranch has been memory-holed by the media and is rarely mentioned even among conservative activists these days. Yet, it was probably one of the most successful patriot actions in the past couple of decades. There are a number of reasons for this: 1) The action was spontaneous, not pre-planned and was in response to criminal activity by the FBI (including assaulting women that were protesting and the use of sniper positions to surround the Bundy property similar to Ruby Ridge). The movement took action to remedy a government trespass rather than creating a standoff out of nothing. 2) There was no single person in charge. Groups showed up from all over the country; some of them squared away and some of them screw-ups. This might sound like a bad thing, but in terms of rebellion it is often better to avoid streamlined top-down leadership. Frankly, I am usually suspicious of anyone that tries to anoint themselves the “leader” of the liberty movement or the sole leader of a protest action. Cult of personality is the most useless thing I can think of when it comes to battling tyranny, and top-down leadership can be easily manipulated or controlled. 3) Because of the decentralized nature of the response to Bundy Ranch, the feds had no way to influence or predict the outcome, and they really hate that. Without informants in key positions, the feds did not have the ability to adapt to the quickly changing circumstances. Contrast this with Malheur, where the feds were basically in control from the very beginning. The site itself was so isolated and ill conceived that the FBI was able to dictate every movement of patriots in and out of the area. It was pointless for any militia to occupy it, but it was a great spot for the feds. 4) Patriots arrived at Bundy Ranch peacefully, but with the will to fight if necessary. The Bundy Ranch response had a clear objective – To stop the FBI from harming the Bundy family and to retrieve the stolen cattle if possible. Both of these objectives were accomplished and with no shots fired. A complete success. The group was motivated and unified by the objective, NOT a singular leadership. Without a clear objective there is no purpose to any action. It is important to understand the difference between a Lexington Bridge moment and a Fort Sumter moment – During Lexington Bridge, the revolutionaries took action to stop a British detachment from arresting colonial leaders and confiscating rifles and powder stores. The British were in the midst of an undeniable attempt to disarm and snuff out the resistance. At Fort Sumter, the Confederate attack was in response to an attempted resupply of the fort itself; which made sense strategically but looked like an act of pure aggression to the wider public. The concept of states rights (more prominent in the minds of the confederates than the issue of slavery) fell by the wayside. Eventually tyranny has to put boots on the ground. A totalitarian system can function for a time on color of law and implied threats, but it will crumble unless it is able to establish a physical presence of force. Once those jackboots touch soil in a visible way and the agents of the state try to expand oppressive measures, rebels then have a free hand to disrupt them or bring them down. But this only works if there are objectives and enough decentralization to prevent misdirection of the movement. Some organization is essential. It cannot be avoided. All the “Gray Men” and secret squirrel preppers out there that think they are going to simply weather the storm in isolation and pop out of their bug-out locations to rebuild are suffering from serious delusions. I can’t help but think of that moment in ‘Lord Of The Rings’ when the Ents refuse to organize to fight against the invading orcs. Pippen suggests to Merry that the problem is too big for them and that they should go back to the Shire to wait out the war. Merry laments: “The fires of Isengard will spread. And the woods of Tuckborough and Buckland will burn. And all that was once green and good in this world will be gone. There won’t be a Shire, Pippin.” If this fight is not pursued now, there will be no world worth coming back to, even if one was able to successfully hide from it. There will be a “new world order” as the globalists like to call it. There will be nothing left of freedom. So, organization must be accomplished, and it should be built at the local level. This is far more important than any dreams of a national organization, at least for now. There is no one we can trust to lead such a nationwide revolt, and that includes political leaders like Donald Trump. Will federal intrusions happen? Of course, but at the local level it is much easier to vet people according to their behaviors and root out bad actors. Hold your local meetings to discuss current events and create a place for people to network and get to know each other. Talk to local businesses or your county sheriff to see where they stand on issues like the vaccine passports and Biden mandates. Put things in motion now or you will regret it later when your community is completely disjointed and paralyzed by fear during crisis or government subjugation. And, what about the first guy at your meetings that starts talking about building bombs, drafting “kill lists” or kidnapping governors? Kick his ass out promptly and make sure everyone knows why you did it. Most likely he is a fed or he is on an informant payroll. As our national composure breaks down and the manure hits the fan, fed informants and agents will suddenly disappear from these groups without a trace. They are not going to stick around for what happens next; the government doesn’t pay them enough for that. And knowing who the patriots are will not help the federal government if the patriots are organized to defend themselves. This is the reality which they do not want us to wake up to. *  *  * If you would like to support the work that Alt-Market does while also receiving content on advanced tactics for defeating the globalist agenda, subscribe to our exclusive newsletter The Wild Bunch Dispatch.  Learn more about it HERE. Tyler Durden Thu, 09/23/2021 - 23:40.....»»

Category: blogSource: zerohedgeSep 24th, 2021

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter ended June 30, 2021. Business Updates Corporate Updates In June 2021, we completed our initial public offering, in which we issued and sold an aggregate of 11,499,999 ordinary shares, including those issued and sold pursuant to the exercise in full of the underwriters' option to purchase additional ordinary shares, at a price of $16.00 per share. The net proceeds of the offering were $167.7 million, after deducting underwriting discounts and offering expenses payable by us. Today we announced that Dermot Hanley and Dr. Duncan Moore have been appointed to our Board of Directors as non-executive directors effective September 24, 2021, expanding the Board to five members. Mr. Hanley and Dr. Moore will also serve as members of the Audit Committee. Mr. Hanley is an experienced independent non-executive director and investment banker, having previously served as Co-Head of Coverage for Barclays Bank Ireland and having spent 16 years in international investment banking and capital markets roles with major global firms, including Claret Capital, JP Morgan, Deutsche Bank and Citibank. Dr. Moore is currently a partner at East West Capital Partners. Prior roles included 17 years as a top-ranked pharmaceutical analyst at Morgan Stanley, including 11 years as a Managing Director leading the firm's global healthcare equity research team. Clinical Development Updates GH001, our inhalable 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) product candidate, is currently being investigated in the Phase 2 part of an ongoing open-label, single-arm Phase 1/2 clinical trial in patients with Treatment-Resistant Depression (TRD). Based on the observed clinical activity in the Phase 1 part of the trial, we believe that administration of a single dose of GH001 has the potential to induce ultra-rapid remissions as measured by the Montgomery–Åsberg Depression Rating Scale, or MADRS, in certain patients. The goal of the ongoing Phase 2 part, which we expect to complete in the fourth quarter of 2021, is to assess whether an individualized dosing regimen with intra-subject dose escalation within a single day can further increase the MADRS remission rate as compared to a single dose of GH001. We have previously announced the plan to conduct a clinical pharmacology trial in healthy volunteers to further elucidate the pharmacokinetic profile of GH001. This trial has been initiated and is expected to be completed in the fourth quarter of 2021. Pending completion of the aforementioned studies, we plan to request a pre-IND meeting with the FDA and a Scientific Advice meeting with the EMA and plan to initiate a multi-center, randomized, controlled Phase 2b trial in TRD. Given GH001's mechanism of action, we believe that GH001 may confer beneficial effects as an earlier line of treatment in MDD, including potential to serve as a front-line treatment, as well as in other psychiatric and neurological disorders with unmet medical need. We plan to initiate proof-of-concept Phase 2a trials in two such disorders. GH002, our injectable 5-MeO-DMT product candidate, is currently in preclinical development. We anticipate developing GH002 in indications within our focus area of psychiatric and neurological disorders. Second Quarter 2021 Financial Results Cash position Cash was $292.6 million as of June 30, 2021, compared to $5.9 million as of December 31, 2020. Research and development expenses R&D expenses were $2 million for the quarter ended June 30, 2021, compared to $39 thousand for the same quarter in 2020. The increase was primarily due to increased activities relating to our technical developments and clinical trials and increases in employee expenses to support these activities. General and administrative expenses G&A expenses were $719 thousand for the quarter ended June 30, 2021, compared to $3 thousand for the same quarter in 2020. The increase was primarily due to costs incurred in preparation for our initial public offering and increased employee expenses. Net loss Net loss was $2.1 million, or $0.053 loss per share, for the quarter ended June 30, 2021, compared to $42 thousand, or $0.002 loss per share, for the same quarter in 2020. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. About GH001 Our lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach. We are currently investigating administration of GH001 as a single-dose induction regimen and in an individualized dosing regimen where up to three escalating doses of GH001 are given on the same day. With GH001, we have completed a Phase 1 healthy volunteer clinical trial, in which administration of GH001 via inhalation was observed to be well tolerated at the investigated single dose levels and in the individualized dosing regimen. GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. In the completed Phase 1 part of this ongoing trial, no serious adverse events were observed and all adverse drug reactions were mild and resolved spontaneously. Based on observed clinical activity, we believe that administration of a single dose of GH001 has the potential to induce ultra-rapid remissions as measured by the Montgomery-Åsberg Depression Rating Scale, or MADRS, in certain patients. The goal of the ongoing Phase 2 part of the trial is to assess whether an individualized dosing regimen with intra-subject dose escalation within a single day can further increase the MADRS remission rate as compared to a single dose of GH001. About GH002 GH002 is our 5-MeO-DMT product candidate formulated for administration via a proprietary injectable approach. GH002 is currently in preclinical development, and we anticipate developing GH002 in indications within our focus area of psychiatric and neurological disorders. About Dermot Hanley Mr. Hanley is an experienced independent non-executive director and investment banker. He is currently a non-executive board member of numerous private equity backed companies and regulated financial investment funds. These include Killiney Maritime since September 2018, Larix Opportunities Master ICAV since February 2020, Varagon Capital Credit Strategies ICAV since October 2020. Additionally, he has served as Chairperson of RTW Investments ICAV since January 2021 and CVP Credit Value Fund (Europe) V GP Limited since May 2021. He founded Nusli in 2012. Previously, Mr. Hanley was Co-Head of Coverage for Barclays Bank Ireland and spent 16 years in international investment banking and capital markets roles with major global firms, including Claret Capital, JP Morgan, Deutsche Bank and Citibank. He is a member of the Governance Advisory Council for The Corporate Governance Institute and is also a longstanding member of the Finance and Economics Committee (Ecotax) at The Irish Business and Employers Confederation. He is a graduate of University College Dublin (BSc) and The Queens University of Belfast (MBA) and holds a diploma in corporate governance from The Governance Institute/Glasgow Caledonia University. About Duncan Moore Dr. Moore is a partner at East West Capital Partners since May 2008. Previously, Dr. Moore was a top-ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firm's global healthcare equity research team. Whilst at the University of Cambridge, he co-founded a medical diagnostics company, Ultra Clone, with two colleagues which led to the beginnings of a 20-year career in healthcare capital markets analysis. In 1986, he was involved in establishing the BankInvest biotechnology funds and was on their scientific advisory board. Dr. Moore was educated in Edinburgh and attended the University of Leeds where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow. Currently, he is an active investor in biomedical companies as Chairman of Lamellar Biomedical and Allarity Therapeutics A/S (previously Oncology Venture A/S). In addition, he has a board position at Forward Pharma A/S and Cycle Pharma. He is also the Chairman of the Scottish Life Sciences Association and serves on the Board of Governors of Merchiston Castle School in Edinburgh and the International School in Shenzhen in the Peoples Republic of China. Forward-Looking Statements This press release contains statements that are, or may deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor Relations:Julie RyanGH Research PLCinvestors@ghres.com GH RESEARCH PLCCondensed Consolidated Interim Statement of Comprehensive Income (Unaudited)(in thousands, except share and per share amounts)     Three months endedJune 30,   Six months endedJune 30,     2021 2020   2021 2020     $'000 $'000   $'000 $'000      .....»»

Category: earningsSource: benzingaSep 23rd, 2021